<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84708</article-id><article-id pub-id-type="doi">10.7554/eLife.84708</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Orai3 and Orai1 mediate CRAC channel function and metabolic reprogramming in B cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-278677"><name><surname>Emrich</surname><given-names>Scott M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4804-7436</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278678"><name><surname>Yoast</surname><given-names>Ryan E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-193800"><name><surname>Zhang</surname><given-names>Xuexin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-298458"><name><surname>Fike</surname><given-names>Adam J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278679"><name><surname>Wang</surname><given-names>Yin-Hu</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-182604"><name><surname>Bricker</surname><given-names>Kristen N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8963-9780</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278681"><name><surname>Tao</surname><given-names>Anthony Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278682"><name><surname>Xin</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-193797"><name><surname>Walter</surname><given-names>Vonn</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6114-6714</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278683"><name><surname>Johnson</surname><given-names>Martin T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278684"><name><surname>Pathak</surname><given-names>Trayambak</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254289"><name><surname>Straub</surname><given-names>Adam C</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-205531"><name><surname>Feske</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-167777"><name><surname>Rahman</surname><given-names>Ziaur SM</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8431-9681</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-178070"><name><surname>Trebak</surname><given-names>Mohamed</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6759-864X</contrib-id><email>TREBAKM@PITT.EDU</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04p491231</institution-id><institution>Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Hershey</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04p491231</institution-id><institution>Department of Microbiology and Immunology, Pennsylvania State University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Hershey</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>Department of Pathology, New York University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Vascular Medicine Institute, University of Pittsburgh School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04p491231</institution-id><institution>Department of Public Health Sciences, Pennsylvania State University College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Hershey</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Prakriya</surname><given-names>Murali</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Northwestern University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Swartz</surname><given-names>Kenton J</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institute of Neurological Disorders and Stroke, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84708</elocation-id><history><date date-type="received" iso-8601-date="2022-11-06"><day>06</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-16"><day>16</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-05-06"><day>06</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.06.490918"/></event></pub-history><permissions><copyright-statement>© 2023, Emrich et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Emrich et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84708-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84708-figures-v2.pdf"/><abstract><p>The essential role of store-operated Ca<sup>2+</sup> entry (SOCE) through Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> (CRAC) channels in T cells is well established. In contrast, the contribution of individual Orai isoforms to SOCE and their downstream signaling functions in B cells are poorly understood. Here, we demonstrate changes in the expression of Orai isoforms in response to B cell activation. We show that both Orai3 and Orai1 mediate native CRAC channels in B cells. The combined loss of Orai1 and Orai3, but not Orai3 alone, impairs SOCE, proliferation and survival, nuclear factor of activated T cells (NFAT) activation, mitochondrial respiration, glycolysis, and the metabolic reprogramming of primary B cells in response to antigenic stimulation. Nevertheless, the combined deletion of Orai1 and Orai3 in B cells did not compromise humoral immunity to influenza A virus infection in mice, suggesting that other in vivo co-stimulatory signals can overcome the requirement of BCR-mediated CRAC channel function in B cells. Our results shed important new light on the physiological roles of Orai1 and Orai3 proteins in SOCE and the effector functions of B lymphocytes.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Orai1</kwd><kwd>Orai3</kwd><kwd>B cells</kwd><kwd>CRAC channels</kwd><kwd>SOCE</kwd><kwd>metabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R35-HL150778</award-id><principal-award-recipient><name><surname>Trebak</surname><given-names>Mohamed</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01-AI162971</award-id><principal-award-recipient><name><surname>Rahman</surname><given-names>Ziaur SM</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01-AI097302 and R01-AI130143</award-id><principal-award-recipient><name><surname>Feske</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>F30-AI164803-01</award-id><principal-award-recipient><name><surname>Tao</surname><given-names>Anthony Y</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Gene knockout in cell lines and mice reveal that store-operated calcium entry is synergistically mediated by Orai1 and Orai3 channel proteins in B cells and is important for signaling to the nucleus and metabolic activity in response to antigenic stimulation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Calcium (Ca<sup>2+</sup>) is an essential regulator of immune cell function (<xref ref-type="bibr" rid="bib42">Prakriya and Lewis, 2015</xref>; <xref ref-type="bibr" rid="bib54">Trebak and Kinet, 2019</xref>). Crosslinking of immunoreceptors like the T cell receptor (TCR) or B cell receptor (BCR) triggers a robust elevation in intracellular Ca<sup>2+</sup> concentrations through the release of endoplasmic reticulum (ER) Ca<sup>2+</sup> stores and a concomitant influx of Ca<sup>2+</sup> from the extracellular space (<xref ref-type="bibr" rid="bib4">Baba and Kurosaki, 2016</xref>; <xref ref-type="bibr" rid="bib30">King and Freedman, 2009</xref>). In lymphocytes, Ca<sup>2+</sup> entry across the plasma membrane (PM) is predominately achieved through CRAC channels, which constitute the ubiquitous SOCE (<xref ref-type="bibr" rid="bib42">Prakriya and Lewis, 2015</xref>; <xref ref-type="bibr" rid="bib54">Trebak and Kinet, 2019</xref>; <xref ref-type="bibr" rid="bib53">Trebak and Putney, 2017</xref>; <xref ref-type="bibr" rid="bib60">Vaeth et al., 2020</xref>). Stimulation of immunoreceptors coupled to phospholipase C isoforms results in the production of the secondary messenger inositol-1,4,5-trisphosphate (IP<sub>3</sub>), which triggers the release of ER Ca<sup>2+</sup> through the activation of ER-resident IP<sub>3</sub> receptors. A reduction in ER Ca<sup>2+</sup> concentrations is sensed by stromal interaction molecule 1 (STIM1) and its homolog STIM2, resulting in a conformational change and clustering in ER-PM junctions where STIM molecules interact with and activate PM hexameric Orai channels (Orai1-3) to mediate SOCE (<xref ref-type="bibr" rid="bib33">Lunz et al., 2019</xref>). Ca<sup>2+</sup> entry through CRAC channels regulates immune cell function through a host of Ca<sup>2+</sup>-sensitive transcription factors including the NFAT, nuclear factor κB (NF-κB), c-Myc, and mTORC1 (<xref ref-type="bibr" rid="bib5">Berry et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Trebak and Kinet, 2019</xref>; <xref ref-type="bibr" rid="bib59">Vaeth and Feske, 2018</xref>; <xref ref-type="bibr" rid="bib60">Vaeth et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Vaeth et al., 2017a</xref>). The coordination of these master transcriptional regulators is indispensable for innate and adaptive immune cell effector function including entry into the cell cycle, clonal expansion, cytokine secretion, differentiation, and antibody production (<xref ref-type="bibr" rid="bib47">Shaw and Feske, 2012</xref>; <xref ref-type="bibr" rid="bib54">Trebak and Kinet, 2019</xref>; <xref ref-type="bibr" rid="bib60">Vaeth et al., 2020</xref>).</p><p>Orai1 has long been established as a central component of the <italic>native</italic> CRAC channel in all cell types studied. Although all three Orai isoforms are ubiquitously expressed across tissue types and can form functional CRAC channels when ectopically expressed, only recently have Orai2 and Orai3 emerged as regulators of <italic>native</italic> CRAC channel function (<xref ref-type="bibr" rid="bib18">Emrich et al., 2022b</xref>; <xref ref-type="bibr" rid="bib55">Tsvilovskyy et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>; <xref ref-type="bibr" rid="bib65">Yoast et al., 2020a</xref>). Patients with inherited loss-of-function (LoF) mutations in <italic>Orai1</italic> (e.g. R91W mutation) develop a CRAC channelopathy with symptoms including combined immunodeficiency, ectodermal dysplasia, muscular hypotonia, and autoimmunity (<xref ref-type="bibr" rid="bib20">Feske et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Lian et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">McCarl et al., 2009</xref>). While these patients display relatively normal frequencies of most immune cell populations, they are highly susceptible to reoccurring viral, bacterial, and fungal infections due to defects in T cell expansion, cytokine secretion, and metabolism (<xref ref-type="bibr" rid="bib60">Vaeth et al., 2020</xref>). There are currently no reported patient mutations in <italic>Orai2</italic> or <italic>Orai3</italic> genes and the role these channels play within the immune system had largely been unclear. Interestingly, recent studies utilizing global Orai2 knockout mice have demonstrated that loss of Orai2 leads to enhanced SOCE and corresponding CRAC currents in bone marrow-derived macrophages, dendritic cells, T cells, enamel cells, and mast cells (<xref ref-type="bibr" rid="bib15">Eckstein et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Tsvilovskyy et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>), suggesting that Orai2 is a negative regulator of CRAC channel activity. Combined knockout in mice of both Orai1 and Orai2 in T cells led to a near ablation of SOCE and impaired humoral immunity, while ectopic expression of pore-dead mutants of Orai1 (E106Q) or Orai2 (E80Q) into individual <italic>Orai1<sup>-/-</sup></italic> or <italic>Orai2<sup>-/-</sup></italic> T cells blocked native SOCE (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>). Similarly, the generation of HEK293 cell lines lacking each Orai isoform individually and in combination resulted in altered Ca<sup>2+</sup> oscillation profiles, CRAC currents, and NFAT isoform activation (<xref ref-type="bibr" rid="bib18">Emrich et al., 2022b</xref>; <xref ref-type="bibr" rid="bib16">Emrich et al., 2021</xref>; <xref ref-type="bibr" rid="bib65">Yoast et al., 2020a</xref>; <xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>). These data provide evidence that Orai2 and Orai3 exert negative regulatory effects on native CRAC channels possibly by forming heteromeric CRAC channels with Orai1.</p><p>In contrast to T cells, much less is known regarding the role of SOCE in B lymphocytes. Early landmark work investigating B cell-specific STIM knockout mice established that STIM1 mediates the vast majority of SOCE in B cells, while only the combined deletion of both STIM1 and STIM2 resulted in substantial impairments in B cell survival, proliferation, and NFAT-dependent IL-10 secretion (<xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). Unexpectedly, mice with STIM1/STIM2-deficient B cells show normal humoral immune responses to immunization with both T cell-dependent and independent antigens. These and other studies suggest that the severe immunodeficiency observed in CRAC channelopathy patients is due to impaired T cell responses (<xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib56">Vaeth et al., 2016</xref>). Investigation of <italic>Orai1<sup>-/-</sup></italic> mice on the mixed Institute for Cancer Research (ICR) background and <italic>Orai1<sup>R93W</sup></italic> knock-in mice (the equivalent of human R91W mutation) demonstrated that SOCE is significantly attenuated in B cells (<xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref>; <xref ref-type="bibr" rid="bib37">McCarl et al., 2010</xref>). However, SOCE in B cells is only partially reduced with the loss of Orai1, suggesting that Orai2 and/or Orai3 mediate the remaining SOCE in B cell populations. A recent study showed that the deletion of Orai3 in mice does not affect B cell function and humoral immune responses (<xref ref-type="bibr" rid="bib62">Wang et al., 2022</xref>), suggesting other Orai homologs compensate for the loss of Orai3. Thus, the contribution of each Orai isoform to native CRAC channel function and downstream signaling in B cells has remained obscure.</p><p>In this study, we investigated the contributions of Orai isoforms to SOCE and its downstream signaling in B cells through multiple CRISPR/Cas9 knockout B cell lines and novel B cell-specific <italic>Orai</italic> knockout mice. Our findings demonstrate that the expression of each Orai isoform is dynamically regulated in response to B cell activation and that the magnitude of SOCE is unique among effector B cell populations. We show that the deletion of Orai1 alone does not alter BCR-evoked cytosolic Ca<sup>2+</sup> oscillations, proliferation, and development. Unexpectedly, we show that Orai3 is involved in regulating B cell SOCE and downstream signaling functions. Deletion of both Orai1 and Orai3 strongly inhibits SOCE and hampers mitochondrial metabolism in B cells. Transcriptome and metabolomic analysis uncovered key signaling pathways that are regulated by SOCE and the phosphatase calcineurin for the efficient transition of B cells from a quiescent to a metabolically active state. Surprisingly, humoral immunity to influenza A virus infection of mice with B cell-specific deletion of both Orai1 and Orai3 was unaltered, suggesting that alternative Ca<sup>2+</sup>-independent signaling pathways activated in vivo through co-stimulatory receptors can overcome the loss of CRAC channel activity in B cells. Our data elucidate the role of SOCE in B cell functions and show that CRAC channel function in B lymphocytes is mediated by both Orai1 and Orai3. This knowledge is important for the potential targeting of CRAC channels in specific lymphocyte subsets in immune and inflammatory diseases.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Orai channel isoforms are dynamically regulated in response to B cell activation</title><p>Throughout their lifespan, B lymphocytes must undergo dramatic periods of metabolic adaptation whereby naïve, metabolically quiescent cells prepare to clonally expand and differentiate into effector populations (<xref ref-type="bibr" rid="bib3">Akkaya and Pierce, 2019</xref>; <xref ref-type="bibr" rid="bib9">Boothby and Rickert, 2017</xref>). Induction of these diverse metabolic programs is driven by downstream BCR-mediated Ca<sup>2+</sup> signals in combination with Ca<sup>2+</sup>-independent costimulatory signals including CD40 activation and/or stimulation with various toll-like receptor (TLR) ligands (<xref ref-type="bibr" rid="bib2">Akkaya et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Baba and Kurosaki, 2016</xref>; <xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>). Thus, using Seahorse assays we first evaluated how activation of wild-type mouse primary splenic B cells (isolated as described in methods) regulates oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) as indicators of oxidative phosphorylation (OXPHOS) and glycolysis, respectively (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Naïve primary B cells from mouse spleens were isolated by negative selection and stimulated for 24 hr under five different conditions as follows: (1) control unstimulated cells (Unstim), (2) stimulation with anti-IgM antibodies (IgM) to activate the BCR, (3) stimulation with anti-CD40 (CD40), (4) stimulation with lipopolysaccharides (LPS), and (5) co-stimulation with anti-IgM and anti-CD40. B cell stimulation for 24 hr led to a robust increase in basal OCR, except for B cells stimulated with anti-CD40 alone where the increase in basal OCR was not statistically significant (<xref ref-type="fig" rid="fig1">Figure 1A and C</xref>). <xref ref-type="fig" rid="fig1">Figure 1B</xref> shows that B cells stimulated with either anti-IgM, anti-IgM +anti-CD40, or LPS become highly energetic and upregulate both OXPHOS and glycolytic pathways. However, B cells stimulated with anti-CD40 alone remain metabolically quiescent like control non-stimulated B cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We used the protonophore trifluoromethoxy carbonylcyanide phenylhydrazone (FCCP) to dissipate the mitochondrial membrane potential and calculate the maximal respiratory capacity of B cells. Consistent with results obtained for basal OCR, stimulated B cells showed a robust increase in maximal respiratory capacity except for cells stimulated with anti-CD40 alone (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Both total mitochondrial content and membrane potential measured with MitoTracker Green and TMRE staining, respectively, were substantially increased following anti-IgM, anti-IgM +anti-CD40, or LPS stimulation while both parameters were only slightly increased with stimulation with anti-CD40 alone (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). While previous studies suggested that Orai1 regulates the majority of SOCE in primary B cells (<xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref>; <xref ref-type="bibr" rid="bib37">McCarl et al., 2010</xref>), the expression of different Orai isoforms both at rest and upon B cell activation is unknown. Utilizing the same five experimental conditions described above, we analyzed the mRNA expression of <italic>Orai1</italic>, <italic>Orai2</italic>, and <italic>Orai3</italic> following 24 hr of stimulation. Stimulation with either anti-IgM or anti-IgM +anti-CD40 dramatically increased <italic>Orai1</italic> expression, while the magnitude of this change following anti-CD40 or LPS stimulation was smaller and did not reach statistical significance (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Interestingly, stimulation conditions that strongly increased mitochondrial respiration (anti-IgM, anti-IgM +anti-CD40, LPS) all significantly reduced expression of <italic>Orai2</italic> while stimulation with anti-CD40 alone had no significant effect on <italic>Orai2</italic> expression (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). The expression of Orai3 has significantly increased only with anti-IgM +anti-CD40 or LPS stimulation, but not with anti-IgM or anti-CD40 alone (<xref ref-type="fig" rid="fig1">Figure 1I</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>B cell activation dynamically regulates Orai channel expression.</title><p>(<bold>A</bold>) Measurement of oxygen consumption rate (OCR) in primary B lymphocytes following 24 hr stimulation with anti-IgM (20 μg/mL), anti-CD40 (10 μg/mL), anti-IgM +anti-CD40, or LPS (10 μg/mL) using the Seahorse Mito Stress Test (n=3 biological replicates). (<bold>B</bold>) Energy map of maximal OCR and extracellular acidification rate (ECAR) following the addition of the protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). (<bold>C, D</bold>) Quantification of basal (<bold>C</bold>) and maximal (<bold>D</bold>) respiration from Seahorse traces in (<bold>A</bold>) (One-way ANOVA with multiple comparisons to Unstimulated). (<bold>E, F</bold>) Measurement of (<bold>E</bold>) total mitochondrial content with the fluorescent dye MitoTracker Green and (<bold>F</bold>) mitochondrial membrane potential with TMRE following 24 hr stimulation (n=3 biological replicates; One-way ANOVA with multiple comparisons to Unstimulated). (<bold>G–I</bold>) Quantitative RT-PCR of (<bold>G</bold>) <italic>Orai1</italic>, (<bold>H</bold>) <italic>Orai2</italic>, and (<bold>I</bold>) <italic>Orai3</italic> mRNA following 24 hr of stimulation with the stimuli indicated (n=3 biological replicates; one-way ANOVA with multiple comparisons to Unstimulated). All scatter plots and Seahorse traces are presented as mean ± SEM. For all figures, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>Both Orai3 and Orai1 mediate SOCE in A20 B lymphoblasts</title><p>Robust activation of primary B cells with anti-IgM/anti-CD40 co-stimulation resulted in upregulation of both <italic>Orai1</italic> and <italic>Orai3</italic> mRNA with downregulation of <italic>Orai2</italic> (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>). We, therefore, reasoned that B cells may sustain long-term cytosolic Ca<sup>2+</sup> signals through Orai1 and/or Orai3, while downregulation of Orai2 might relieve the inhibition of native CRAC channels, as recently demonstrated for activated T cells (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>). To gain insights into the molecular composition of CRAC channels in B cells, we first developed an in vitro system utilizing the mouse A20 B lymphoblast cell line to generate single and double Orai1 and Orai3 knockout cell lines with CRISPR/Cas9 technology. Two guide RNA (gRNA) sequences were utilized to cut at the beginning and end of the coding region of mouse <italic>Orai1</italic> and <italic>Orai3</italic> (<italic>mOrai1</italic> and <italic>mOrai3</italic>), effectively excising the entirety of the genomic DNA for each <italic>Orai</italic> gene (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We generated multiple A20 clones that were lacking Orai1 and Orai3 individually and in combination and these knockout clones were validated through genomic DNA sequencing (<xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>) and the absence of <italic>Orai1</italic> or <italic>Orai3</italic> transcripts by qPCR (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). We measured SOCE in A20 cells after passive store depletion with thapsigargin, an inhibitor of the sarcoplasmic/endoplasmic reticulum ATPase (SERCA). A20 cells lacking Orai1 demonstrated a large reduction in maximal SOCE by ~62%, while in cells lacking Orai3 SOCE was reduced by ~28% (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). Importantly, the combined deletion of both Orai1 and Orai3 caused a near abrogation of SOCE by ~91% (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). Furthermore, measurements of cytosolic Ca<sup>2+</sup> oscillations induced by anti-IgG stimulation demonstrated that the oscillation frequency was substantially reduced with combined Orai1/Orai3 knockout, while only slightly reduced with the loss of either Orai1 or Orai3 individually (<xref ref-type="fig" rid="fig2">Figure 2G–K</xref>). These data suggest that both Orai3 and Orai1 were involved in optimal CRAC channel function in A20 B lymphoblasts. These data are consistent with the function of Orai channels in other cell types. Indeed, we recently utilized a series of single, double, and triple Orai CRISPR/Cas9 knockout HEK293 cell lines and showed that SOCE, but not Orai1, is required for agonist-induced Ca<sup>2+</sup> oscillations (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>). Under conditions of physiological agonist stimulation that causes modest ER store depletion while eliciting Ca<sup>2+</sup> oscillations, Orai2 and Orai3 were sufficient to maintain cytosolic Ca<sup>2+</sup> oscillations, while having relatively minor contributions to SOCE induced by maximal store depletion (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Orai1 and Orai3 mediate the bulk of store-operated Ca2+ entry (SOCE) in A20 B lymphoblasts.</title><p>(<bold>A</bold>) Cartoon schematic of the two gRNA CRISPR strategies we used to excise mouse <italic>Orai1</italic> and <italic>Orai3</italic> genes. (<bold>B–D</bold>) Quantitative RT-PCR of (<bold>B</bold>) <italic>Orai1</italic>, (<bold>C</bold>) <italic>Orai2</italic>, and (<bold>D</bold>) <italic>Orai3</italic> mRNA in A20 Orai CRISPR clones (n=3 biological replicates). (<bold>E</bold>) Measurement of SOCE with Fura2 upon store depletion with 2 µM thapsigargin in 0 mM Ca<sup>2+</sup> followed by re-addition of 2 mM Ca<sup>2+</sup> to the external bath solution. (<bold>F</bold>) Quantification of peak SOCE in (<bold>E</bold>) (from left to right n=99, 100, 89, and 98 cells; Kruskal-Wallis test with multiple comparisons to WT A20). (<bold>G–J</bold>) Representative Ca<sup>2+</sup> oscillation traces from 5 cells/condition measured with Fura2 upon stimulation with 10 μg/mL anti-IgG antibodies at 60 s (indicated by arrows) in the presence of 2 mM external Ca<sup>2+</sup>. (<bold>K</bold>) Quantification of total oscillations in 9 min from (<bold>G–J</bold>) (from left to right n=76, 79, 79, and 78 cells; Kruskal-Wallis test with multiple comparisons to WT A20). All scatter plots are presented as mean ± SEM. For all figures, *p&lt;0.05; **p&lt;0.01; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title>Orai1 is dispensable for cytosolic Ca<sup>2+</sup> oscillations in primary B cells</title><p>To determine the contribution of Orai1-mediated Ca<sup>2+</sup> signals to primary B cell function, we generated B cell-specific Orai1 knockout (<italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup>) mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Compared to <italic>Orai1<sup>fl/fl</sup></italic> controls, the average surface expression of Orai1 was significantly reduced on B220<sup>+</sup> B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<italic><sup>/+</sup></italic> mice by~70% (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). The residual signal of ~30% above FMO (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) is likely the result of the non-specific binding of the Orai1 antibody by its variable region to other Orai homologs (Orai2, Orai3), which partially share the peptide epitope recognized by the anti-Orai1 antibody. This residual Orai1 antibody signal is consistent with previous studies showing that Cre-mediated deletion of Orai1<sup>fl/fl</sup> alleles is very efficient in other cell types including T cells (<xref ref-type="bibr" rid="bib28">Kaufmann et al., 2016</xref>), and neuronal progenitor cells (<xref ref-type="bibr" rid="bib48">Somasundaram et al., 2014</xref>). Indeed, other lines of evidence indicate that Orai1 is deleted in B cells of <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice: our qPCR data show that B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice showed a near abrogation of <italic>Orai1</italic> mRNA (to ~3% of control) compared to Mb1-Cre<sup>/+</sup> control mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) without any significant change in <italic>Orai2</italic> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) or <italic>Orai3</italic> (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) mRNA expression. Further, Ca<sup>2+</sup> measurements demonstrated that SOCE is reduced by ~69% in B cells isolated from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). We measured cytosolic Ca<sup>2+</sup> oscillations in response to anti-IgM stimulation in the presence of 1 mM extracellular Ca<sup>2+</sup>. In agreement with previous reports and consistent with our data with A20 B lymphoblasts (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>), Orai1-deficient B cells display a comparable frequency of agonist-induced Ca<sup>2+</sup> oscillations as control B cells (<xref ref-type="fig" rid="fig3">Figure 3H–J</xref>). Thus, while Orai1 knockout significantly decreased SOCE in primary B cells, it is dispensable for maintaining Ca<sup>2+</sup> oscillations in response to physiological agonist stimulation. In control Mb1-Cre<sup>/+</sup> mice, Orai1 expression was comparable between B220<sup>+</sup> B cells and CD8<sup>+</sup> T cells, with CD4<sup>+</sup> T cells showing a slightly lower signal (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref> ). After 24 hour stimulation of control B cells under the five conditions described above, Orai1-deficient B cells showed no apparent defects in activation as the expression of MHC-II was comparable to control B cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C–E</xref>), while expression of CD86 was slightly reduced with anti-IgM stimulation or anti-IgM +anti-CD40 co-stimulation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F–H</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Orai1 is dispensable for BCR-induced Ca<sup>2+</sup> oscillations in primary B cells.</title><p>(<bold>A</bold>) Representative flow cytometry histogram of B cells isolated from <italic>Orai1<sup>fl/fl</sup></italic> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. Splenocytes from naïve <italic>Orai1<sup>fl/fl</sup></italic> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice were fixed, permeabilized, and stained with rabbit anti-Orai1 polyclonal antibody (YZ6856, epitope: human ORAI1#275–291 intra-cellular C-terminal, cross-reacts with the mouse). The numbers inside the panel represent the mean fluorescence intensity (MFI) for the Orai1 antibody staining for each sample. (<bold>B</bold>) Quantification of Orai1 MFI minus fluorescence minus one (FMO) in B cells is shown. (n=4 biological replicates; unpaired T-test). (<bold>C–E</bold>) Quantitative RT-PCR of (<bold>C</bold>) <italic>Orai1</italic>, (<bold>D</bold>) <italic>Orai2</italic>, and (<bold>E</bold>) <italic>Orai3</italic> mRNA in isolated B cells (n=6 biological replicates for each; Mann-Whitney test). (<bold>F</bold>) Measurement of SOCE with Fura2 upon store depletion with 2 µM thapsigargin in 0 mM Ca<sup>2+</sup> followed by re-addition of 1 mM Ca<sup>2+</sup> to the external bath solution. (<bold>G</bold>) Quantification of peak store-operated Ca2+ entry (SOCE) in (<bold>F</bold>) n=169 and 178 cells; Mann-Whitney test. (<bold>H–I</bold>) Representative Ca<sup>2+</sup> oscillation traces from 5 cells/condition measured with Fura2 upon stimulation with 20 μg/mL anti-IgM antibodies at 1 min (indicated by arrows) in the presence of 1 mM external Ca<sup>2+</sup>. (<bold>J</bold>) Quantification of total oscillations in 9 min from (<bold>I, J</bold>) (n=97 and 111 cells; Mann-Whitney test). All scatter plots are presented as mean ± SEM. For all figures, **p&lt;0.01; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source Data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Loss of Orai1 does not overtly affect B cell activation.</title><p>(<bold>A</bold>) Representative histograms of Orai1 fluorescence gated on B220<sup>+</sup> B cells, CD3<sup>+</sup>CD4<sup>+</sup> T cells, and CD3<sup>+</sup>CD8<sup>+</sup> T cells from Mb1-Cre<sup>/+</sup> mice. (<bold>B</bold>) Quantification of Orai1 mean fluorescence intensity (MFI) from each condition shown in (<bold>A</bold>) (n=8 biological replicates for each; one-way ANOVA). (<bold>C–D</bold>) Flow cytometry histograms of MHC-II expression on isolated B cells from (<bold>C</bold>) Mb1-Cre<sup>/+</sup> and (<bold>D</bold>) <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice following 24 hr stimulation. (<bold>E</bold>) Quantification of MHC-II MFI from (<bold>C–D</bold>) (n=3 biological replicates for each; Mann-Whitney test). (<bold>F–G</bold>) Histograms of CD86 expression following 24 hr stimulation. (<bold>H</bold>) Quantification of CD86 MFI from (<bold>F–G</bold>) (n=3 biological replicates for each; Mann-Whitney test). All scatter plots are presented as mean ± SEM. For all figures, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ns, not significant.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig3-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Loss of Orai1 does not alter B cell development</title><p>While patients and mouse models with loss of function (LoF) mutations in <italic>Orai1</italic> present with severe immunodeficiency due to impaired T cell function, the development of most immune cell populations is largely unaltered, suggesting SOCE is dispensable for initial immune cell selection and development (<xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref>; <xref ref-type="bibr" rid="bib31">Lacruz and Feske, 2015</xref>; <xref ref-type="bibr" rid="bib37">McCarl et al., 2010</xref>). We evaluated B cell development within the bone marrow and spleen of <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In agreement with previous reports that investigated B cell development in global <italic>Orai1</italic> deficient mice, the development of early B cell progenitors in fractions A-F within the bone marrow were unaltered in <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). Similarly, we observed no significant differences in peripheral transitional type 1 (T1), T2, and T3 immature B cells in the spleen (<xref ref-type="fig" rid="fig4">Figure 4D and F</xref>). Mature B cell populations in the spleen are predominately follicular B cells with a smaller fraction of marginal zone B cells, and these ratios were largely comparable between control and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Orai1 is dispensable for B cell development.</title><p>(<bold>A–B</bold>) Flow cytometric analysis of bone marrow populations for B cell fractions A (B220<sup>+</sup>CD43<sup>+</sup>HSA<sup>−</sup>BP-1<sup>−</sup>), B (B220<sup>+</sup>CD43<sup>+</sup>HSA<sup>+</sup>BP-1<sup>−</sup>), C (B220<sup>+</sup>CD43<sup>+</sup>HSA<sup>+</sup>BP-1<sup>+</sup>), D (B220<sup>+</sup>CD43<sup>−</sup>IgM<sup>−</sup>CD93<sup>+</sup>), E (B220<sup>+</sup>CD43<sup>−</sup>IgM<sup>+</sup>CD93<sup>+</sup>), and F (B220<sup>+</sup>CD43<sup>−</sup>IgM<sup>+</sup>CD93<sup>−</sup>). (<bold>C</bold>) Quantification of bone marrow populations in (<bold>A, B</bold>) (n=7 and six biological replicates; Mann-Whitney test). (<bold>D</bold>) Flow cytometric analysis of isolated populations in the spleen for B cell developmental stages T1 (B220<sup>+</sup>AA4.1<sup>+</sup>CD23<sup>−</sup>IgM<sup>+</sup>), T2 (B220<sup>+</sup>AA4.1<sup>+</sup>CD23<sup>+</sup>IgM<sup>+</sup>), and T3 (B220<sup>+</sup>AA4.1<sup>+</sup>CD23<sup>+</sup>IgM<sup>−</sup>). (<bold>E</bold>) Flow cytometric analysis of isolated populations in the spleen for marginal zone (MZ) B cells (B220<sup>+</sup>CD93<sup>−</sup>CD23<sup>−</sup>IgM<sup>+</sup>) and follicular (FO) B cells (B220<sup>+</sup>CD93<sup>−</sup>CD23<sup>+</sup>IgM<sup>+</sup>). (<bold>F</bold>) Quantification of splenic populations in (<bold>D, E</bold>) (n=7 and six biological replicates; Mann-Whitney test). All scatter plots are presented as mean ± SEM.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>Both Orai3 and Orai1 synergistically contribute to SOCE in primary B cells</title><p>To determine whether Orai3 regulates Ca<sup>2+</sup> signals and function of primary B cells, we generated B cell-specific Orai3 knockout mice (<italic>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup>) and B cell-specific double Orai1/Orai3 knockout mice (<italic>Orai1</italic>/<italic>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup>). Primary B cells isolated from spleens of Orai1, Orai3, and Orai1/Orai3 knockout mice showed near complete ablation of their respective <italic>Orai</italic> isoform mRNA (to ~0.3–4% of control) with no compensatory changes in <italic>Orai2</italic> mRNA expression (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). As documented above (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>), depletion of ER Ca<sup>2+</sup> stores with thapsigargin demonstrated that SOCE was significantly reduced in Orai1 knockout B cells (by ~69%), and this remaining Ca<sup>2+</sup> entry was further reduced in Orai1/Orai3 double knockout B cells (by ~83%; <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). However, SOCE in single Orai3 knockout B cells was ~102% of control, which was not significantly different from control B cells.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Orai1 and Orai3 synergistically mediate store-operated Ca2+ entry (SOCE) in primary B cells.</title><p>(<bold>A</bold>) Quantitative RT-PCR of <italic>Orai1</italic>, <italic>Orai2</italic>, and <italic>Orai3</italic> mRNA in negatively isolated B cells from B cell-specific Orai knockout mice (n=3 biological replicates per genotype). (<bold>B</bold>) Measurement of SOCE in naïve B cells with Fura2 upon store depletion with 2 µM thapsigargin in 0 mM Ca<sup>2+</sup> followed by re-addition of 1 mM Ca<sup>2+</sup> to the external bath solution. Subsequently, SOCE was inhibited with the addition of 50 µM 2-APB at 13 min followed by 5 µM Gd<sup>3+</sup> at 18 min. (<bold>C</bold>) Quantification of peak SOCE in (<bold>B</bold>) (from left to right n=200, 200, 199, and 149 cells; Kruskal-Wallis test with multiple comparisons to Mb1-Cre<sup>/+</sup>). (<bold>D</bold>) Quantification of the rate of 2-APB inhibition from 13 to 18 min. (<bold>E</bold>) Quantitative RT-PCR of <italic>Orai1</italic>, <italic>Orai2</italic>, and <italic>Orai3</italic> mRNA in negatively isolated B cells from wild-type and Orai2<sup>-/-</sup> mice (n=3 and six biological replicates). (<bold>F</bold>) Measurement of SOCE in naïve B cells with Fura2 from wild-type and <italic>Orai2<sup>-/-</sup></italic> mice. (<bold>G</bold>) Quantification of peak SOCE in (<bold>F</bold>) (n=147 and 240 cells; Mann-Whitney test). All scatter plots are presented as mean ± SEM. For all figures, ***p&lt;0.001; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Store-operated Ca2+ entry (SOCE) in B cells activated for 48 hr with Anti-IgM +Anti CD40.</title><p>(<bold>A</bold>) Measurement of SOCE in B cells stimulated for 48 hr with anti-IgM +anti-CD40. (<bold>B</bold>) Quantification of peak SOCE in (<bold>A</bold>) (from left to right n=287, 288, 290, and 172 cells; Kruskal-Wallis test with multiple comparisons to Mb1-Cre<sup>/+</sup>). (<bold>C</bold>) Quantification of the rate of 2-APB inhibition from (<bold>A</bold>). All scatter plots are presented as mean ± SEM. For all figures, ***p&lt;0.001; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig5-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Orai channel isoforms demonstrate distinct pharmacological profiles and sensitivities to various CRAC channel modifiers (<xref ref-type="bibr" rid="bib7">Bird and Putney, 2018</xref>; <xref ref-type="bibr" rid="bib74">Zhang et al., 2020</xref>). One of the most extensively utilized CRAC channel modifiers is 2-aminoethyl diphenyl borate (2-APB) (<xref ref-type="bibr" rid="bib41">Prakriya and Lewis, 2001</xref>), which at high (25–50 µM) concentrations strongly inhibits Orai1, partially inhibits Orai2, and potentiates Orai3 channel activity (<xref ref-type="bibr" rid="bib10">DeHaven et al., 2008</xref>; <xref ref-type="bibr" rid="bib68">Zhang et al., 2008</xref>; <xref ref-type="bibr" rid="bib74">Zhang et al., 2020</xref>). After allowing Ca<sup>2+</sup> entry to the plateau, 50 µM 2-APB was added, followed by the addition of 5 µM gadolinium (Gd<sup>3+</sup>) which potently blocks all Orai isoforms (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>; <xref ref-type="bibr" rid="bib74">Zhang et al., 2020</xref>). In wild-type B cells, 2-APB led to a gradual inhibition of SOCE over the course of 5 min, which completely returned to baseline following the addition of Gd<sup>3+</sup>. Interestingly, the remaining SOCE in Orai1 knockout B cells showed essentially no inhibition by 2-APB but was strongly inhibited by Gd<sup>3+</sup>. The lack of effect of 2-APB is likely due to the residual SOCE mediated by the remaining Orai3 isoform, which is resistant to inhibition by 2-APB. Furthermore, SOCE in Orai3 knockout B cells was inhibited at a significantly faster rate by 2-APB compared to wild-type B cells and was not further inhibited by Gd<sup>3+</sup> (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>). The small amount of SOCE remaining in Orai1/Orai3 double knockout cells was reduced to baseline following the addition of 2-APB. This remaining SOCE in Orai1/Orai3 double knockout B cells prompted us to measure SOCE in B cells isolated from global Orai2 knockout mice (<italic>Orai2<sup>-/-</sup></italic>). B cells from <italic>Orai2<sup>-/-</sup></italic> mice showed complete loss of <italic>Orai2</italic> mRNA with no apparent compensation in <italic>Orai1</italic> or <italic>Orai3</italic> mRNA (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). SOCE stimulated by thapsigargin in B cells from <italic>Orai2<sup>-/-</sup></italic> mice was enhanced by comparison to B cells from wild-type littermate controls (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>), suggesting that, as was shown in T cells (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>), Orai2 is also a negative regulator of SOCE in B cells. Thus, these experiments indicate that the remaining SOCE in B cells from Orai3/Orai1 double knockout mice is most likely mediated by Orai2.</p><p>Given the modulation of Orai channel isoforms in response to B cell activation, we performed Ca<sup>2+</sup> imaging recordings, similar to those in <xref ref-type="fig" rid="fig5">Figure 5</xref>, on primary B cells that were first activated for 48 hr with anti-IgM +anti-CD40 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). While similar trends were observed in experiments with naïve primary B cells, several exceptions were notable. SOCE in Orai3 knockout B cells was reduced compared to control cells, like data in A20 Orai knockout cell lines (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, B</xref> ). Differences in inhibition by 50 µM 2-APB also became less pronounced between control and Orai3 knockout cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–C</xref>). Collectively, these data demonstrate that Orai3 contributes to SOCE in activated B cells.</p></sec><sec id="s2-6"><title>SOCE is an essential regulator of NFAT activation in B cells</title><p>Ca<sup>2+</sup> entry through CRAC channels is critical for the activation of multiple NFAT isoforms (<xref ref-type="bibr" rid="bib42">Prakriya and Lewis, 2015</xref>; <xref ref-type="bibr" rid="bib54">Trebak and Kinet, 2019</xref>; <xref ref-type="bibr" rid="bib59">Vaeth and Feske, 2018</xref>). NFAT nuclear translocation mostly requires Ca<sup>2+</sup> entry through native Orai1, while native Orai2 and Orai3 caused marginal NFAT activation in cells lacking Orai1 despite mediating a Ca<sup>2+</sup> signal (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>). To determine the role of Orai1 in regulating NFAT1 activation in B cells, primary B cells from control Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice were stimulated with anti-IgM antibodies and native NFAT1 nuclear translocation was evaluated using ImageStream analysis (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). In unstimulated B cells, colocalization of endogenous NFAT1 with nuclear DAPI staining was relatively low, and this colocalization increased three-fold following anti-IgM stimulation (<xref ref-type="fig" rid="fig6">Figure 6A–C</xref>). However, this anti-IgM mediated NFAT1 translocation was significantly reduced in B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Orai1 is a regulator of nuclear factor of activated T cells (NFAT) activation in naïve and activated B cells.</title><p>(<bold>A</bold>) Representative Imagestream images following intracellular staining for NFAT1 and DAPI in naïve B cells from Mb1-Cre<sup>/+</sup> mice before and after 20 μg/mL anti-IgM stimulation for 15 min. Merge image indicates similarity score co-localization between NFAT1/DAPI. (<bold>B</bold>) Histograms of NFAT1/DAPI similarity scores before (black trace) and after (red trace) anti-IgM stimulation in naïve B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. (<bold>C</bold>) Quantification of similarity scores following anti-IgM stimulation in (<bold>B</bold>) (n=3 biological replicates for each; unpaired T-test). (<bold>D</bold>) Western blot analysis of NFAT1 and α-tubulin in naïve B cells isolated from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. B cells were left unstimulated or treated with 2 µM thapsigargin (Tg) for 15 min before harvesting. (<bold>E</bold>) Quantification of NFAT1 dephosphorylation in (<bold>D</bold>) (n=4 biological replicates for each; Mann-Whitney test). (<bold>F</bold>) Western blot analysis of NFAT1 and α-tubulin in B cells stimulated for 48 hr with anti-IgM +anti-CD40. (<bold>G</bold>) Quantification of NFAT1 dephosphorylation in (<bold>F</bold>) (n=3 biological replicates for each; Mann-Whitney test). All scatter plots are presented as mean ± SEM. For all figures, *p&lt;0.05; **p&lt;0.01; ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig6">Figure 6</xref> including labeled blots for NFAT1 and α-tubulin from <xref ref-type="fig" rid="fig6">Figure 6D</xref> and <xref ref-type="fig" rid="fig6">Figure 6F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Panel D and F-Raw unedited uncropped blots for NFAT1 and α-tubulin from <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig6-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Nuclear factor of activated T cells (NFAT) activation in primary Orai1/Orai3-deficient B cells.</title><p>(<bold>A</bold>) Western blot analysis of NFAT1, NFAT2, and α-tubulin in naïve B cells isolated from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. B cells were either unstimulated or treated with 20 μg/mL anti-IgM or 2 µM thapsigargin (Tg) for 15 min before harvesting. (<bold>B</bold>) Western blot analysis of NFAT1 in naïve B cells isolated from Mb1-Cre<sup>/+</sup>, <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup>, <italic>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+,</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice following thapsigargin treatment. (<bold>C</bold>) Same as in (<bold>B</bold>) but with B cells stimulated for 48 hr with anti-IgM +anti-CD40.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Labeled western blots for NFAT1, NFAT2, and α-tubulin from <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig6-figsupp1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Raw unedited uncropped blots for NFAT1, NFAT2, and α-tubulin from <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig6-figsupp1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We used another complimentary biochemical protocol to assess the nuclear translocation of native NFAT1 in response to stimulation with thapsigargin. After B cell stimulation, proteins were harvested and processed for Western blotting using a specific NFAT1 antibody (<xref ref-type="fig" rid="fig6">Figure 6D–G</xref>). In unstimulated samples, NFAT1 appears as a single band corresponding to its highly phosphorylated, non-activated state (<xref ref-type="fig" rid="fig6">Figure 6D and F</xref>). Stimulation of naïve B cells with thapsigargin, which completely empties ER stores and maximally activates SOCE, led to a complete shift of the phosphorylated single band into lower molecular weight bands (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>, <italic>left</italic>) and this shift in NFAT1 molecular weight was inhibited by 43.6% in Orai1-deficient B cells (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>, <italic>right</italic>). Given the dynamic expression of each Orai isoform following B cell activation (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>), we also evaluated NFAT1 activation in B cells stimulated for 48 hr with anti-IgM +anti-CD40. While thapsigargin stimulation also led to a complete shift in NFAT1 molecular weight in activated control B cells, this shift was reduced by 78% in activated B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6F and G</xref>). Similar results were obtained when we analyzed NFAT2 isoform dephosphorylation in naïve B cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Furthermore, when naïve B cells were stimulated with anti-IgM (instead of thapsigargin), we observed similar trends of NFAT1 and NFAT2 dephosphorylation, although this dephosphorylation was not as robust as with thapsigargin (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Nevertheless, this anti-IgM mediated dephosphorylation of NFAT1 and NFAT2 was inhibited in B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Our findings that B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice have maintained BCR-induced Ca<sup>2+</sup> oscillations with defects in NFAT activation is in agreement with previous studies in HEK293 cells showing that NFAT activation depends mostly on native Orai1 (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>). In these studies, intact Ca<sup>2+</sup> oscillations in Orai1 knockout cells were mediated by Orai2/3, yet NFAT nuclear translocation was largely reduced (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>).</p><p>We also evaluated NFAT1 activation in response to thapsigargin in both naïve B cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>) and activated B cells (48 hr with anti-IgM +anti-CD40; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>) isolated from either <italic>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> or <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. Loss of Orai3 alone from naïve B cells had no effect on NFAT1 activation, while naïve B cells isolated from double Orai1/Orai3 knockout cells showed reductions in NFAT1 activation comparable to B cell isolated from single Orai1 knockout mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Importantly, this impairment of NFAT1 activation was further exacerbated in activated B cells isolated from Orai1 knockout and Orai1/Orai3 double knockout mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Collectively, these data reveal that Orai1 plays a more prominent role in the activation of NFAT isoforms in activated B cells compared to naïve cells.</p></sec><sec id="s2-7"><title>The combined deletion of Orai3 and Orai1 inhibits B cell proliferation</title><p>BCR-induced Ca<sup>2+</sup> signals that are sustained through SOCE are critical for the activation of gene programs that regulate proliferation and apoptosis (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). Interestingly, suboptimal proliferation and survival of B cells in response to BCR stimulation can largely be rescued through the addition of secondary co-stimulatory signals (e.g. CD40 or TLR stimulation) (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Tang et al., 2017</xref>). To understand how Ca<sup>2+</sup> signals downstream of Orai isoforms regulate B cell expansion, primary B cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cell divisions tracked in response to multiple conditions of stimulation (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). BCR stimulation with anti-IgM alone resulted in multiple rounds of cell division in most wild-type cells (87.7%) with 28.6% of viable cells at 72 hr post-stimulation (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>, <italic>black</italic>). B cell viability at 72 hr was dramatically increased to 67.4% when cells were co-stimulated with anti-IgM +anti-CD40, with an increase in the number of cells undergoing several cycles of cell division. Following anti-IgM stimulation Orai1-deficient B cells showed a similar percentage of proliferating cells (83.1%) as controls, with a moderate reduction in cell viability to 20.9% (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>, <italic>red</italic>). While anti-IgM mediated proliferation of Orai3-deficient B cells was comparable to controls (90.3%), their viability was higher, at 34.8% (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>, <italic>blue</italic>). The combined deletion of Orai1 and Orai3 resulted in a substantial reduction in the percentage of both viable (10%) and proliferating (60.8%) cells in response to anti-IgM stimulation (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>, <italic>teal</italic>). These defects in survival and proliferation of Orai1/Orai3-deficient B cells were partially rescued when cells were co-stimulated with anti-IgM +anti-CD40, albeit to a lesser extent than control and single Orai knockout B cells. Similar percentages of viability and proliferation were observed in all experimental groups when B cells were stimulated with either anti-CD40 or LPS, suggesting that activation of the toll-like receptor 4 (TLR4) signaling pathway is able to compensate for the loss of Orai1/Orai3. We also analyzed the proliferation and survival of B cells isolated from Orai2<sup>-/-</sup> mice and their wildtype littermates exposed to the same stimuli. We found only marginal or no effects of Orai2 knockout on B cell proliferation and survival (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A, B</xref>). Furthermore, we performed RNA sequencing on B cells isolated from control Mb1-Cre<sup>/+</sup> and <italic>Orai3</italic>/<italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice after stimulation with anti-IgM for 24 hr (<xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>) and differential expression analysis was performed with edgeR (<xref ref-type="supplementary-material" rid="sdata3">Source data 3</xref>). Based on the edgeR output, GSEA software was applied to perform, we performed pathway analyses using gene set enrichment analysis (GSEA) (<xref ref-type="supplementary-material" rid="sdata4">Source data 4</xref>). In agreement with our proliferation and survival data, GSEA showed significant downregulation of pathways that govern survival and cell cycle progression in Orai1/Orai3-deficient B cells (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>). Together, these findings reveal that only loss of both Orai1 and Orai3 affects B cell survival and proliferation in response to anti-IgM stimulation while single knockout of either Orai1 or Orai3 had marginal effects.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Orai1 and Orai3 regulate B cell proliferation and survival.</title><p>(<bold>A</bold>) Measurement of B cell proliferation by tracking cabroxyfluorescein diacetate succinimidyl ester (CFSE) dilution. B lymphocytes from control, Orai1, Orai3, and Orai1/Orai3 knockout mice were loaded with CFSE (3 μM) and stimulated with anti-IgM (20 μg/mL), anti-CD40 (10 μg/mL), anti-IgM +anti-CD40, or LPS (10 μg/mL). CFSE dilution was determined 72 hr after stimulation for all conditions. (<bold>B</bold>) Quantification of the percentage of proliferating cells for each condition in (<bold>A</bold>) (from left to right n=9, 8, 4, and 4 biological replicates; one-way ANOVA with multiple comparisons to Mb1-Cre<sup>/+</sup>). CFSE dilution gate is drawn relative to unstimulated controls. (<bold>C</bold>) Quantification of the percentage of viable cells for each condition in (<bold>A</bold>) as determined by a Live/Dead viability dye (from left to right n=9, 8, 4, and 4 biological replicates; one-way ANOVA with multiple comparisons to Mb1-Cre<sup>/+</sup>). (<bold>D</bold>) Top KEGG pathways showing differential expression from RNA-sequencing analysis of B cells from Mb1-Cre<sup>/+</sup> vs <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice stimulated for 24 hr with anti-IgM (20 μg/mL) (n=3 biological replicates for each). (<bold>E</bold>) Gene set enrichment analysis (GSEA) plots show enrichment statistics (ES) in the Hallmark G2M Checkpoint, E2F Targets, and Cell Cycle gene sets. Large positive ES values suggest activation of these pathways. Normalized enrichment score (NES) values are used to assess statistical significance, and the results for these gene sets are highly significant. All scatter plots are presented as mean ± SEM. For all figures, **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Loss of Orai2 does not alter primary B cell proliferation or viability.</title><p>(<bold>A</bold>) Quantification of B cell proliferation by tracking cabroxyfluorescein diacetate succinimidyl ester (CFSE) dilution. B lymphocytes from wild-type and <italic>Orai2<sup>-/-</sup></italic> mice were loaded with CFSE (3 μM) and stimulated with a titration of anti-IgM antibodies, anti-CD40 (10 μg/mL), anti-IgM +anti-CD40, or LPS (10 μg/mL). CFSE dilution was determined 72 hr after stimulation for all conditions (n=3 biological replicates for each; unpaired T-test). (<bold>B</bold>) Quantification of the percentage of viable cells for each condition in (<bold>A</bold>) as determined by a Live/Dead viability dye (n=3 biological replicates for each; unpaired T-test). All scatter plots are presented as mean ± SEM. For all figures, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ns, not significant.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig7-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig7-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-8"><title>The combined deletion of Orai3 and Orai1 inhibits B cell metabolism</title><p>Metabolic reprogramming results in dramatically enhanced OXPHOS and remodeling of the mitochondrial network (<xref ref-type="bibr" rid="bib2">Akkaya et al., 2018</xref>; <xref ref-type="bibr" rid="bib63">Waters et al., 2018</xref>). Indeed, GSEA of B cells stimulated for 24 hr with anti-IgM identified the Oxidative Phosphorylation gene set as one of the most highly enriched pathways relative to unstimulated controls (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Additionally, anti-IgM stimulated B cells to demonstrate a significant increase in the total number of mitochondria per cell compared to naïve B cells as determined by transmission electron microscopy (TEM; <xref ref-type="fig" rid="fig8">Figure 8B and C</xref>). However, this increase in mitochondrial mass triggered by B cell activation was not affected by the depletion of Orai1 from B cells, as determined by Mitotracker Green staining (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). We measured OCR and ECAR in B cells isolated from control and B cell-specific Orai knockout mice after B cell stimulation with anti-IgM for 24 hr (<xref ref-type="fig" rid="fig8">Figure 8E</xref>). Anti-IgM stimulation of wild-type B cells led to a robust increase in both OCR and ECAR (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). Furthermore, Anti-IgM stimulation led to an increase in both basal and maximal respiration of wild-type B cells (<xref ref-type="fig" rid="fig8">Figure 8E–H</xref>). The increase in OCR and ECAR following BCR activation was significantly blunted in Orai1-deficient B cells, and further reduced in Orai1/Orai3-deficient B cells (<xref ref-type="fig" rid="fig8">Figure 8E–H</xref>). Interestingly, GSEA analysis showed that anti-IgM mediated enrichment of the Oxidative Phosphorylation gene set and Myc targets gene set were specifically inhibited in B cells from <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice, but not in B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>). However, the glycolysis gene set was inhibited in B cells from both <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>). Loss of Orai3 alone only partially reduced glycolytic flux and basal respiration but did not affect maximal respiration (<xref ref-type="fig" rid="fig8">Figure 8E–H</xref>). Previous research has shown that loss of SOCE in the chicken DT40 B cell line impaired mitochondrial metabolism by reducing CREB-mediated expression of the mitochondrial calcium uniporter (MCU) (<xref ref-type="bibr" rid="bib46">Shanmughapriya et al., 2015</xref>). We observed no differences in CREB phosphorylation on Ser133 (a surrogate for CREB activation) or MCU expression in primary Orai1-deficient B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). Likewise, we observed no differences in MCU expression in mouse A20 B cells lacking either Orai1, Orai3, or both Orai1 and Orai3 (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>). Both naïve and activated (24 hr with anti-IgM) B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice showed no obvious changes in the expression of different components of the electron transport chain (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C, D</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Orai1 and Orai3 regulate B cell mitochondrial respiration.</title><p>(<bold>A</bold>) Gene set enrichment analysis (GSEA) of the KEGG Oxidative Phosphorylation gene set in B cells stimulated for 24 hr with anti-IgM (20 μg/mL) relative to unstimulated controls. (<bold>B</bold>) Representative transmission electron microscopy (TEM) images of B cells from Mb1-Cre<sup>/+</sup> mice. Shown are naïve, unstimulated B cells (top) and B cells stimulated for 24 hr with anti-IgM (bottom). (<bold>C</bold>) Quantification of total mitochondria per cell in unstimulated B cells and B cells stimulated for 24 hr with anti-IgM (n=25 for each; Mann-Whitney test). (<bold>D</bold>) Measurement of total mitochondrial content with MitoTracker Green in B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice following 24 hr stimulation (n=3 biological replicates for each; Mann-Whitney test). (<bold>E</bold>) Measurement of oxygen consumption rate (OCR) in primary B lymphocytes following 24 hr stimulation with anti-IgM (20 μg/mL) using the Seahorse Mito Stress Test. (<bold>F</bold>) Energy map of maximal oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) following carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) addition. (<bold>G, H</bold>) Quantification of basal (<bold>G</bold>) and maximal (<bold>H</bold>) respiration from Seahorse traces in (<bold>E</bold>) (n=4 biological replicates for each genotype; one-way ANOVA with multiple comparisons to Mb1-Cre<sup>/+</sup>). All scatter plots and Seahorse traces are presented as mean ± SEM. For all figures, **p&lt;0.01; ****p&lt;0.0001; ns, not significant.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source data for GSEA summary statistics for <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig8-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig8sdata2"><label>Figure 8—source data 2.</label><caption><title>Source data for <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig8-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Loss of Orai1 does not alter CREB phosphorylation, MCU expression, or expression of electron transport chain proteins.</title><p>(<bold>A</bold>) Western blot analysis of total and phosphorylated CREB (S133), MCU, and GAPDH in isolated B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. B cells were either unstimulated or stimulated with anti-IgM (20 μg/mL) for 10, 20, or 30 min before harvesting. (<bold>B</bold>) Western blot analysis of MCU and GAPDH protein in single Orai1, and Orai3 knockout and double Orai1/Orai3 knockout A20 cell clones. (<bold>C, D</bold>) Western blot analysis of electron transport chain components in B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice either (<bold>C</bold>) unstimulated or (<bold>D</bold>) stimulated with anti-IgM for 24 hr.</p><p><supplementary-material id="fig8s1sdata1"><label>Figure 8—figure supplement 1—source data 1.</label><caption><title>Labeled western blots for <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig8-figsupp1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata2"><label>Figure 8—figure supplement 1—source data 2.</label><caption><title>Raw unedited uncropped blots for GAPDH and MCU from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata3"><label>Figure 8—figure supplement 1—source data 3.</label><caption><title>Raw unedited uncropped blots for Phospho-CREB (pCREB) from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata4"><label>Figure 8—figure supplement 1—source data 4.</label><caption><title>Raw unedited uncropped blots for MCU and GAPDH from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata5"><label>Figure 8—figure supplement 1—source data 5.</label><caption><title>Raw unedited uncropped blots for electron transport chain (ETC) proteins from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data5-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata6"><label>Figure 8—figure supplement 1—source data 6.</label><caption><title>Raw unedited uncropped blots for GAPDH from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data6-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig8s1sdata7"><label>Figure 8—figure supplement 1—source data 7.</label><caption><title>Raw unedited uncropped blots for electron transport chain (ETC) proteins and GAPDH from <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84708-fig8-figsupp1-data7-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig8-figsupp1-v2.tif"/></fig></fig-group><p>To further investigate how Orai-mediated Ca<sup>2+</sup> signaling regulates B cell metabolism, we profiled polar metabolites utilizing liquid chromatography followed by mass spectrometry in control and Orai1/Orai3-deficient B cells (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Isolated B cells from each genotype were either unstimulated or stimulated for 24 hr with anti-IgM alone, anti-IgM +anti-CD40, anti-IgM +the calcineurin inhibitor FK506, or anti-IgM +the CRAC channel inhibitor GSK-7975A. We utilized GSK-7975A as we recently demonstrated that this compound inhibited all Orai isoforms compared to differential effects on Orai isoforms with other common SOCE inhibitors like Synta66 (<xref ref-type="bibr" rid="bib74">Zhang et al., 2020</xref>). Stimulation of control B cells with anti-IgM led to a significant increase of glycolytic and TCA cycle metabolites along with most non-essential amino acids. This effect was further enhanced with anti-IgM +anti-CD40 co-stimulation (<xref ref-type="fig" rid="fig9">Figure 9A</xref>; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). Inclusion of FK506 or GSK-7975A strongly blunted the effects of anti-IgM activation as overall metabolic profiles remained like those of unstimulated cells (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). Importantly, this upregulation in polar metabolites upon B cell activation was significantly reduced in Orai1/Orai3-deficient B cells with either anti-IgM stimulation or anti-IgM +anti-CD40 co-stimulation (<xref ref-type="fig" rid="fig9">Figure 9B and C</xref>; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>). Of note, upregulation of most polar metabolites from Orai1/Orai3 knockout B cells co-stimulated with anti-IgM +anti-CD40 typically reached levels comparable to those of control B cells stimulated with anti-IgM alone. The inhibitory effects of FK506 and GSK-7975A on the metabolite status of wildtype B cells were comparable to those of Orai1/Orai3-deficient B cells (<xref ref-type="fig" rid="fig9">Figure 9A</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). Collectively, these results reveal that SOCE mediated through Orai1/Orai3 channels contributes to the metabolic reprogramming of B lymphocytes.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Orai1/Orai3-mediated SOCE-calcineurin-NFAT pathway regulates B cell metabolism.</title><p>(<bold>A</bold>) Analysis of polar metabolites in B cells from Mb1-Cre<sup>/+</sup> mice utilizing liquid chromatography followed by mass spectrometry. B cells were either unstimulated or stimulated for 24 hr with anti-IgM, anti-IgM +anti-CD40, anti-IgM with 1 µM FK506, or anti-IgM with 10 µM GSK-7975A. (<bold>B, C</bold>). Heat maps of statistically significant polar metabolites in B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice following (<bold>B</bold>) 24 hr anti-IgM stimulation or (<bold>C</bold>) 24 hr anti-IgM +anti-CD40 stimulation. (n=3 biological replicates for each condition).</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig9">Figure 9</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig9-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Polar metabolite analysis in Orai1/Orai3 deficient-B cells.</title><p>(<bold>A</bold>) Analysis of polar metabolites in B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup>. B cells were either unstimulated or stimulated for 24 hr with anti-IgM, anti-IgM +anti-CD40, anti-IgM +1 µM FK506, or anti-IgM +10 µM GSK-7975A. Profiling was performed on B cells from 3 mice per group. (<bold>B</bold>) Heat maps of statistically significant amino acids and nucleotide precursors in B cells from Mb1-Cre<sup>/+</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice following anti-IgM stimulation for 24 hr.</p><p><supplementary-material id="fig9s1sdata1"><label>Figure 9—figure supplement 1—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig9-figsupp1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig9-figsupp1-v2.tif"/></fig></fig-group><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Deletion of <italic>Orai1</italic> and <italic>Orai3</italic> in B cells does not compromise immunity to influenza A virus (IAV).</title><p>(<bold>A</bold>) Experimental outline. Littermate controls and <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice have infected intranasally with 1x10<sup>5</sup> TCID<sub>50</sub> of the x31 H3N2 strain of influenza A virus. Serum was collected on days 9 and 14, and mice were sacrificed on day 14 for analysis. (<bold>B</bold>) Representative H&amp;E stains of lung sections. Scale bar: 500 µm. (<bold>C</bold>) Alveolar volume fraction of 10 mice per cohort. (<bold>D</bold>) Representative flow cytometry plots of B cells isolated from mediastinal lymph nodes (med LN). (<bold>E</bold>) Summary of the frequencies (%) and total cell numbers of B220<sup>–</sup>CD138<sup>+</sup> plasma cells and Fas<sup>+</sup>GL-7<sup>+</sup> GC B cells shown in panel D from 10 mice per cohort. (<bold>F</bold>) Representative flow cytometry plots of plasma cells isolated from the bone marrow of five IAV-infected mice per cohort. (<bold>G</bold>) Representative flow cytometry plots (left) and summary (right) of the frequencies of class-switched IgG1<sup>+</sup> GC B cells in med LN of five IAV-infected mice per cohort. (<bold>H</bold>) IAV-specific IgM and IgG levels in the serum of 10 mice per cohort were measured on days 9 and 14. Panels B-H show the results of two independent experiments. Statistical analysis by unpaired Student’s t-test: ***p&lt;0.001, **p&lt;0.01, *p&lt;0.05.</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>Source data for <xref ref-type="fig" rid="fig10">Figure 10</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84708-fig10-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig10-v2.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Cytokine profiling of B cells from <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice.</title><p>(<bold>A–D</bold>) Heatmap display of genes comprising the KEGG Cytokine/Cytokine Receptor Interaction gene set from 24 hr anti-IgM stimulated B cells isolated from Mb1-Cre<sup>/+</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. Each column represents B cells isolated from an individual mouse from the respective genotype.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84708-fig10-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-9"><title>Immunity to influenza A virus is intact in mice with B cell-specific deletion of Orai1 and Orai3</title><p>Given the important role of Orai1 and Orai3 for multiple B cell functions in vitro, we hypothesized that deletion of <italic>Orai1</italic> and <italic>Orai3</italic> affects the B cell cytokine profile and compromises immune responses to influenza A virus (IAV) infection. Profiling of B cell cytokines and cytokine receptors by RNA-sequencing of B cells from <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> and littermate control mice stimulated ex vivo with anti-IgM showed no obvious differences between the two groups (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1C–D</xref>). To evaluate the role of Orai1/Orai3 for B cell function and humoral immunity in vivo, we infected <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice and <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> littermate controls intranasally with a single dose of the laboratory strain A/HK/x31 (Hkx31, H3N2) (<xref ref-type="bibr" rid="bib51">Thomas et al., 2006</xref>) and analyzed immune responses 14 days later (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). All infected WT and <italic>Orai1/3</italic>-deficient mice survived and experienced a similar reduction in body weight over the two week-course of infection (not shown). Lung histology at day 14 post-infection (p.i.) showed comparable pulmonary inflammation and alveolar volume in <italic>Orai1/3</italic>-deficient and littermate control mice (<xref ref-type="fig" rid="fig10">Figure 10B and C</xref>). To directly investigate the effects of Orai1 and Orai3 on humoral immunity during IAV infection, we analyzed total B cells, germinal center (GC) B cells, and plasma cells in mice at day 14 p.i. The frequencies and numbers of B220<sup>–</sup>CD138<sup>+</sup> plasma cells and B220<sup>+</sup>Fas<sup>+</sup>GL-7<sup>+</sup> GC B cells were similar in the mediastinal lymph nodes of WT and <italic>Orai1/3</italic>-deficient mice (<xref ref-type="fig" rid="fig10">Figure 10D and E</xref>). Moreover, the numbers of CD138<sup>+</sup> plasma cells in the bone marrow of infected <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice were comparable to those in control littermate mice (<xref ref-type="fig" rid="fig10">Figure 10F</xref>). We next investigated if deletion of <italic>Orai1</italic> and <italic>Orai3</italic> in B cells affects their ability to induce class switch recombination. The percentages of class-switched IgG1<sup>+</sup> cells (and those of IgM<sup>–</sup>IgG<sup>–</sup> non-switched B cells) among GC B cells, however, were comparable in control and <italic>Orai1/3</italic>-deficient mice (<xref ref-type="fig" rid="fig10">Figure 10G</xref>). Consistent with these results, we found normal levels of IAV-specific IgM and class-switched IgG antibodies in the serum (<xref ref-type="fig" rid="fig10">Figure 10H</xref>). Taken together, our data show that B cell-specific deletion of <italic>Orai1</italic> and <italic>Orai3</italic> does not significantly impair immune responses to influenza A virus infection.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Given the essential role of B lymphocytes in driving humoral immunity against foreign pathogens, a comprehensive understanding of the molecular pathways that govern their development, differentiation, and effector functions is critical for future targeted therapies. One of the earliest signaling events upon crosslinking of the BCR is a biphasic increase in intracellular Ca<sup>2+</sup> concentrations (<xref ref-type="bibr" rid="bib4">Baba and Kurosaki, 2016</xref>). Early landmark studies established that multiple Ca<sup>2+</sup> dependent transcription factors display unique activation requirements by relying on either ER Ca<sup>2+</sup> release (e.g. JNK, NF-κB) or sustained Ca<sup>2+</sup> signals driven by SOCE (NFAT) (<xref ref-type="bibr" rid="bib11">Dolmetsch et al., 1997</xref>; <xref ref-type="bibr" rid="bib24">Healy et al., 1998</xref>). While the SOCE-calcineurin-NFAT pathway is well established in the context of B cell effector function, recent reports have shed light on the mechanisms by which SOCE also regulates NF-κB activation and its downstream target genes (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Berry et al., 2018</xref>). These two BCR-activated signaling pathways are sustained by Ca<sup>2+</sup> entry through CRAC channels and synergize with one another to activate a series of Ca<sup>2+</sup>-regulated checkpoints that determine B cell survival, entry into the cell cycle, and proliferation (<xref ref-type="bibr" rid="bib2">Akkaya et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>). Unlike recent findings that have established Orai1 and Orai2 as the major Orai isoforms mediating SOCE in T cells (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>), the relative contributions of Orai isoforms to the native CRAC channel in B cells remained, until now, unclear.</p><p>Our results herein establish that B cell activation through BCR stimulation alone or co-stimulation with secondary signals like CD40 or TLR ligands significantly enhanced metabolic activity. Concurrently, these stimulation conditions drive dynamic changes in the expression of each Orai isoform. Interestingly, we observe that robust B cell activation with BCR and CD40 co-stimulation results in upregulation of both <italic>Orai1</italic> and <italic>Orai3</italic>, and downregulation of <italic>Orai2</italic>. However, we do not see any apparent increase in SOCE in activated B cells versus naive B cells, suggesting that Orai1 and Orai3 upregulation in activated B cells helps maintain the magnitude of SOCE, commensurate with the enhanced volume of activated B cells. While Orai1 has previously been shown to contribute to the majority of SOCE in B cells under conditions of maximal ER Ca<sup>2+</sup> depletion (<xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref>; <xref ref-type="bibr" rid="bib37">McCarl et al., 2010</xref>), we show using B-cell specific Orai1 knockout mice that Orai1 is dispensable for maintaining cytosolic Ca<sup>2+</sup> oscillations in response to BCR crosslinking. In agreement with our previous results in HEK293 cells (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>), we also show that Orai1 is an essential regulator of NFAT1 and NFAT2 isoforms in B cells and that its role becomes more prominent for NFAT induction in activated B cells compared to naïve unstimulated B cells. By generating CRISPR/Cas9 B cell lines and B-cell specific knockout mice lacking Orai1 or Orai3 individually and in combination, we found that both Orai1 and Orai3 contribute to the native CRAC channels in B cells. However, the oligomeric state of native CRAC channels in B cells and whether Orai1 and Orai3 form homomeric or heteromeric assemblies or both in primary B cells remains an open question.</p><p>The combined loss of Orai1 and Orai3, but not either isoform alone, led to a significant reduction in both B cell proliferation and survival. The original study by Gwack et al showed a partial inhibition of proliferation in B cells from <italic>Orai1<sup>-/-</sup></italic> mice. While we observe only a marginal inhibition of proliferation in B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice and a moderate reduction in the viability of these cells. The reason for the difference between our results on B cell proliferation and those of <xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref> is unknown. However, one potential explanation could be that in B cells from <italic>Orai1<sup>-/-</sup></italic> mice in <xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref> Orai1 is deleted from early B cell development in mice on a mixed ICR background (note that <italic>Orai1<sup>-/-</sup></italic> mice on the C57BL/6 background show perinatal lethality) whereas in our <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice, Orai1 is deleted later in B cell development in mice that are on a pure C57Bl/6 background. Another potential explanation could be the complete deletion of the Orai1 gene in the studies of <xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref> vs the 97% reduction in mRNA expression we observe in B cells from <italic>Orai1<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice.</p><p>We show that SOCE is important for the metabolic reprogramming of B cells by regulating mitochondrial metabolism and the flux of polar metabolites in response to B cell activation. This shift in metabolic profiles in response to B cell activation could be neutralized by inhibition of either calcineurin or CRAC channels with FK506 or GSK-7975A, respectively, suggesting that this metabolic flux is driven through SOCE and NFAT-dependent mechanisms. Our data demonstrate that both Orai1 and Orai3 contribute to CRAC channel activity and to shaping cytosolic Ca<sup>2+</sup> signaling in B cells. While our data has provided evidence for the contribution of Orai3 to CRAC channels in naïve B cells, this contribution was only apparent within the context of double Orai1 and Orai3 knockout. Our data with B cell-specific Orai3 knockout is consistent with a recent study reporting a lack of SOCE inhibition in B cells, T cells, and macrophages from Orai3 global knockout mice (<xref ref-type="bibr" rid="bib62">Wang et al., 2022</xref>). Our data and the study of <xref ref-type="bibr" rid="bib62">Wang et al., 2022</xref>, showed that Orai3 is highly expressed in B cells compared to other immune cells like T cells. Nevertheless, Orai3 knockout, on its own, has no measurable contribution to SOCE in naïve B cells while moderately reducing SOCE in activated B cells. This reduced SOCE in activated B cells from Orai3 knockout mice is consistent with the reduced basal respiration of B cells stimulated with anti-IgM for 24 hr. This could also explain why the double knockout of Orai1 and Orai3, which inhibits SOCE more dramatically, has a larger effect on mitochondrial respiration and metabolomic reprogramming of B cells. Alternatively, it is possible that Orai3 couples to alternative cytosolic signaling pathways that synergize with SOCE-mediated Ca<sup>2+</sup> influx. Orai3 could mediate its effects on mitochondrial respiration through the store-independent Ca<sup>2+</sup> influx pathway activated by arachidonic acid or its metabolite, leukotrieneC<sub>4</sub> (<xref ref-type="bibr" rid="bib52">Thompson et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Zhang et al., 2013</xref>; <xref ref-type="bibr" rid="bib72">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Zhang et al., 2014</xref>). Earlier studies investigating human effector T cells demonstrated that Orai3 becomes upregulated in response to oxidative stress, which may act as a potential mechanism to maintain a threshold of Ca<sup>2+</sup> influx and T cell function in various inflammatory conditions (<xref ref-type="bibr" rid="bib8">Bogeski et al., 2010</xref>). In support of this model, new findings have demonstrated that Orai3 expression is increased in CD4<sup>+</sup> T cells from patients with rheumatoid arthritis and psoriatic arthritis and that silencing of Orai3 reduces tissue inflammation in a human synovium adoptive transfer model (<xref ref-type="bibr" rid="bib64">Ye et al., 2021</xref>). Interestingly, these effects were proposed to be through the store-independent function of Orai3 (<xref ref-type="bibr" rid="bib52">Thompson et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Zhang et al., 2013</xref>; <xref ref-type="bibr" rid="bib72">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Zhang et al., 2014</xref>). However, a recent study showed that Orai3 deficient mice have no altered susceptibility in a model of collagen-induced arthritis (<xref ref-type="bibr" rid="bib62">Wang et al., 2022</xref>), challenging a role for Orai3, on its own, in the immune system.</p><p>The situation in T cells is different as the combined loss of Orai1 and Orai2 in murine T cells led to a near complete ablation of SOCE and substantially impaired T cell function (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>). Whether Orai3 contributes to the small, residual amount of SOCE in Orai1/Orai2-deficient T cells and/or mediates store-independent signaling functions in murine T and B cells is unknown. Furthermore, differences in Orai channel contributions are apparent between mice and humans, as SOCE and CRAC currents are completely inhibited in T cells from patients with LoF mutations in <italic>Orai1</italic>, while SOCE is only partially inhibited in Orai1-deficient murine T cells (<xref ref-type="bibr" rid="bib20">Feske et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Lian et al., 2018</xref>; <xref ref-type="bibr" rid="bib36">McCarl et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Vig et al., 2008</xref>). Curiously, B cells from <italic>Orai1</italic> LoF mutation patients still retain residual SOCE, suggesting that another Orai isoform may contribute to SOCE in human B cells than in T cells (<xref ref-type="bibr" rid="bib19">Feske et al., 2001</xref>), in agreement with our data herein on mouse B cells. Thus, the composition of native CRAC channels among lymphocytes appears cell-type and context-specific.</p><p>While SOCE is substantially reduced in Orai1/Orai3-deficient B cells, defects in their ability to proliferate and survive in response to antigenic stimulation are not as severe as the phenotype observed in STIM1/STIM2-deficient B cells (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). Our data establish additivity between Orai1 and Orai3 channels in controlling B cell survival and proliferation, but we cannot exclude a potential role for Orai2 in the regulation of SOCE in B cells. Quite the opposite, we show that Orai2 is functional in B cells by documenting that B cells from Orai2<sup>-/-</sup> mice have enhanced SOCE. This suggests that Orai2 acts as a negative regulator of SOCE in B cells as was shown for T cells (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>), mast cells (<xref ref-type="bibr" rid="bib55">Tsvilovskyy et al., 2018</xref>), and HEK293 cells (<xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>), and that the remaining SOCE activity in B cells from Orai1/Orai3 double knockout mice is likely mediated by Orai2. This is consistent with our results showing that the SOCE inhibitor GSK-7975A inhibits the upregulation of polar metabolites by B cells, in response to anti-IgM +anti-CD40 stimulation, to a greater extent than Orai1/Orai3 double knockout. Therefore, the development of Orai triple knockout mice and additional Orai knockout pairs is needed to further clarify this issue. Similarly, how SOCE and the composition of the native CRAC channel vary among different B cell subsets and during pathological conditions is completely unknown. Indeed, earlier studies have demonstrated that effector populations like germinal center B cells display unique metabolic and Ca<sup>2+</sup> signaling requirements (<xref ref-type="bibr" rid="bib29">Khalil et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Luo et al., 2018</xref>). Our data also suggest that the expression of each Orai isoform is dynamic in response to B cell activation, similar to the case of naïve vs effector T cells (<xref ref-type="bibr" rid="bib58">Vaeth et al., 2017b</xref>).</p><p>Considering the clear effects of B cell-specific deletion of Orai1 and Orai3 on SOCE, NFAT activation, metabolic reprogramming, survival, and proliferation, it was surprising that humoral immunity to influenza A virus (IAV) infection was unaffected in <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice. This raises the question regarding the role of Orai1, Orai3, and SOCE in general for B cell function and humoral immunity in vivo. Our results are, however, consistent with those from B cell-specific deletion of <italic>Stim1</italic> and <italic>Stim2</italic> genes, which was shown to result in abolished SOCE causing impaired expression of two key anti-apoptotic genes and blunted activation of the mTORC1 and c-Myc metabolic signaling pathways, resulting in decreased B cell survival and proliferation (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>). While this study did not investigate the effects of <italic>Stim1</italic>/<italic>Stim2</italic> deletion on B cell function in vivo, Baba and colleagues had reported normal B cell development as well as T-dependent and T-independent antibody responses following immunization of mice with B cell-specific deletion of <italic>Stim1</italic> and <italic>Stim2</italic> genes (<xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). This was surprising, because <italic>Stim1</italic>/<italic>Stim2</italic> deletion almost completely abolished thapsigargin and anti-IgM induced SOCE, and strongly impaired B cell survival and proliferation in vitro (<xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). A potential explanation for the normal humoral immune responses in <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> and <italic>Stim1<sup>fl/fl</sup>Stim2<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice is provided by the fact that, in contrast to anti-IgM stimulation, stimulation of <italic>Stim1/Stim2</italic>-deficient B cells <italic>via</italic> CD40 or TLR4 results in normal B cell survival and proliferation (<xref ref-type="bibr" rid="bib35">Matsumoto et al., 2011</xref>). When combined with anti-IgM stimulation, CD40 was able to rescue the proliferation defect of <italic>Stim1/Stim2</italic>-deficient B cells. A similar rescue of defective B cell proliferation by CD40 and TLR9 agonists in <italic>Stim1/Stim2</italic>-deficient B cells was reported by Berry at al. (<xref ref-type="bibr" rid="bib6">Berry et al., 2020</xref>). Our data with <italic>Orai1/Orai3</italic>-deficient B cells show only a partial rescue of B cell proliferation by anti-IgM and anti-CD40 co-stimulation compared to anti-IgM alone. We did, however, observe normal B cell survival and proliferation in <italic>Orai1/Orai3</italic>-deficient B cells stimulated with the TLR4 agonist LPS. Collectively, these data demonstrate that co-stimulatory pathways such as CD40, TLR4, and TLR9 can bypass the requirement for BCR-induced SOCE to induce B cell activation. IAV is a dsRNA virus that is detected by TLR7 in plasmacytoid dendritic cells and B cells (<xref ref-type="bibr" rid="bib27">Iwasaki and Pillai, 2014</xref>). TLR7 is widely expressed in B cells and antibody responses to IAV were shown to depend on TLR7 (<xref ref-type="bibr" rid="bib22">Geeraedts et al., 2008</xref>). Although we did not investigate if TLR7 stimulation with synthetic agonists such as imiquimod can rescue the proliferation and survival defects of <italic>Orai1/Orai3</italic>-deficient B cells in vitro, we speculate that it would, given the fact that TLR7 and TLR4, whose activation by LPS rescues the function of <italic>Stim1/Stim2</italic> and <italic>Orai1/Orai3</italic>-deficient B cells, signal through the same Myd88-IRAK4-TRAF6 pathway to activate NF-κB and other transcription factors (<xref ref-type="bibr" rid="bib12">Duan et al., 2022</xref>). Activation of TLR7 and potentially other costimulatory pathways, in <italic>Orai1/Orai3</italic>-deficient B cells is, therefore, a likely explanation for their normal humoral immune response to IAV in vivo. Although Ca<sup>2+</sup> and SOCE are clearly important for B cell function, B cells have developed other Ca<sup>2+</sup>-independent means to ensure their proper activation. Future studies with <italic>Orai1<sup>fl/fl</sup>Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice might reveal indispensable in vivo contributions of SOCE to B cell populations such as memory B cells or to immune disease in other in vivo models such as the experimental autoimmune encephalomyelitis (EAE) mouse model. Taken together, our results uncover additive functions of Orai3 and Orai1 in B cell Ca<sup>2+</sup> signaling that regulates NFAT activation, metabolism, survival, and proliferation of B cells.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Mice</title><p>All animal experiments were carried out in compliance with the Institutional Animal Care and use Committee (IACUC) guidelines of the Pennsylvania State University College of Medicine. All mice were housed under specific pathogen-free conditions and experiments were performed in accordance with protocols approved by the IACUC of the Pennsylvania State University College of Medicine. Mb1-Cre mice (<xref ref-type="bibr" rid="bib26">Hobeika et al., 2006</xref>) were obtained from The Jackson Laboratory (strain#: 020505; <ext-link ext-link-type="uri" xlink:href="https://www.jax.org/strain/020505">https://www.jax.org/strain/020505</ext-link>). <italic>Orai1<sup>fl/fl</sup></italic> mice (<xref ref-type="bibr" rid="bib1">Ahuja et al., 2017</xref>) were obtained from Dr. Paul Worley (Johns Hopkins University). <italic>Orai3<sup>fl/fl</sup></italic> mice were generated by our laboratory through the MMRC at the University of California Davis. A trapping cassette was generated including ‘SA-βgeo-pA’ (splice acceptor-beta-geo-polyA) flanked by Flp-recombinase target ‘FRT’ sites, followed by a critical <italic>Orai3</italic> coding exon flanked by Cre-recombinase target ‘loxP’ sites. This cassette was inserted within an intron upstream of the <italic>Orai3</italic> critical exon, where it tags the <italic>Orai3</italic> gene with the lacZ reporter. This creates a constitutive null <italic>Orai3</italic> mutation in the target <italic>Orai3</italic> gene through efficient splicing to the reporter cassette resulting in the truncation of the endogenous transcript. Mice carrying this allele were bred with FLP deleter C57BL/6 N mice to generate the <italic>Orai3<sup>fl/fl</sup></italic> mouse. All experiments were performed with 8–12 week-old age and sex-matched mice.</p></sec><sec id="s4-2"><title>Cell culture</title><p>Parental A20 cells were purchased from ATCC (Catalog # TIB-208) and cultured in RPMI 1640 with L-glutamine supplemented with 10% fetal bovine serum and 1 X Antibiotic-Antimycotic and were routinely tested for lack of mycoplasma contamination (<xref ref-type="bibr" rid="bib17">Emrich et al., 2022a</xref>). Naïve splenic B lymphocytes were purified by negative selection using the EasySep Mouse B Cell Isolation Kit (STEMCELL Technologies). Primary B cells from each transgenic mouse line were cultured in RPMI 1640 with L-glutamine supplemented with 10% fetal bovine serum, 1 X GlutaMAX, 1 X Penicillin-Streptomycin Solution, sodium pyruvate (1 mM), 2-ME (5 uM), and HEPES (10 mM). Primary lymphocytes were stimulated with F(ab')₂ Fragment Goat Anti-Mouse IgM antibody (Jackson ImmunoResearch, 20 µg/mL), anti-mouse CD40 antibody (BioXCell, 10 µg/mL), or LPS (Sigma-Aldrich, 10 µg/mL). All cell lines and primary lymphocytes were cultured at 37 °C in a humidified incubator with 5% CO<sub>2</sub>.</p></sec><sec id="s4-3"><title>Generation of A20 Orai CRISPR/Cas9 knockout cells</title><p>For the generation of A20 Orai knockout clones, we used a similar strategy to our previous studies (<xref ref-type="bibr" rid="bib16">Emrich et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Yoast et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Yoast et al., 2020b</xref>; <xref ref-type="bibr" rid="bib73">Zhang et al., 2019</xref>). Briefly, two gRNAs targeting the beginning and end of the mouse <italic>Orai1</italic> or <italic>Orai3</italic> coding region were cloned into two fluorescent vectors (pSpCas9(BB)–2A-GFP and pU6-(BbsI)_CBh-Cas9-T2AmCherry; Addgene). For <italic>mOrai1</italic> knockout, the gRNA sequences are the following: mOrai1n: <named-content content-type="sequence">5’-GCCTTCGGATCCGGTGCGTC-3’</named-content>; mOrai1c: <named-content content-type="sequence">5’-CACAGGCCGTCCTCCGGACT-3’</named-content>. For <italic>mOrai3</italic> knockout, the gRNA sequences are the following: mOrai3n: <named-content content-type="sequence">5’- GCGTCCGTAACTGTTCCCGC-3’</named-content>; mOrai3c: <named-content content-type="sequence">5- GAAGGAGGTCTGTCGATCCC-3’</named-content>. A20 cells were electroporated with both N- and C-terminal gRNA combinations with an Amaxa Nucleofector II and single cells with high GFP and mCherry expression were sorted at one cell per well into 96-well plates 24 hr after transfection using a FACS Aria SORP Cell Sorter. Individual clones were obtained and genomic DNA was tested using primers targeting the N- and C-terminal gRNA cut sites to resolve wild-type and knockout PCR products. Knockout PCR products were cloned into pSC-B-amp/kan with the StrataClone Blunt PCR Cloning Kit (Agilent) and Sanger sequenced to determine the exact deletion. Knockout clones were also confirmed for the absence of mRNA with qRT-PCR and functionally through Ca<sup>2+</sup> imaging experiments.</p></sec><sec id="s4-4"><title>Fluorescence imaging</title><p>A20 cell lines and primary B cells were seeded onto poly-L-lysine (Sigma-Aldrich) coated coverslips. Coverslips were mounted in Attofluor cell chambers (Thermo Scientific) and loaded with 2 µM Fura-2AM (Molecular Probes) in a HEPES-buffered saline solution (HBSS) containing 120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 20 mM HEPES, 10 mM D-glucose, at pH 7.4 for 30 min at room temperature. Following Fura-2 loading, cells were washed three times with HBSS and mounted on a Leica DMi8 fluorescence microscope. Fura-2 fluorescence was measured every 2 s by excitation at 340 nm and 380 nm using a fast shutter wheel and the emission at 510 nm was collected through a 40 X fluorescence objective. Fluorescence data was collected from individual cells on a pixel-by-pixel basis and processed using Leica Application Suite X. All cytosolic Ca<sup>2+</sup> concentrations are presented as the ratio of F<sub>340</sub>/F<sub>380</sub>.</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>Spleens were processed into single-cell suspensions and stained using the following antibodies: B220-BV605 (RA3-6B2, Biolegend), CD86-PE/Cy5 (GL-1, Biolegend), MHC-II-PE/Cy7 (M5/114.15.2, Biolegend), Orai1 rabbit polyclonal (<xref ref-type="bibr" rid="bib23">Gwack et al., 2008</xref>; <xref ref-type="bibr" rid="bib36">McCarl et al., 2009</xref>), CD3e-PE (145–2 C11, BD Biosciences), CD8a-V500 (53–6.7, BD Biosciences), CD4-BB700 (RM4-5, BD Biosciences), APC–anti-CD24 (HSA; M1/69), FITC–anti-CD23 (B3B4), PE–anti-IgM (eB121-15F9, eBioscience), APC–anti-CD93 (AA4.1, eBioscience), PE–Cy5-streptavidin (Biolegend), and Pacific blue–anti-B220 (RA3-6B2, Biolegend). All staining was performed in FACS buffer (DPBS, 2% FBS, 1 mM EDTA) for 30 min at 4 °C. Prior to surface staining, all cells were stained with eBioscience Fixable Viability Dye eFluor 780 (Thermo Fisher) and anti-CD16/32 Fc block (2.4G2, Tonbo Biosciences). Measurement of mitochondrial content was performed using MitoTracker Green (Molecular Probes) and mitochondrial membrane potential was performed using TMRE (Molecular Probes). For all CFSE dilution experiments, primary B lymphocytes were stained with 3 µM CFSE (C1157, Thermo Fischer) in PBS with 5% FBS for 5 min at room temperature, followed by the addition of FBS and two washes in PBS before resuspension in complete RPMI media. CFSE dilution of labeled cells was assessed 72 hr after plating and stimulation. All flow cytometry data were collected on a BD LSR II flow cytometer using FACSDiva software (BD Biosciences) and analyzed with FlowJo 9.9.6 software (Tree Star).</p></sec><sec id="s4-6"><title>Analysis of NFAT nuclear translocation</title><p>Primary B cells were purified using the EasySep Mouse B Cell Isolation Kit (STEMCELL Technologies) and stimulated with anti-IgM (20 µg/mL) for 15 min at room temperature in complete RPMI media. Cells were fixed and permeabilized using the Foxp3 /Transcription Factor Staining Buffer Set (eBioscience) following the manufacturer’s instructions. Cells were stained in 1 X permeabilization buffer for 1 hr at room temperature with NFAT1-Alexa Fluor 488 (D43B1, Cell Signaling Technology). Nuclei were stained with DAPI prior to acquisition on an Amnis ImageStream X Mark II Imaging Flow Cytometer and analyzed with IDEAS software using the ‘‘Nuclear Localization’’ feature (EMD Millipore).</p></sec><sec id="s4-7"><title>Western blot analysis</title><p>A20 and primary B lymphocytes were harvested from the culture and lysed for 10 min in RIPA buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0; Sigma) containing 1 X Halt protease/phosphatase inhibitors (Thermo Scientific). Following lysis, samples were clarified by centrifugation at 15,000 × g for 10 min at 4°C. Supernatants were collected and protein concentration was determined using the Pierce Rapid Gold BCA Protein Assay Kit (Thermo Scientific). Equal concentrations of protein extract were loaded into 4–12% NuPAGE BisTris gels (Life Technologies) and transferred to PVDF membranes utilizing the Transblot Turbo Transfer System (Bio-Rad). Membranes were blocked for 1 hr at room temperature in Odyssey Blocking Buffer in TBS (LI-COR) and incubated overnight at 4°C with primary antibody. The following antibodies and dilutions were used: MCU (1:2000; 14997 S, Cell Signaling Technology), GAPDH (1:5000; MAB374, Sigma), Total OXPHOS Rodent Antibody Cocktail (1:1000, ab110413, Abcam), NFAT1 (1:1000, 4389 S, Cell Signaling Technology), NFAT2 (1:1000, 8032 S, Cell Signaling Technology), α-Tubulin (1:5000, 3873 S, Cell Signaling Technology), phospho-CREB (Ser133, 1:1000, 9198 S, Cell Signaling Technology), and CREB (1:1000, 9104 S, Cell Signaling Technology). Membranes were washed with TBST and incubated for 1 hr at room temperature with the following secondary antibodies: IRDye 680RD goat anti-mouse (1:10,000 LI-COR) or IRDye 800RD donkey anti-rabbit (1:10,000 LI-COR). Membranes were imaged on an Odyssey CLx Imaging System (LI-COR) and analysis was performed in Image Studio Lite version 5.2 (LI-COR) and ImageJ.</p></sec><sec id="s4-8"><title>Quantitative RT-PCR</title><p>Total mRNA was isolated from A20 cells and primary B lymphocytes using an RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. RNA concentrations were measured using a NanoDrop 2000 (Thermo Scientific) and 1 µg of DNAse I treated RNA was used with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA was amplified on a QuantStudio 3 Real-Time PCR System (Applied Biosystems) using PowerUp SYBR Green Master Mix (Applied Biosystems). PCR amplification was performed by initial activation for 2  min at 50°C, followed by a 95°C 2 min melt step. The initial melt steps were then followed by 40 cycles of 95°C for 15  s, 60°C for 15 s, and 72°C for 30 s. Data were analyzed with the instrument software v1.3.1 (Applied Biosystems) and analysis of each target was carried out using the comparative Ct method.</p></sec><sec id="s4-9"><title>Seahorse extracellular flux analysis</title><p>Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured using an XFe24 Extracellular Flux Analyzer (Seahorse Bioscience). A20 cells (0.8 × 10<sup>6</sup> per well) and primary B lymphocytes (2 × 10<sup>6</sup> per well) were resuspended in XF DMEM pH 7.4 media supplemented with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose (Mito Stress Test) and plated in poly-L-lysine coated microchamber wells. For the Mito Stress Test, 1.5 μM oligomycin, 2 μM FCCP, and 0.5 μM antimycin/rotenone were utilized. Data were analyzed using the Agilent Seahorse Wave Software and normalized to total protein context per well using the Pierce Rapid Gold BCA Protein Assay Kit (Thermo Scientific).</p></sec><sec id="s4-10"><title>Transmission electron microscopy</title><p>Primary B cells (unstimulated or 24 hr IgM stimulated) were seeded onto poly-L-lysine coated cell culture dishes and fixed with 1% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.3. After fixation, the cells were washed with 100 mM Tris (pH 7.2) and 160 mM sucrose for 30 mins. The cells were washed twice with phosphate buffer (150 mM NaCl, 5 mM KCl, 10 mM Na3PO4, pH 7.3) for 30 min, followed by treatment with 1% OsO4 in 140 mM Na3PO4 (pH 7.3) for 1 hr. The cells were washed twice with water and stained with saturated uranyl acetate for 1 hr, dehydrated in ethanol, and embedded in Epon (Electron Microscopy Sciences, Hatfield, PA). Roughly 60 nm sections were cut and stained with uranyl acetate and lead nitrate. The stained grids were analyzed using a Philips CM-12 electron microscope (FEI; Eindhoven, The Netherlands) and photographed with a Gatan Erlangshen ES1000W digital camera (Model 785, 4 k 3 2.7 k; Gatan, Pleasanton, CA).</p></sec><sec id="s4-11"><title>RNA sequencing and differential expression analysis</title><p>Total mRNA was isolated from primary B lymphocytes using an RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. RNA concentrations were quantitated using a NanoDrop 2000 (Thermo Scientific) and library preparation was performed by Novogene. A total amount of 1 µg RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext Ultra TM RNA Library Prep Kit for Illumina (NEB, USA) following the manufacturer’s recommendations, and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in NEBNext First-strand Synthesis Reaction Buffer (5 X). First-strand cDNA was synthesized using random hexamer primer and M-MuLV Reverse Transcriptase (RNase H-). Second-strand cDNA synthesis was subsequently performed using DNA Polymerase I and RNase H. Remaining overhangs were converted into blunt ends via exonuclease/polymerase activities. After adenylation of 3’ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure was ligated to prepare for hybridization. To select cDNA fragments of preferentially 150~200 bp in length, the library fragments were purified with AMPure XP system (Beckman Coulter, Beverly, USA). Then 3 µl USER Enzyme (NEB, USA) was used with size-selected, adaptor-ligated cDNA at 37°C for 15 min followed by 5 min at 95°C before PCR. Then PCR was performed with Phusion High-Fidelity DNA polymerase, Universal PCR primers, and Index (X) Primer. Lastly, PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using PE Cluster Kit cBot-HS (Illumina) according to the manufacturer’s instructions. After cluster generation, the library preparations were sequenced on an Illumina NovaSeq 6000 Platform (Illumina, San Diego, CA, USA) using a paired-end 150 run (2 × 150 bases).</p></sec><sec id="s4-12"><title>Differential expression analysis</title><p>Ensembl gene identifiers were converted to gene symbols, and identifiers with duplicated or missing gene symbols were removed from the analysis. Exploratory analyses were performed on the gene-level read count data, and lowly expressed genes were removed from the data set. The EDASeq R package (<xref ref-type="bibr" rid="bib43">Risso et al., 2011</xref>) was used to create a SeqExpressionSet object based on the read counts, then upper quantile normalization was applied. The RUVSeq R package (<xref ref-type="bibr" rid="bib43">Risso et al., 2011</xref>) was then applied using k=1 and a set of 14 mouse housekeeping genes identified by <xref ref-type="bibr" rid="bib25">Ho and Patrizi, 2021</xref> to identify factors of unwanted variation that were included as a covariate in the differential expression analysis performed with edgeR (<xref ref-type="bibr" rid="bib38">McCarthy et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Robinson et al., 2010</xref>). Differentially expressed genes were chosen based on a false discovery rate threshold of q&lt;0.05. R 4.0.5 was used for all analyses (<ext-link ext-link-type="uri" xlink:href="https://www.R-project.org">https://www.R-project.org</ext-link>).</p></sec><sec id="s4-13"><title>Gene set enrichment analysis (GSEA)</title><p>Based on the edgeR output, GSEA software was applied to perform pathway analyses (<xref ref-type="bibr" rid="bib39">Mootha et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Subramanian et al., 2005</xref>). The edgeR output includes likelihood ratio (LR) test statistics, p-values, and false discovery rate q-values, as well as log fold change (logFC) values based on the expression values of each gene in the comparison groups of interest. Because the LR statistics are non-negative, their values alone cannot distinguish up- and down-regulated genes, as is required for a GSEA pre-ranked analysis. Thus, we computed a signed version of the LR statistic that was defined to be the product of LR statistic times and the sign of the logFC, thereby enabling us to rank the genes according to both the statistical significance and the direction of the expression differences. A GSEA pre-ranked analysis was performed using the ranked genes and gene sets available at the Molecular Signature Database (<ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/msigdb/index.jsp">https://www.gsea-msigdb.org/gsea/msigdb/index.jsp</ext-link>). After the biomaRt R package (<xref ref-type="bibr" rid="bib13">Durinck et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Durinck et al., 2009</xref>) was used to convert mouse gene symbols to human gene symbols. Statistical significance was assessed at the q&lt;0.05 level.</p></sec><sec id="s4-14"><title>Metabolite profiling</title><sec id="s4-14-1"><title>Metabolite extraction</title><p>A metabolite extraction was carried out on each sample based on a previously described method (<xref ref-type="bibr" rid="bib40">Pacold et al., 2016</xref>). An approximate cell count (5 × 10<sup>6</sup> cells for all samples) of the samples was used to scale the metabolite extraction to a ratio of 1 × 10<sup>6</sup> cells/1 mL extraction solution [80% LCMS grade methanol (aq) with 500 nM labeled amino acid internal standard (Cambridge Isotope Laboratories, Inc, Cat No. MSK-A2-1.2)]. The lysis was carried out in two steps as follows. First, 1 mL of freezing extraction solution was added to the tubes containing each pellet. That suspension was transferred to tubes along with zirconium disruption beads (0.5 mm, RPI) and homogenized for 5 min at 4 °C in a BeadBlaster with a 30 s on/30 s off pattern. The resulting lysate was then diluted to a fixed concentration of 1 × 10<sup>6</sup> cells/1 mL in a new tube with disruption beads in that same buffer and then re-homogenized in the same way as above. The homogenate was centrifuged at 21,000 × g for 3 min, and 450 μL of the supernatant volume was transferred to a 1.5 mL microfuge tube for speed vacuum concentration, no heating. The dry extracts were resolubilized in 50 μL of LCMS grade water, sonicated in a water bath for 2 min, centrifuged as above, and transferred to a glass insert for analysis.</p></sec><sec id="s4-14-2"><title>LC-MS/MS methodology</title><p>Samples were subjected to an LC-MS/MS analysis to detect and quantify known peaks. The LC column was a Millipore ZIC-pHILIC (2.1 × 150 mm, 5 μm) coupled to a Dionex Ultimate 3000 system and the column oven temperature was set to 25 °C for the gradient elution. A flow rate of 100 μL/min was used with the following buffers; (A) 10 mM ammonium carbonate in water, pH 9.0, and (B) neat acetonitrile. The gradient profile was as follows; 80–20% B (0–30 min), 20–80% B (30–31 min), 80–80% B (31–42 min). Injection volume was set to 2 μL for all analyses (42 min total run time per injection). MS analyses were carried out by coupling the LC system to a Thermo Q Exactive HF mass spectrometer operating in heated electrospray ionization mode (HESI). Method duration was 30 min with a polarity switching data-dependent Top five method for both positive and negative modes. Spray voltage for both positive and negative modes was 3.5 kV and the capillary temperature was set to 320 °C with a sheath gas rate of 35, aux gas of 10, and max spray current of 100 μA. The full MS scan for both polarities utilized 120,000 resolution with an AGC target of 3 × 10<sup>6</sup> and a maximum IT of 100ms, and the scan range was from 67 to 1000 <italic>m</italic>/<italic>z</italic>. Tandem MS spectra for both positive and negative modes used a resolution of 15,000, AGC target of 1 × 10<sup>5</sup>, maximum IT of 50 ms, isolation window of 0.4 m/z, isolation offset of 0.1 m/z, fixed first mass of 50 m/z, and 3-way multiplexed normalized collision energies (nCE) of 10, 35, 80. The minimum AGC target was 1 × 10<sup>4</sup> with an intensity threshold of 2 × 10<sup>5</sup>. All data were acquired in profile mode.</p></sec><sec id="s4-14-3"><title>Data analysis</title><p>Metabolomics data were processed with an in-house pipeline for statistical analyses and plots were generated using a variety of custom Python code and R libraries including: heatmap, MetaboAnalystR, and manhattanly. Peak height intensities were extracted based on the established accurate mass and retention time for each metabolite as adapted from the Whitehead Institute and verified with authentic standards and/or high-resolution MS/MS manually curated against the NIST14MS/MS and METLIN spectral libraries. The theoretical m/z of the metabolite molecular ion was used with a±10 ppm mass tolerance window, and a±0.2 min peak apex retention time tolerance within the expected elution window (1–2 min). To account for sample-to-sample variance in the estimated cell counts, a sum-normalization step was carried out on a per-column (sample) basis. Detected metabolite intensities in a given sample were summed, and a percentage intensity was calculated for each metabolite (custom Rscript available from NYU Metabolomics Laboratory at <ext-link ext-link-type="uri" xlink:href="https://med.nyu.edu/research/scientific-cores-shared-resources/metabolomics-laboratory">https://med.nyu.edu/research/scientific-cores-shared-resources/metabolomics-laboratory</ext-link>, contact the Laboratory Director Dr. Drew Jones at: drew.jones@nyulangone.org). The median mass accuracy vs the theoretical m/z for the library was −0.7 ppm (n=90 detected metabolites). Median retention time range (time between earliest and latest eluting sample for a given metabolite) was 0.23 min (30 min LCMS method). A signal-to-noise ratio (S/N) of 3 X was used compared to blank controls throughout the sequence to report detection, with a floor of 10,000 (arbitrary units). Labeled amino acid internal standards in each sample were used to assess instrument performance (median CV=5%).</p></sec></sec><sec id="s4-15"><title>Influenza A virus (IAV) infection</title><p><italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> (control) mice were anesthetized with isoflurane and infected intranasally (i.n.) with 10<sup>5</sup> TCID<sub>50</sub> of the laboratory strain A/HK/x31 (x31-IAV) of the influenza A virus subtype H3N2. Lungs were isolated for histology. Mediastinal lymph nodes and bone marrow were used to prepare single-cell suspensions followed by flow cytometric analysis. Serum was harvested for analyzing virus-specific antibody titers.</p></sec><sec id="s4-16"><title>Histology</title><p>Lungs were fixed with 4% paraformaldehyde in PBS, embedded in paraffin, and cut at 5 μm. Sample slides were stained with hematoxylin and eosin (H&amp;E) using standard methods. Images were acquired using an SCN400 slide scanner (Leica), viewed with Omero Slidepath (Open Microscope Environment). The total alveolar volume fraction was determined using the following procedure: (i) regions representing empty space were acquired by setting a color threshold in ImageJ (<xref ref-type="bibr" rid="bib45">Schneider et al., 2012</xref>); (ii) to calculate the total alveolar volume fraction, the area of empty space was divided by the total lung area using MATLAB (v2018a).</p></sec><sec id="s4-17"><title>ELISA</title><p>To measure X31-specific antibodies, half-area ELISA plates (Corning, Cat#3690) were coated with heat-inactivated x31-IAV overnight at 4 °C. ELISA plates were blocked with 20% FBS in PBS at 37 °C for 1 hr followed by washing three times with wash buffer (0.05% v/v Tween-20 in PBS). Plates were incubated with gradient dilutions of serum from control and <italic>Orai1/Orai3<sup>fl/fl</sup></italic> Mb1-Cre<sup>/+</sup> mice for 1 hr at 37 °C followed by incubation with alkaline phosphatase (AP) goat anti-rabbit IgG secondary antibody (SouthernBiotech, Cat#1030–04), goat anti-rabbit IgM (SouthernBiotech, Cat#1021–04) at room temperature for 2 hr. After the addition of substrate solution, absorption was measured at 405 nm using a Flexstation three plate reader (Molecular Devices).</p></sec><sec id="s4-18"><title>Cell preparation of mediastinal lymph nodes and bone marrow</title><p>Single-cell suspensions of mediastinal lymph nodes (medLNs) and bone marrow were grounded and passed through 70 µm cell strainer (BD, 22-363-548). Cells were treated with ACK buffer for 3 min and then washed and spun at 800 g for 5 min, resuspended in RPMI medium plus 2% fetal bovine serum, and stained with antibodies as described below. Cells isolated from medLNs and bone marrow were counted with trypan blue, washed, and prepared for flow cytometry analysis in PBS containing 2% FBS and 2 mM EDTA. For surface staining, cells were stained with fluorescently labeled antibodies at 4°C for 15 min in the dark, followed by Live/Dead Blue (Invitrogen, Cat# L23105) staining following the manufacturer’s instructions. Samples were acquired on an LSR Fortessa (BD Biosciences) and analyzed using FlowJo software (TreeStar, versions 9.3.2 and 10.5.3.). The list of antibodies used is as follows: B220- BV510 (RA3-6B2, Biolegend), CD138-PE (281–2, Biolegend), CD95-BV421 (Jo2, BD Bioscience), GL-7-Alexa-Fluor647 (GL7, Biolegend), CD4-APC-Cy7 (GK1.5, Biolegend), and CD38-PE-Cy7 (T10, Biolegend).</p></sec><sec id="s4-19"><title>Statistics</title><p>All statistical tests were conducted using GraphPad Prism 9 and data was presented as mean ± SEM. When comparing two groups the Student’s t-test was used. If greater than two groups were compared, then a One-way analysis of variance was used. For all results with normally distributed data, parametric statistical tests were used. When data were not normally distributed, non-parametric statistical tests were used. Data normality was determined using Prism 9.0. Biological replicates were defined as primary cells isolated from an individual mouse from their respective genotype. Statistically significant differences between groups were identified within the figures where *, **, ***, and **** indicating p-values of &lt; 0.05, &lt; 0.01, &lt; 0.001, and &lt;0.0001, respectively.</p></sec><sec id="s4-20"><title>Materials availability statement</title><p>All materials generated from this study including mice strains are available upon request from the lead PI (email: trebakm@pitt.edu).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>owns stock options and is a consultant for Creegh Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf4"><p>is scientific co-founder of Calcimedica</p></fn><fn fn-type="COI-statement" id="conf5"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Resources, Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Resources</p></fn><fn fn-type="con" id="con13"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Funding acquisition, Visualization, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of Penn State University: Protocols #: 46290, 47477, and 47350.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84708-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Genomic sequencing data of A20 Orai CRISPR clones.</title></caption><media xlink:href="elife-84708-data1-v2.txt" mimetype="text" mime-subtype="plain"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Raw RNA sequencing read count data from primary Orai KO B cells.</title></caption><media xlink:href="elife-84708-data2-v2.txt" mimetype="text" mime-subtype="plain"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>RNA sequencing analysis of primary Orai KO B cells.</title></caption><media xlink:href="elife-84708-data3-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata4"><label>Source data 4.</label><caption><title>GSEA analysis of RNA sequencing data from primary Orai KO B cells.</title></caption><media xlink:href="elife-84708-data4-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All antibodies, cell lines, chemicals, mice strains, and sequences of primers and gRNA used in the study are listed in the key resources table. Source data files have been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Han Chen from The Pennsylvania State University College of Medicine EM facility for assistance with TEM imaging and Dr. Drew Jones and Mr. Leonard Ash from New York University Langone Health Metabolomics Core Resource Laboratory for assistance with metabolomics experiments. We are grateful to the Flow Cytometry and Informatic and Data Analysis Core facilities from The Pennsylvania State University College of Medicine. This work was supported by National Institutes of Health (MIH) grants R35-HL150778 (to M.T.) and in part by R35-HL161177 (to A.C.S), R01-AI162971 (to ZSMR) and R01-AI097302 and R01-AI130143 (to SF), and training grant F30-AI164803-01 (to AYT).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>DM</given-names></name><name><surname>Tandon</surname><given-names>M</given-names></name><name><surname>Son</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Swaim</surname><given-names>W</given-names></name><name><surname>Eckhaus</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>V</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Muallem</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Orai1-Mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity</article-title><source>Cell Metabolism</source><volume>25</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.02.007</pub-id><pub-id pub-id-type="pmid">28273482</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkaya</surname><given-names>M</given-names></name><name><surname>Traba</surname><given-names>J</given-names></name><name><surname>Roesler</surname><given-names>AS</given-names></name><name><surname>Miozzo</surname><given-names>P</given-names></name><name><surname>Akkaya</surname><given-names>B</given-names></name><name><surname>Theall</surname><given-names>BP</given-names></name><name><surname>Sohn</surname><given-names>H</given-names></name><name><surname>Pena</surname><given-names>M</given-names></name><name><surname>Smelkinson</surname><given-names>M</given-names></name><name><surname>Kabat</surname><given-names>J</given-names></name><name><surname>Dahlstrom</surname><given-names>E</given-names></name><name><surname>Dorward</surname><given-names>DW</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name><name><surname>Sack</surname><given-names>MN</given-names></name><name><surname>Pierce</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Second signals rescue B cells from activation-induced mitochondrial dysfunction and death</article-title><source>Nature Immunology</source><volume>19</volume><fpage>871</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0156-5</pub-id><pub-id pub-id-type="pmid">29988090</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkaya</surname><given-names>M</given-names></name><name><surname>Pierce</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>From zero to sixty and back to zero again: The metabolic life of B cells</article-title><source>Current Opinion in Immunology</source><volume>57</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2018.09.019</pub-id><pub-id pub-id-type="pmid">30312894</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of calcium signaling in B cell activation and biology</article-title><source>Current Topics in Microbiology and Immunology</source><volume>393</volume><fpage>143</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/82_2015_477</pub-id><pub-id pub-id-type="pmid">26369772</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>CT</given-names></name><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>Freedman</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>STIM- and Orai-mediated calcium entry controls NF-κB activity and function in lymphocytes</article-title><source>Cell Calcium</source><volume>74</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2018.07.003</pub-id><pub-id pub-id-type="pmid">30048879</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>CT</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Myles</surname><given-names>A</given-names></name><name><surname>Nandi</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Hershberg</surname><given-names>U</given-names></name><name><surname>Brodsky</surname><given-names>IE</given-names></name><name><surname>Cancro</surname><given-names>MP</given-names></name><name><surname>Lengner</surname><given-names>CJ</given-names></name><name><surname>May</surname><given-names>MJ</given-names></name><name><surname>Freedman</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BCR-induced ca2+ signals dynamically tune survival, metabolic reprogramming, and proliferation of naive B cells</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107474</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.03.038</pub-id><pub-id pub-id-type="pmid">32294437</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>GS</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Pharmacology of store-operated calcium entry channels</chapter-title><person-group person-group-type="editor"><name><surname>J.A.</surname><given-names>Kozak</given-names></name><name><surname>J.W.</surname><given-names>Putney</given-names></name></person-group><source>In: Calcium entry channels in non-excitable cells</source><publisher-name>CRC Press/Taylor &amp; Francis</publisher-name><fpage>311</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1201/9781315152592</pub-id><pub-id pub-id-type="pmid">30299647</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogeski</surname><given-names>I</given-names></name><name><surname>Kummerow</surname><given-names>C</given-names></name><name><surname>Al-Ansary</surname><given-names>D</given-names></name><name><surname>Schwarz</surname><given-names>EC</given-names></name><name><surname>Koehler</surname><given-names>R</given-names></name><name><surname>Kozai</surname><given-names>D</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Peinelt</surname><given-names>C</given-names></name><name><surname>Griesemer</surname><given-names>D</given-names></name><name><surname>Bozem</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Hoth</surname><given-names>M</given-names></name><name><surname>Niemeyer</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differential redox regulation of Orai ion channels: A mechanism to tune cellular calcium signaling</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>ra24</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2000672</pub-id><pub-id pub-id-type="pmid">20354224</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boothby</surname><given-names>M</given-names></name><name><surname>Rickert</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic regulation of the immune humoral response</article-title><source>Immunity</source><volume>46</volume><fpage>743</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.009</pub-id><pub-id pub-id-type="pmid">28514675</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeHaven</surname><given-names>WI</given-names></name><name><surname>Smyth</surname><given-names>JT</given-names></name><name><surname>Boyles</surname><given-names>RR</given-names></name><name><surname>Bird</surname><given-names>GS</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Complex actions of 2-aminoethyldiphenyl borate on store-operated calcium entry</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>19265</fpage><lpage>19273</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801535200</pub-id><pub-id pub-id-type="pmid">18487204</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name><name><surname>Healy</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Differential activation of transcription factors induced by Ca2+ response amplitude and duration</article-title><source>Nature</source><volume>386</volume><fpage>855</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/386855a0</pub-id><pub-id pub-id-type="pmid">9126747</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Toll-like receptor signaling and its role in cell-mediated immunity</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>812774</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.812774</pub-id><pub-id pub-id-type="pmid">35309296</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>BioMart and bioconductor: A powerful link between biological databases and microarray data analysis</article-title><source>Bioinformatics</source><volume>21</volume><fpage>3439</fpage><lpage>3440</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti525</pub-id><pub-id pub-id-type="pmid">16082012</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomart</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.97</pub-id><pub-id pub-id-type="pmid">19617889</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckstein</surname><given-names>M</given-names></name><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Aulestia</surname><given-names>FJ</given-names></name><name><surname>Costiniti</surname><given-names>V</given-names></name><name><surname>Kassam</surname><given-names>SN</given-names></name><name><surname>Bromage</surname><given-names>TG</given-names></name><name><surname>Pedersen</surname><given-names>P</given-names></name><name><surname>Issekutz</surname><given-names>T</given-names></name><name><surname>Idaghdour</surname><given-names>Y</given-names></name><name><surname>Moursi</surname><given-names>AM</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name><name><surname>Lacruz</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential regulation of Ca2+ influx by Orai channels mediates enamel mineralization</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaav4663</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aav4663</pub-id><pub-id pub-id-type="pmid">31015290</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Arige</surname><given-names>V</given-names></name><name><surname>Wagner</surname><given-names>LE</given-names></name><name><surname>Hempel</surname><given-names>N</given-names></name><name><surname>Gill</surname><given-names>DL</given-names></name><name><surname>Sneyd</surname><given-names>J</given-names></name><name><surname>Yule</surname><given-names>DI</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Omnitemporal choreographies of all five STIM/orai and ip3rs underlie the complexity of mammalian ca2+ signaling</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108760</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108760</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Fike</surname><given-names>AJ</given-names></name><name><surname>Bricker</surname><given-names>KN</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Rahman</surname><given-names>ZSM</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>The mitochondrial sodium/calcium exchanger NCLX (slc8b1) in B lymphocytes</article-title><source>Cell Calcium</source><volume>108</volume><elocation-id>102667</elocation-id><pub-id pub-id-type="doi">10.1016/j.ceca.2022.102667</pub-id><pub-id pub-id-type="pmid">36308855</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Physiological functions of CRAC channels</article-title><source>Annual Review of Physiology</source><volume>84</volume><fpage>355</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-052521-013426</pub-id><pub-id pub-id-type="pmid">34637326</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feske</surname><given-names>S</given-names></name><name><surname>Giltnane</surname><given-names>J</given-names></name><name><surname>Dolmetsch</surname><given-names>R</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Gene regulation mediated by calcium signals in T lymphocytes</article-title><source>Nature Immunology</source><volume>2</volume><fpage>316</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/86318</pub-id><pub-id pub-id-type="pmid">11276202</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feske</surname><given-names>S</given-names></name><name><surname>Gwack</surname><given-names>Y</given-names></name><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Srikanth</surname><given-names>S</given-names></name><name><surname>Puppel</surname><given-names>SH</given-names></name><name><surname>Tanasa</surname><given-names>B</given-names></name><name><surname>Hogan</surname><given-names>PG</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function</article-title><source>Nature</source><volume>441</volume><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1038/nature04702</pub-id><pub-id pub-id-type="pmid">16582901</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gammons</surname><given-names>J</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name><name><surname>Mancarella</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cardiac-specific deletion of orai3 leads to severe dilated cardiomyopathy and heart failure in mice</article-title><source>Journal of the American Heart Association</source><volume>10</volume><elocation-id>e019486</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.120.019486</pub-id><pub-id pub-id-type="pmid">33849280</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geeraedts</surname><given-names>F</given-names></name><name><surname>Goutagny</surname><given-names>N</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Severa</surname><given-names>M</given-names></name><name><surname>de Haan</surname><given-names>A</given-names></name><name><surname>Pool</surname><given-names>J</given-names></name><name><surname>Wilschut</surname><given-names>J</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Huckriede</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling</article-title><source>PLOS Pathogens</source><volume>4</volume><elocation-id>e1000138</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000138</pub-id><pub-id pub-id-type="pmid">18769719</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwack</surname><given-names>Y</given-names></name><name><surname>Srikanth</surname><given-names>S</given-names></name><name><surname>Oh-Hora</surname><given-names>M</given-names></name><name><surname>Hogan</surname><given-names>PG</given-names></name><name><surname>Lamperti</surname><given-names>ED</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Gelinas</surname><given-names>C</given-names></name><name><surname>Neems</surname><given-names>DS</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hair loss and defective T- and B-cell function in mice lacking Orai1</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>5209</fpage><lpage>5222</lpage><pub-id pub-id-type="doi">10.1128/MCB.00360-08</pub-id><pub-id pub-id-type="pmid">18591248</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>JI</given-names></name><name><surname>Dolmetsch</surname><given-names>RE</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name><name><surname>Goodnow</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Quantitative and qualitative control of antigen receptor signalling in tolerant B lymphocytes</article-title><source>Novartis Foundation</source><volume>215</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1002/9780470515525.ch10</pub-id><pub-id pub-id-type="pmid">9760576</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KH</given-names></name><name><surname>Patrizi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Assessment of common housekeeping genes as reference for gene expression studies using RT-qpcr in mouse choroid plexus</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>3278</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-82800-5</pub-id><pub-id pub-id-type="pmid">33558629</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobeika</surname><given-names>E</given-names></name><name><surname>Thiemann</surname><given-names>S</given-names></name><name><surname>Storch</surname><given-names>B</given-names></name><name><surname>Jumaa</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>PJ</given-names></name><name><surname>Pelanda</surname><given-names>R</given-names></name><name><surname>Reth</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Testing gene function early in the B cell lineage in mb1-cre mice</article-title><source>PNAS</source><volume>103</volume><fpage>13789</fpage><lpage>13794</lpage><pub-id pub-id-type="doi">10.1073/pnas.0605944103</pub-id><pub-id pub-id-type="pmid">16940357</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innate immunity to influenza virus infection</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nri3665</pub-id><pub-id pub-id-type="pmid">24762827</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>U</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Kozhaya</surname><given-names>L</given-names></name><name><surname>Subramanian</surname><given-names>R</given-names></name><name><surname>Gaida</surname><given-names>K</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>McBride</surname><given-names>HJ</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Selective orai1 inhibition ameliorates autoimmune central nervous system inflammation by suppressing effector but not regulatory T cell function</article-title><source>Journal of Immunology</source><volume>196</volume><fpage>573</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1501406</pub-id><pub-id pub-id-type="pmid">26673135</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>AM</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name><name><surname>Shlomchik</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity</article-title><source>Science</source><volume>336</volume><fpage>1178</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1126/science.1213368</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>LB</given-names></name><name><surname>Freedman</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>B-Lymphocyte calcium influx</article-title><source>Immunological Reviews</source><volume>231</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00822.x</pub-id><pub-id pub-id-type="pmid">19754903</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacruz</surname><given-names>RS</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Diseases caused by mutations in ORAI1 and STIM1</article-title><source>Annals of the New York Academy of Sciences</source><volume>1356</volume><fpage>45</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/nyas.12938</pub-id><pub-id pub-id-type="pmid">26469693</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Cuk</surname><given-names>M</given-names></name><name><surname>Kahlfuss</surname><given-names>S</given-names></name><name><surname>Kozhaya</surname><given-names>L</given-names></name><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Benson</surname><given-names>MJ</given-names></name><name><surname>Jakovcevic</surname><given-names>A</given-names></name><name><surname>Bilic</surname><given-names>K</given-names></name><name><surname>Martinac</surname><given-names>I</given-names></name><name><surname>Stathopulos</surname><given-names>P</given-names></name><name><surname>Kacskovics</surname><given-names>I</given-names></name><name><surname>Vraetz</surname><given-names>T</given-names></name><name><surname>Speckmann</surname><given-names>C</given-names></name><name><surname>Ehl</surname><given-names>S</given-names></name><name><surname>Issekutz</surname><given-names>T</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Orai1 mutations abolishing store-operated ca2+ entry cause anhidrotic ectodermal dysplasia with immunodeficiency</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>142</volume><fpage>1297</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.10.031</pub-id><pub-id pub-id-type="pmid">29155098</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunz</surname><given-names>V</given-names></name><name><surname>Romanin</surname><given-names>C</given-names></name><name><surname>Frischauf</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Stim1 activation of Orai1</article-title><source>Cell Calcium</source><volume>77</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2018.11.009</pub-id><pub-id pub-id-type="pmid">30530091</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Weisel</surname><given-names>F</given-names></name><name><surname>Shlomchik</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>B cell receptor and CD40 signaling are rewired for synergistic induction of the c-myc transcription factor in germinal center B cells</article-title><source>Immunity</source><volume>48</volume><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.01.008</pub-id><pub-id pub-id-type="pmid">29396161</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>A</given-names></name><name><surname>Hikida</surname><given-names>M</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production</article-title><source>Immunity</source><volume>34</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.03.016</pub-id><pub-id pub-id-type="pmid">21530328</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarl</surname><given-names>C-A</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Khalil</surname><given-names>S</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Röther</surname><given-names>J</given-names></name><name><surname>Papolos</surname><given-names>A</given-names></name><name><surname>Kutok</surname><given-names>J</given-names></name><name><surname>Hivroz</surname><given-names>C</given-names></name><name><surname>LeDeist</surname><given-names>F</given-names></name><name><surname>Plogmann</surname><given-names>K</given-names></name><name><surname>Ehl</surname><given-names>S</given-names></name><name><surname>Notheis</surname><given-names>G</given-names></name><name><surname>Albert</surname><given-names>MH</given-names></name><name><surname>Belohradsky</surname><given-names>BH</given-names></name><name><surname>Kirschner</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Orai1 deficiency and lack of store-operated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia</article-title><source>Journal of Allergy and Clinical Immunology</source><volume>124</volume><fpage>1311</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.10.007</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarl</surname><given-names>C-A</given-names></name><name><surname>Khalil</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Oh-hora</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Roether</surname><given-names>J</given-names></name><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Jairaman</surname><given-names>A</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Store-Operated Ca2+ entry through Orai1 is critical for T cell-mediated autoimmunity and allograft rejection</article-title><source>The Journal of Immunology</source><volume>185</volume><fpage>5845</fpage><lpage>5858</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001796</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>4288</fpage><lpage>4297</lpage><pub-id pub-id-type="doi">10.1093/nar/gks042</pub-id><pub-id pub-id-type="pmid">22287627</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Eriksson</surname><given-names>K-F</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Sihag</surname><given-names>S</given-names></name><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Carlsson</surname><given-names>E</given-names></name><name><surname>Ridderstråle</surname><given-names>M</given-names></name><name><surname>Laurila</surname><given-names>E</given-names></name><name><surname>Houstis</surname><given-names>N</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Patterson</surname><given-names>N</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>B</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Groop</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes</article-title><source>Nature Genetics</source><volume>34</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/ng1180</pub-id><pub-id pub-id-type="pmid">12808457</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacold</surname><given-names>ME</given-names></name><name><surname>Brimacombe</surname><given-names>KR</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Rohde</surname><given-names>JM</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Swier</surname><given-names>LJYM</given-names></name><name><surname>Possemato</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Fiske</surname><given-names>BP</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Shaul</surname><given-names>YD</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Koh</surname><given-names>MJ</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>AQ</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Yasgar</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Rai</surname><given-names>G</given-names></name><name><surname>Westover</surname><given-names>KD</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Boxer</surname><given-names>MB</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A Phgdh inhibitor reveals coordination of serine synthesis and one-carbon unit fate</article-title><source>Nature Chemical Biology</source><volume>12</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2070</pub-id><pub-id pub-id-type="pmid">27110680</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Potentiation and inhibition of Ca (2+) release-activated Ca (2+) channels by 2-aminoethyldiphenyl borate (2-APB) occurs independently of IP (3) receptors</article-title><source>The Journal of Physiology</source><volume>536</volume><fpage>3</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.2001.t01-1-00003.x</pub-id><pub-id pub-id-type="pmid">11579153</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Store-Operated calcium channels</article-title><source>Physiological Reviews</source><volume>95</volume><fpage>1383</fpage><lpage>1436</lpage><pub-id pub-id-type="doi">10.1152/physrev.00020.2014</pub-id><pub-id pub-id-type="pmid">26400989</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risso</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>K</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gc-Content normalization for RNA-Seq data</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-480</pub-id><pub-id pub-id-type="pmid">22177264</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>EdgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nih image to imagej: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmughapriya</surname><given-names>S</given-names></name><name><surname>Rajan</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>NE</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Kolesar</surname><given-names>JE</given-names></name><name><surname>Hines</surname><given-names>KJ</given-names></name><name><surname>Ragheb</surname><given-names>J</given-names></name><name><surname>Jog</surname><given-names>NR</given-names></name><name><surname>Caricchio</surname><given-names>R</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Kaufman</surname><given-names>BA</given-names></name><name><surname>Cheung</surname><given-names>JY</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Gill</surname><given-names>DL</given-names></name><name><surname>Madesh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ca2+ signals regulate mitochondrial metabolism by stimulating CREB-mediated expression of the mitochondrial Ca2+ uniporter gene MCU</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra23</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005673</pub-id><pub-id pub-id-type="pmid">25737585</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of lymphocyte function by Orai and STIM proteins in infection and autoimmunity</article-title><source>The Journal of Physiology</source><volume>590</volume><fpage>4157</fpage><lpage>4167</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2012.233221</pub-id><pub-id pub-id-type="pmid">22615435</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Somasundaram</surname><given-names>A</given-names></name><name><surname>Shum</surname><given-names>AK</given-names></name><name><surname>McBride</surname><given-names>HJ</given-names></name><name><surname>Kessler</surname><given-names>JA</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>RJ</given-names></name><name><surname>Prakriya</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Store-Operated CRAC channels regulate gene expression and proliferation in neural progenitor cells</article-title><source>The Journal of Neuroscience</source><volume>34</volume><fpage>9107</fpage><lpage>9123</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0263-14.2014</pub-id><pub-id pub-id-type="pmid">24990931</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Loss of IP3 receptor–mediated Ca2+ release in mouse B cells results in abnormal B cell development and function</article-title><source>The Journal of Immunology</source><volume>199</volume><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700109</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Brown</surname><given-names>SA</given-names></name><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>So</surname><given-names>J</given-names></name><name><surname>Webby</surname><given-names>RJ</given-names></name><name><surname>Doherty</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An unexpected antibody response to an engineered influenza virus modifies CD8+ T cell responses</article-title><source>PNAS</source><volume>103</volume><fpage>2764</fpage><lpage>2769</lpage><pub-id pub-id-type="doi">10.1073/pnas.0511185103</pub-id><pub-id pub-id-type="pmid">16473934</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Mignen</surname><given-names>O</given-names></name><name><surname>Shuttleworth</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Arc channel -- an endogenous store-independent Orai channel</article-title><source>Current Topics in Membranes</source><volume>71</volume><fpage>125</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-407870-3.00006-8</pub-id><pub-id pub-id-type="pmid">23890114</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebak</surname><given-names>M</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Orai calcium channels</article-title><source>Physiology</source><volume>32</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1152/physiol.00011.2017</pub-id><pub-id pub-id-type="pmid">28615316</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trebak</surname><given-names>M</given-names></name><name><surname>Kinet</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Calcium signalling in T cells</article-title><source>Nature Reviews. Immunology</source><volume>19</volume><fpage>154</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0110-7</pub-id><pub-id pub-id-type="pmid">30622345</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsvilovskyy</surname><given-names>V</given-names></name><name><surname>Solís-López</surname><given-names>A</given-names></name><name><surname>Schumacher</surname><given-names>D</given-names></name><name><surname>Medert</surname><given-names>R</given-names></name><name><surname>Roers</surname><given-names>A</given-names></name><name><surname>Kriebs</surname><given-names>U</given-names></name><name><surname>Freichel</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deletion of Orai2 augments endogenous CRAC currents and degranulation in mast cells leading to enhanced anaphylaxis</article-title><source>Cell Calcium</source><volume>71</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2017.11.004</pub-id><pub-id pub-id-type="pmid">29604961</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Eckstein</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>PJ</given-names></name><name><surname>Kozhaya</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Berberich-Siebelt</surname><given-names>F</given-names></name><name><surname>Clancy</surname><given-names>R</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Store-Operated Ca (2+) entry in follicular T cells controls humoral immune responses and autoimmunity</article-title><source>Immunity</source><volume>44</volume><fpage>1350</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.04.013</pub-id><pub-id pub-id-type="pmid">27261277</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Maus</surname><given-names>M</given-names></name><name><surname>Klein-Hessling</surname><given-names>S</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Eckstein</surname><given-names>M</given-names></name><name><surname>Cameron</surname><given-names>S</given-names></name><name><surname>Turvey</surname><given-names>SE</given-names></name><name><surname>Serfling</surname><given-names>E</given-names></name><name><surname>Berberich-Siebelt</surname><given-names>F</given-names></name><name><surname>Possemato</surname><given-names>R</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Store-operated ca2+ entry controls clonal expansion of T cells through metabolic reprogramming</article-title><source>Immunity</source><volume>47</volume><fpage>664</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.09.003</pub-id><pub-id pub-id-type="pmid">29030115</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Zee</surname><given-names>I</given-names></name><name><surname>Eckstein</surname><given-names>M</given-names></name><name><surname>Knosp</surname><given-names>C</given-names></name><name><surname>Kaufmann</surname><given-names>U</given-names></name><name><surname>Karoly Jani</surname><given-names>P</given-names></name><name><surname>Lacruz</surname><given-names>RS</given-names></name><name><surname>Flockerzi</surname><given-names>V</given-names></name><name><surname>Kacskovics</surname><given-names>I</given-names></name><name><surname>Prakriya</surname><given-names>M</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Orai2 modulates store-operated calcium entry and T cell-mediated immunity</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14714</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14714</pub-id><pub-id pub-id-type="pmid">28294127</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nfat control of immune function: New frontiers for an abiding trooper</article-title><source>F1000Research</source><volume>7</volume><elocation-id>260</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.13426.1</pub-id><pub-id pub-id-type="pmid">29568499</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaeth</surname><given-names>M</given-names></name><name><surname>Kahlfuss</surname><given-names>S</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crac channels and calcium signaling in T cell-mediated immunity</article-title><source>Trends in Immunology</source><volume>41</volume><fpage>878</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.it.2020.06.012</pub-id><pub-id pub-id-type="pmid">32711944</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vig</surname><given-names>M</given-names></name><name><surname>DeHaven</surname><given-names>WI</given-names></name><name><surname>Bird</surname><given-names>GS</given-names></name><name><surname>Billingsley</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>PE</given-names></name><name><surname>Hutchings</surname><given-names>AB</given-names></name><name><surname>Jouvin</surname><given-names>MH</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name><name><surname>Kinet</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Defective mast cell effector functions in mice lacking the CRACM1 pore subunit of store-operated calcium release-activated calcium channels</article-title><source>Nature Immunology</source><volume>9</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/ni1550</pub-id><pub-id pub-id-type="pmid">18059270</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Noyer</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Tao</surname><given-names>AY</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Saavedra</surname><given-names>P</given-names></name><name><surname>Hoda</surname><given-names>ST</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Feske</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Orai3 is dispensable for store-operated ca2+ entry and immune responses by lymphocytes and macrophages</article-title><source>The Journal of General Physiology</source><volume>154</volume><elocation-id>104</elocation-id><pub-id pub-id-type="doi">10.1085/jgp.202213104</pub-id><pub-id pub-id-type="pmid">35861698</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>LR</given-names></name><name><surname>Ahsan</surname><given-names>FM</given-names></name><name><surname>Wolf</surname><given-names>DM</given-names></name><name><surname>Shirihai</surname><given-names>O</given-names></name><name><surname>Teitell</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Initial B cell activation induces metabolic reprogramming and mitochondrial remodeling</article-title><source>IScience</source><volume>5</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.isci.2018.07.005</pub-id><pub-id pub-id-type="pmid">30240649</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Jadhav</surname><given-names>RR</given-names></name><name><surname>Sheth</surname><given-names>K</given-names></name><name><surname>Weyand</surname><given-names>CM</given-names></name><name><surname>Goronzy</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>907</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21242-z</pub-id><pub-id pub-id-type="pmid">33568645</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>The anatomy of native CRAC channel (S)</article-title><source>Current Opinion in Physiology</source><volume>17</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.cophys.2020.07.012</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>MT</given-names></name><name><surname>Fike</surname><given-names>AJ</given-names></name><name><surname>Walter</surname><given-names>V</given-names></name><name><surname>Hempel</surname><given-names>N</given-names></name><name><surname>Yule</surname><given-names>DI</given-names></name><name><surname>Sneyd</surname><given-names>J</given-names></name><name><surname>Gill</surname><given-names>DL</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>The native orai channel trio underlies the diversity of ca2+ signaling events</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2444</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16232-6</pub-id><pub-id pub-id-type="pmid">32415068</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Arige</surname><given-names>V</given-names></name><name><surname>Pathak</surname><given-names>T</given-names></name><name><surname>Benson</surname><given-names>JC</given-names></name><name><surname>Johnson</surname><given-names>MT</given-names></name><name><surname>Abdelnaby</surname><given-names>AE</given-names></name><name><surname>Lakomski</surname><given-names>N</given-names></name><name><surname>Hempel</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>JM</given-names></name><name><surname>Dupont</surname><given-names>G</given-names></name><name><surname>Yule</surname><given-names>DI</given-names></name><name><surname>Sneyd</surname><given-names>J</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The mitochondrial ca2+ uniporter is a central regulator of interorganellar ca2+ transfer and NFAT activation</article-title><source>Journal of Biological Chemistry</source><volume>297</volume><elocation-id>101174</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101174</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>SL</given-names></name><name><surname>Kozak</surname><given-names>JA</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Yeromin</surname><given-names>AV</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Penna</surname><given-names>A</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Chi</surname><given-names>V</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Store-Dependent and -independent modes regulating Ca2+ release-activated Ca2+ channel activity of human Orai1 and Orai3</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>17662</fpage><lpage>17671</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801536200</pub-id><pub-id pub-id-type="pmid">18420579</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>González-Cobos</surname><given-names>JC</given-names></name><name><surname>Schindl</surname><given-names>R</given-names></name><name><surname>Muik</surname><given-names>M</given-names></name><name><surname>Ruhle</surname><given-names>B</given-names></name><name><surname>Motiani</surname><given-names>RK</given-names></name><name><surname>Bisaillon</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Fahrner</surname><given-names>M</given-names></name><name><surname>Barroso</surname><given-names>M</given-names></name><name><surname>Matrougui</surname><given-names>K</given-names></name><name><surname>Romanin</surname><given-names>C</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms of STIM1 activation of store-independent leukotriene C4-regulated ca2+ channels</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>3715</fpage><lpage>3723</lpage><pub-id pub-id-type="doi">10.1128/MCB.00554-13</pub-id><pub-id pub-id-type="pmid">23878392</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>González-Cobos</surname><given-names>JC</given-names></name><name><surname>Jardin</surname><given-names>I</given-names></name><name><surname>Romanin</surname><given-names>C</given-names></name><name><surname>Matrougui</surname><given-names>K</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complex role of STIM1 in the activation of store-independent orai1/3 channels</article-title><source>The Journal of General Physiology</source><volume>143</volume><fpage>345</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1085/jgp.201311084</pub-id><pub-id pub-id-type="pmid">24567509</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>González-Cobos</surname><given-names>JC</given-names></name><name><surname>Stolwijk</surname><given-names>JA</given-names></name><name><surname>Matrougui</surname><given-names>K</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Leukotriene-C4 synthase, a critical enzyme in the activation of store-independent Orai1/Orai3 channels, is required for neointimal hyperplasia</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>5015</fpage><lpage>5027</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.625822</pub-id><pub-id pub-id-type="pmid">25540197</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Gueguinou</surname><given-names>M</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Store-independent orai channels regulated by STIM</chapter-title><person-group person-group-type="editor"><name><surname>J.A.</surname><given-names>Kozak</given-names></name><name><surname>J.W.</surname><given-names>Putney</given-names></name></person-group><source>In: Calcium entry channels in non-excitable cells</source><publisher-name>CRC Press/Taylor &amp; Francis</publisher-name><fpage>197</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1201/9781315152592-11</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Pathak</surname><given-names>T</given-names></name><name><surname>Yoast</surname><given-names>R</given-names></name><name><surname>Emrich</surname><given-names>S</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Nwokonko</surname><given-names>RM</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Delierneux</surname><given-names>C</given-names></name><name><surname>Gueguinou</surname><given-names>M</given-names></name><name><surname>Hempel</surname><given-names>N</given-names></name><name><surname>Putney</surname><given-names>JW</given-names></name><name><surname>Gill</surname><given-names>DL</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A calcium/camp signaling loop at the orai1 mouth drives channel inactivation to shape NFAT induction</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1971</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09593-0</pub-id><pub-id pub-id-type="pmid">31036819</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xin</surname><given-names>P</given-names></name><name><surname>Yoast</surname><given-names>RE</given-names></name><name><surname>Emrich</surname><given-names>SM</given-names></name><name><surname>Johnson</surname><given-names>MT</given-names></name><name><surname>Pathak</surname><given-names>T</given-names></name><name><surname>Benson</surname><given-names>JC</given-names></name><name><surname>Azimi</surname><given-names>I</given-names></name><name><surname>Gill</surname><given-names>DL</given-names></name><name><surname>Monteith</surname><given-names>GR</given-names></name><name><surname>Trebak</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct pharmacological profiles of orai1, orai2, and orai3 channels</article-title><source>Cell Calcium</source><volume>91</volume><elocation-id>102281</elocation-id><pub-id pub-id-type="doi">10.1016/j.ceca.2020.102281</pub-id><pub-id pub-id-type="pmid">32896813</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Total OXPHOS Rodent WB Antibody Cocktail (Mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab110413, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2629281">AB_2629281</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GAPDH (Mouse monoclonal)</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">Cat# MAB374, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2107445">AB_2107445</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MCU (D2Z3B) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 14997, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2721812">AB_2721812</ext-link></td><td align="char" char="." valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">α-Tubulin (DM1A) (Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 3873, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1904178">AB_1904178</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NFAT1 Antibody<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 4389, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1950418">AB_1950418</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NFAT1 (D43B1) XP (Rabbit monoclonal) (Alexa Fluor 488 Conjugate)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 14324, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2798450">AB_2798450</ext-link></td><td align="char" char="." valign="bottom">(1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NFAT2 (D15F1) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 8032, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10829466">AB_10829466</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-CREB (Ser133) (87G3) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 9198, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2561044">AB_2561044</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CREB (86B10) (Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">Cat# 9104, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_490881">AB_490881</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 680RD Goat anti-Mouse IgG antibody</td><td align="left" valign="bottom">LI-COR Biosciences</td><td align="left" valign="bottom">Cat# 925–68070, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2651128">AB_2651128</ext-link></td><td align="char" char="." valign="bottom">(1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 800CW Donkey anti-Rabbit IgG antibody</td><td align="left" valign="bottom">LI-COR Biosciences</td><td align="left" valign="bottom">Cat# 926–32213, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_621848">AB_621848</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Orai1 (Rabbit polyclonal)</td><td align="left" valign="bottom">Feske Lab</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A-21244, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2535812">AB_2535812</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgM, µ chain specific (Goat polyclonal)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 115-006-020</td><td align="char" char="." valign="bottom">(20 ug/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-Mouse IgG (H&amp;L) - Affinity Pure</td><td align="left" valign="bottom">Tonbo Biosciences</td><td align="left" valign="bottom">Cat# 70–8076 M002</td><td align="char" char="." valign="bottom">(10 ug/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">InVivoMAb anti-mouse CD40 FGK4.5/FGK45 (Rat monoclonal)</td><td align="left" valign="bottom">Bio X Cell</td><td align="left" valign="bottom">Cat# BE0016-2</td><td align="char" char="." valign="bottom">(10 ug/mL)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 605 anti-mouse/human CD45R/B220 Antibody (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 103243</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine5 anti-mouse CD86 Antibody (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 105015</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine7 anti-mouse I-A/I-E Antibody (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 107629</td><td align="char" char="." valign="bottom">(1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD3e Monoclonal Antibody (145–2 C11), PE (Hamster monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-0031-82</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">V500 Rat anti-Mouse CD8a (Rat monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 560776</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BB700 Rat Anti-Mouse CD4 (Rat monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 566408</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC Rat Anti-Mouse CD24 (Rat monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 562349</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">FITC Rat Anti-Mouse CD23 (Rat monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 553138</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgM Monoclonal Antibody (eB121-15F9) (Rat monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 12-5890-82</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD93 (AA4.1) Monoclonal Antibody (AA4.1), APC (Rat monoclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 17-5892-82</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine5 Streptavidin</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 405205</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Pacific Blue anti-mouse/human CD45R/B220 Antibody (Rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 103230</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">A20</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">ATCC Cat# TIB-208, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1940">CVCL_1940</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FK506</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat# 74152</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CRAC Channel Inhibitor IV, GSK-7975A</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# 5343510001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">2-APB</td><td align="left" valign="bottom">Tocris Bioscience</td><td align="left" valign="bottom">Cat# 1224</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Thapsigargin</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# T7458</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">5 (6)-CFDA, SE; CFSE (5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl Ester), mixed isomers</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# C1157</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Gadolinium(III) Chloride</td><td align="left" valign="bottom">ACROS Organics</td><td align="left" valign="bottom">Cat# AC383560050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">cDNA Reverse Transcription Kit</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4368814</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Seahorse XF Cell Mito Stress Test Kit</td><td align="left" valign="bottom">Agilent Technologies</td><td align="left" valign="bottom">Cat# 103015–100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce Rapid Gold BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A53225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Tetramethylrhodamine, Ethyl Ester, <break/>Perchlorate (TMRE)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# T669</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MitoTracker Green FM - Special Packaging</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# M7514</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Cell Line Nucleofector Kit V</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">Cat# VCA-1003</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">StrataClone Blunt PCR Cloning Kit</td><td align="left" valign="bottom">Agilent Technologies</td><td align="left" valign="bottom">Cat# 240207</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep Mouse B Cell Isolation Kit</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat# 19854</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">eBioscience Foxp3 /Transcription Factor Staining Buffer Set</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 00-5523-00</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 74106</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# L34975</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSpCas9(BB)–2A-GFP (PX458)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat# 48138</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pU6-(BbsI)_CBh-Cas9-T2A-mCherry</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Cat# 64324</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.C(Cg)-Cd79atm1(cre)Reth/EhobJ</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Strain #:020505 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:020505">IMSR_JAX:020505</ext-link></td><td align="left" valign="bottom">Mb1-Cre on C57BL/6</td></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Orai1fl/fl</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib1">Ahuja et al., 2017</xref> PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28273482/">28273482</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Orai3fl/fl</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Gammons et al., 2021</xref> <break/>PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/33849280/">33849280</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Orai1fl/fl Mb1cre/+</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Orai1fl/fl mice crossed with Mb1-Cre on C57BL/6</td></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Orai3fl/fl Mb1cre/+</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Orai3fl/fl mice crossed with Mb1-Cre on C57BL/6</td></tr><tr><td align="left" valign="bottom">Genetic Reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Orai1/Orai3fl/fl Mb1cre/+</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Orai1/Orai3fl/fl mice crossed with Mb1-Cre on C57BL/6</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fura-2, AM, cell permeant</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# F1221</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SYBR Select Master Mix</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 4472920</td><td align="left" valign="bottom">Master mix for qRT-PCR</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Lipopolysaccharides <break/>from <break/><italic>Escherichia coli</italic> <break/>O111:B4</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# L2630-10MG</td><td align="left" valign="bottom">Stimulation of primary B lymphocytes</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Intercept (TBS) Blocking Buffer</td><td align="left" valign="bottom">LI-COR Biosciences</td><td align="left" valign="bottom">Cat# 927–60001</td><td align="left" valign="bottom">Western blot blocking buffer</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Halt Protease and Phosphatase Inhibitor</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# PI78443</td><td align="left" valign="bottom">Western blot lysis buffer component</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RIPA Buffer</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# R0278-50ML</td><td align="left" valign="bottom">Western blot lysis buffer component</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# D9542</td><td align="left" valign="bottom">Nuclear localization staining for ImageStream</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">EasySep Buffer</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat# 20144</td><td align="left" valign="bottom">B cell isolation kit buffer</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">NuPAGE 4 to 12%, Bis-Tris, 1.0–1.5 mm, Mini Protein Gels</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# NP0321BOX</td><td align="left" valign="bottom">Western blot denaturing gels</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Poly-L-lysine solution</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# P4832-50ML</td><td align="left" valign="bottom">Attachment of suspension cells to coverslips</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai1n</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNA primers for mouse Orai1 CRISPR knockout</td><td align="left" valign="bottom">GCCTTCGGATCCGGTGCGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai1c</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNA primers for mouse Orai1 CRISPR knockout</td><td align="left" valign="bottom">CACAGGCCGTCCTCCGGACT</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai3n</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNA primers for mouse Orai3 CRISPR knockout</td><td align="left" valign="bottom">GCGTCCGTAACTGTTCCCGC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai3c</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNA primers for mouse Orai3 CRISPR knockout</td><td align="left" valign="bottom">GAAGGAGGTCTGTCGATCCC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Mb1 Cre Common Primer</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Mb1 Cre</td><td align="left" valign="bottom">ACT GAG GCA GGA GGA TTG G</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Wild Type Forward Primer</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Mb1 Cre</td><td align="left" valign="bottom">CTC TTT ACC TTC CAA GCA CTG A</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Mutant Forward Primer</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Mb1 Cre</td><td align="left" valign="bottom">CAT TTT CGA GGG AGC TTC A</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Orai1 fl/fl Forward</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Orai1 flox</td><td align="left" valign="bottom">ACC CAT GTG GTG GAA AGA AA</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Orai1 fl/fl Reverse</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Orai1 flox</td><td align="left" valign="bottom">TGC AGG CAC TAA AGA CGA TG</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Orai3 fl/fl Forward</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Orai3 flox</td><td align="left" valign="bottom">GAG CTG GGA TTA AAG GTG TAT GCC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">Orai3 fl/fl Reverse</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers for genotyping Orai3 flox</td><td align="left" valign="bottom">TGA CTT CAC CTC AGT CTC AAA GGG G</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai1 F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">CCA AGC TCA AAG CTT CCA GC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai1 R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">GCA CTA AAG ACG ATG AGC AAC C</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai2 F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">GCAGCTACCTGGAACTCGTC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai2 R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">GTTGTGGATGTTGCTCACCG</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai3 F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">ACC AAC GAC TGC ACA GAT AC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mOrai3 R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">CCA ATG GGC ACA AAC TTG AC</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mGAPDH F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">GTG GCA AAG TGG AGA TTG TTG</td></tr><tr><td align="left" valign="bottom">Sequence-based Reagent</td><td align="left" valign="bottom">mGAPDH R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-PCR primers</td><td align="left" valign="bottom">CGT TGA ATT TGC CGT GAG TG</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image J</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/">https://imagej.net/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Graphpad Prism</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">http://www.graphpad.com/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Leica Application Suite X</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.leica-microsystems.com/">https://www.leica-microsystems.com/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016555">SCR_016555</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Image Studio Lite</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.licor.com/bio/image-studio-lite/download">https://www.licor.com/bio/image-studio-lite/download</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013715">SCR_013715</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo 9.9.6</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84708.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Prakriya</surname><given-names>Murali</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Northwestern University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study shows that Orai1 and Orai3 are important elements of the calcium signaling machinery in mouse B cells and regulate downstream responses of proliferation, energetics, and metabolic reprogramming that occur after stimulation of the B cell antigen receptor. This work provides new information of interest to a broad range of readers in the fields of immunology, ion channels, and calcium signaling.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84708.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Prakriya</surname><given-names>Murali</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000e0be47</institution-id><institution>Northwestern University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting the paper &quot;Orai3 and Orai1 are essential for CRAC channel function and metabolic reprogramming in B cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Yousang Gwack (Reviewer #2).</p><p>Comments to the Authors:</p><p>While all three reviewers expressed interest in the work including its conceptual framework, they identified major weaknesses and essential revisions that will be needed to support the main conclusions. In particular, the reviewers raised strong concerns regarding the effects of the Orai1 KO in native B cells and about the data in Figure 3, showing only a 25% reduction in Orai1 protein at the cell surface. Additional concerns dealing with the rather limited range of B cell functions examined reduced enthusiasm for the study. These gaps will likely require more time than <italic>eLife</italic> policy allows for inviting revisions (~two months). Thus, we are sorry to say that we cannot consider this manuscript for publication by <italic>eLife</italic> at this time. However, given the enthusiasm of the reviewers, we would be willing to consider a revised manuscript that addresses these concerns as a new submission. To assist you with the revision, we list below the most significant concerns.</p><p>Essential revisions:</p><p>1) Verify the true extent of cell surface Orai1 expression in Orai1 KO B cells: The data in Figure 3A, B clearly show that expression in the MB1-Cre cells is ~75% of the wildtype controls implying that most Orai1 protein is in fact still retained at the cell surface. This makes it very difficult to draw any realistic conclusions about the role of Orai1, and by extension, Orai3 using the Orai1/Orai3 DKOs. The Orai1 antibody should be validated, and if it is not specific, a better one should be used with appropriate validation.</p><p>2) Related to the above point, the strong residual NFAT activation in Orai1 KO cells (surprising!), and lack of effect on B cell proliferation (which contradicts Gwack et al., 2008) seems consistent with the persistence of functional Orai1 protein at the cell surface.</p><p>3) The paper seems to imply that CRAC channels in B cells are heteromultimers of Orai1/Orai3 proteins. Without electrophysiological analysis, this claim realistically cannot be made and the study needs to demonstrate this point more definitively than simply looking at increases or decreases in cellular calcium concentrations.</p><p>4) The difference in phenotypes between Orai1 and Orai1/3 DKO B cells needs to be presented side by side to allow direct comparison. This should be done for Ca oscillations, NFAT activation and kinetics, proliferation, OCR, and respiration. See reviewer 2's comments on this matter. Experiments pertaining to Orai1 KO B cells in Figures 3 and 4 should also include those from Orai1/3 DKO B cells.</p><p>5) The functional significance of the study in its current form is very limited. Additional functional analysis to include cytokine production or antibody production is needed to increase the significance of the study.</p><p>6) B cell development. Check whether B cell development is affected in Orai1/3 Mb1cre KO mice. As noted by reviewer 2, Orai3 KO alone is unlikely to affect B cell development, however, does co-deletion of Orai1 and Orai3 affect B cell development or mature B cell populations in the spleen and peritoneum (Figure 4)?</p><p>7) What is the reason for reduced respiration in the Orai1/3 KO B cells which seems more than that observed in Orai1 KO cells? Use RNA-seq to examine this question.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>In this study, Emrich and coworkers examine the consequences of ablating Orai3 and Orai1 on store-operated calcium entry and B cell functions. It is known that SOCE is important for T cell function including T cell activation, proliferation, and cytokine synthesis. But less is known about Orai channel contributions to B cell function. Using conditional deletion of Orai1 and Orai3 in B cells, the authors examine several functional endpoints including B cell proliferation, development, and metabolism. These endpoints are diminished by Orai1 deletion. Deletion of Orai3 evokes no phenotype for most endpoints. The results indicating a lack of developmental effects on B cells with Orai1 deletion are not surprising and replicate previous work on these topics both in B cells and in T cells (relevant papers from Feske lab). Orai1 deletion also prevents NFAT activation, a well-known consequence of Orai1 inhibition in many cells. However, in several cases, the double Orai1/Orai3 knockout shows phenotypes that are slightly larger than those seen in Orai1-alone deficient B cells, suggesting that Orai3 plays a modest role in residual calcium entry and cellular functions.</p><p>While the experiments are carefully conducted, I think the paper exaggerates the role of Orai3 in B cell function. Many statements such as &quot;Orai3 and Orai1 coordinate for efficient B cell proliferation&quot; are not meaningful and vague and overstate the role of Orai3. In fact, Orai1 or Orai3 deletion has no effect on B cell proliferation. The lack of effect of Orai1 deletion is somewhat surprising and contradicts earlier findings (Gwack et al., 2008) indicating that Orai1 is critical for B cell proliferation and this contradiction is not explained. The double Orai3/Orai1 KO evokes a modest reduction of B cell proliferation but it is unclear whether this is a specific effect or downstream of more general suppression of metabolism since it is well known that rapidly proliferating cells require a high level of metabolism and glycolysis which is suppressed in the double KO. Perhaps the most interesting part of the paper is that the double KO shows a greater suppression of oxygen consumption and maximal respiration than Orai1 KO cells alone. But no effect is seen with Orai3 KO ablation and none on basal respiration even though deletion of Orai1 alone evokes the strongest effects. Thus, statements indicating that Orai1/Orai3 channels are crucial for metabolic reprogramming do not easily follow from the data shown, which seem to indicate very minor contributions of Orai3 for these endpoints.</p><p>Overall, the role of Orai3 is greatly over-emphasized and is not supported by the results. One could easily conclude based on the results that Orai3 is largely dispensable/redundant for the B cell responses that were studied here. But it is also worth noting that only a small subset of physiologically relevant B cell responses was assessed and notably cytokine and antibody production were not studied at all. These issues reduce the significance of the study.</p><p>Additional comments:</p><p>1) What is the effect of deleting Orai3 on NFAT1 activation? A lack of effect on cell proliferation in vitro is not surprising and is reminiscent of the lack of effects on proliferation in T cells with non-function Orai1 channels (McCarl, Feske et al., JI 2010).</p><p>2) Are Orai channels in a complex with Orai1 and Orai3 subunits in the same channel or are they expressed separately to form distinct channels in B cells? 2-APB appears to inhibit the residual SOCE in Orai3 deficient cells but not in Orai1 deficient cells. What are the implications of this result? The 2-APB experiment is uninterpreted in terms of the molecular composition of the SOCE channels.</p><p>3) In order to really assess the contributions of Orai3 to B cell physiological responses, it is important to directly compare the outcomes side-by-side for the different endpoints. Thus, the metrics for NFAT activation, proliferation, OCR, respiration, etc. should be directly compared as in Figure 2.</p><p>4) Figure 6: the fact that Orai1 deletion in primary B cells causes a substantial decrease in NFAT1 activation but has no effects on Ca oscillations (Figure 2/3) implies that the Ca oscillations have no direct relevance for NFAT activation in B cells. This result seems to contradict previous literature on this issue and should be discussed. Is NFAT1 activation more dependent on the plateau Ca responses instead of oscillations?</p><p>5) There is a large discrepancy between mRNA and protein levels in Figure 3. What is the true efficiency of deletion?</p><p>6) Two key functions of B cells are antibody production and secretion of cytokines that fosters T cell activation. It is hard to assess the importance of Orai channels for B cell physiology without at least some measurement of these functions. As such, the narrow focus on the study on B cell proliferation and metabolism falls short of truly understanding the role of SOCE in B cell physiology.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This manuscript examines the roles of Orai channels, the predominant ca<sup>2+</sup> channels in T cells, in the development and activation of B cells. This manuscript evaluates the detailed role of the members of the Orai family, Orai1, Orai2, and Orai3 channels, in ca<sup>2+</sup> signaling, proliferation, and metabolism in B cells. The authors find a positive contribution of Orai1 and Orai3 in B cell activation and metabolic functions using knockout mouse studies. This study has significant novelty and impact.</p><p>Overall, the manuscript has novelty in terms of examining the role of the Orai channels in B lymphocytes, which is currently understudied. While the role of Orai1 in B cell activation and proliferation has been described before, that of Orai3 is not studied. The major weakness of the current work is that the authors need to emphasize experiments showing comparative studies between Orai1 KO, Orai3 KO, and Orai1/3 DKO B cells. Ideally, these results must be compared to Orai1/2 DKO B cells. To strengthen their conclusions, I have the following recommendations:</p><p>1. To emphasize the role of Orai3 in B cells, the authors should check whether B cell development is affected in Orai1/3 Mb1cre KO mice. Orai3 KO alone is unlikely to affect B cell development, however, does co-deletion of Orai1 and Orai3 affect B cell development or mature B cell populations in the spleen and peritoneum (Figure 4)?</p><p>2. The difference in phenotypes between Orai1 and Orai1/3 DKO B cells (which is the novelty of this paper) needs to be presented side by side. Experiments pertaining to Orai1 KO B cells in Figures 3 and 4 should also include those from Orai1/3 DKO B cells. For example, does the loss of both Orai1 and Orai3 affect ca<sup>2+</sup> oscillations in DKO primary B cells (Figure 4), similar to their observation with cell line in Figure 3? The NFAT immunoblots from Figure 6 supplement should move to the main Figure 6. And it will be useful to compare NFAT translocation kinetics shown in Figure 6A among Orai1 KO and Orai1/3 DKO B cells.</p><p>3. What is the physiological output of reduced proliferation in Orai1/3 DKO B cells seen in Figure 7? As shown in the STIM1/2 DKO B cell paper, the authors can check IL-10 production by all 4 genotypes by ELISA to get a quantitative comparison between Orai1 and Orai1/3 DKO cells. The authors should also show a heat map of the B cell cytokine profile (after IgM stimulation) from the RNA-seq results (Figure 7D and E).</p><p>4. In Figure 8, are the mitochondria numbers affected in Orai1/3 DKO (Figure 8D)? What is the cause of reduced respiration (more reduction than that observed in Orai1 KO cells) in the Orai1/3 KO B cells? Using RNA-seq data can the authors uncover the mechanisms linking loss of mitochondrial metabolism to reduced SOCE via Orai1/3?</p><p>5. Ideally, the metabolomic analysis in Figure 9 should be compared between Orai1 KO and Orai1/3 DKO B cells.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Orai channels mediate calcium influx which is essential for immune cell activation. While the role of Orai1 and Orai2 are well established in T lymphocytes, the particular Orai isoforms that function in B cells are not well established. This study uses CRISPR-mediated gene deletion in the A20 B-cell line and primary B cells in mice to examine the functional roles of Orai1, 2, and 3. The authors show evidence that Orai1 and Orai3 are critical components of store-operated Ca channels in B cells and help drive downstream events in B cell activation. New findings include:</p><p>Orai1 and Orai3 are upregulated and Orai2 is downregulated during B cell activation by different stimuli in vitro, including anti-IgM, anti-IgM + anti-CD40, and LPS. The significance of this result is undetermined, as the impact of Orai regulation on B cell responses and Ca signal generation was not studied.</p><p>Based on the effects of CRISPR-mediated deletion, Orai1 and Orai3 both contribute to the magnitude of store-operated Ca entry evoked by full ER Ca depletion in A20 B cells and primary B cells. The combination of Orai1 and Orai3 was critical for the generation of sustained Ca oscillations after BCR stimulation, while deletion of one or the other channel had little effect. However, surface staining of the Orai1 knockout B cells with polyclonal anti-Orai1 antibodies indicated that despite complete suppression of mRNA, surface protein levels were ~75% of wild-type cells. The persistence of Orai1 protein weakens many of the conclusions about the functions of Orai1 based on the knockout cells, e.g. that Orai1 is dispensable for B cell differentiation in vivo, proliferation, and survival after stimulation in vitro, and has only a modest effect on NFAT activation in vitro.</p><p>The double knockout of Orai1 and Orai3 has greater effects on proliferation and survival than Orai1 knockout alone, and greatly inhibits metabolic reprogramming of B cells after in vitro stimulation. However, due to the persistence of Orai1 protein the magnitude of these effects may underestimate the true contribution of Orai1.</p><p>1. Orai1 and Orai3 are shown to be upregulated, while Orai2 is downregulated after stimulation of B cells in vitro (Figure 1), and the effects are dependent on the type of stimulating agent. These same stimulation conditions are used later in experiments on NFAT activation, proliferation and survival, and metabolic reprogramming. However, an essential link between upregulation and functional effects is how are the Ca signals affected? SOCE (with TG) and oscillations (with anti-IgG) should be measured.</p><p>2. A serious problem that affects many of the conclusions of the paper is that CRISPR-mediated deletion of Orai1 in mouse B cells causes only a ~25% decrease in Orai1 protein as detected by the polyclonal antibody. The characteristics of this antibody are not described, and there are questions about its specificity. Has it been validated against cells known to lack Orai1? Was it directly labeled or was a secondary Ab used for FACS? Surface labeling should also be assessed in the A20 Orai1 KO lines.</p><p>Assuming the antibody is specific, the persistence of 75% of the surface Orai1 undermines or changes the interpretations of many of the experiments in the paper:</p><p>a) Cannot say that Orai1 is dispensable for ca<sup>2+</sup> oscillations (line 206-7), B cell development (Figure 4), B cell proliferation and survival (Figure 7), or increased mitochondrial mass in activated B cells (Figure 8).</p><p>b) The enhancement of SOCE in Orai2 KO cells does not actually indicate that residual SOCE in Orai1/Orai3 DKO is due to Orai2 (Figure 5; lines 251-2). An alternative explanation is that the residual SOCE is due to Orai1, and the very low SOCE seen is from Orai2 suppressing the already reduced function of Orai1.</p><p>c) Cannot conclude that Orai3 is an &quot;essential&quot; component of the native SOCE pathway in B cells if Orai1 was not totally eliminated in the Orai1 KO (and therefore had a minimal effect) (line 413).</p><p>It is also worth noting that because Orai1 is the only isoform that supports NFAT activation, the persistence of NFAT translocation in the Orai1 KO cells is another sign that Orai1 protein is still present and functional at significant levels (Figure 6). Moreover, the persistence of residual Orai1 may explain why the phenotype of the Orai1/Orai3 DKO is not as severe as the STIM1/STIM2 DKO studied by other groups (line 446-8).</p><p>3. At several points in the paper, the authors imply that the CRAC channel in B cells is a heteromultimer of Orai1 and Orai3 (e.g., lines 259-60). Orai3 contributes to SOCE, but no arguments are made to rule out the alternative that Orai1 and Orai3 make separate channels. Pharmacology, kinetic profiling (CDI), or permeation properties of CRAC currents in whole-cell recordings may be an approach to distinguish between these possibilities. Otherwise, it remains an open question.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Orai3 and Orai1 are essential for CRAC channel function and metabolic reprogramming in B cells&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Kenton Swartz (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining key issues that need to be addressed in the reviewers' comments. The essential points are:</p><p>1) The patch-clamp data are not credible and the currents do not show the classic inward rectification that is the hallmark of CRAC. Given that no other features are shown, these data should be removed as they are not critical for the study.</p><p>2) There continue to be claims indicating that Orai3 and Orai1 form heteromeric channels. There is no evidence in the study to support this conclusion and the results can be fully explained considering that Orai1 and Orai3 form functional but separate channels. Since the conclusions don't depend on this finding, these claims should be removed.</p><p>3) Reviewers had a problem with language that make claims about Orai3 being essential (or &quot;critical&quot;) for CRAC channel function, or other things such as proliferation (in the Title, Abstract, Discussion, and Results headers). These appear to be left over from the previous version and were not revised. Since the SOCE measurements clearly show that Orai3 is not critical or essential for CRAC channel activity nor &quot;essential&quot; for function including proliferation the language should be changed to &quot;involved&quot; in or something analogous.</p><p>4) Discuss why the Orai3 cKO cells have a respiration defect as SOCE measurements do not show any change in SOCE (Figure 5).</p><p>5) Kudos to the authors for evaluating several in vivo metrics of B cells lacking both Orai1 and Orai3 for B cell cytokine production, IgG antibodies, receptors, and overall immunity for infection (Figure 11). The lack of any effects is extremely surprising. This raises a key concern regarding the in vivo significance of Orai1 and Orai3 for B cell function. In particular, what do all the in vitro data mean if knocking out Orai1 and Orai3 has no effect on B cell development or function? This should be tackled in the Discussion.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>This revised manuscript by Emrich et al. has addressed most of the concerns brought up in the previous round of reviews. The authors have done a nice job and appropriately revised the text and discussion, but a couple of key points remain. Please see the detailed comments below.</p><p>– The new patch-clamp data in Figure 6 are confusing; the currents do not show the classic inward rectification of CRAC currents, and the ramps shown in A-C in fact seem to have the wrong curvature. Since these data do not support the idea of heteromeric Orai1/Orai3 channels and are of unclear origin, I suggest removing these data as they are not needed to support the main conclusions.</p><p>– Supplementary Figure 10: An interesting result here is that upregulation of most polar metabolites co-stimulated with anti-IgM + anti-CD40 is similar to that of control cells stimulated with IgM alone and much larger than the levels seen in WT cells exposed to the GSK compound. This difference means that the effects of the GSK compound are not equivalent to that of the compound. This should be discussed in light of the fact that the DKO eliminates SOCE almost entirely.</p><p>– On page 6, the heading &quot;Both Orai3 and Orai1 are essential components of SOCE in B cells&quot;. The word essential here is incorrect as the data shows that removing Orai3 has no effects on SOCE (Figure 5B, C, and Figure 6E). Please remove the word &quot;essential&quot; in this heading.</p><p>Similarly, in the abstract, the sentence &quot;We show that Orai3 and Orai1 are essential components of native CRAC channels in B cells …&quot; should be modified to remove the word essential for the reason above.</p><p>– Finally, the title remains unchanged from the previous version. The title should be amended since the data clearly shows that Orai3 is not essential for CRAC channel function. Please revise.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Comments on authors' rebuttal:</p><p>1. The effects of Orai protein up- or down-regulation in response to stimulation in vitro need to be related to their effects on NFAT activation, proliferation and survival, and metabolic reprogramming. The authors compare SOCE in naïve vs. stimulated cells after full store depletion (TG), but a comparison of Ca oscillations evoked by IgM stimulation is the relevant one and should be done since these are presumably the kind of Ca signals that are involved in regulating downstream behavior under more physiological conditions.</p><p>2. The updated data on Orai1 expression in the Orai1fl/fl Mb1cre/+ cells makes more sense than the original dataset. It is still not totally clear why there is only a 70% reduction in Orai1 staining. The argument that the antibody for Orai1 crossreacts with Orai2 and Orai3 is not documented here, but the fact that qPCR data show an almost complete absence of Orai1 mRNA is sufficient here to conclude that Orai1 protein is effectively suppressed.</p><p>3. The new patch clamp data are problematic (see comment #2 below) and cannot be used to support the idea that CRAC channels are heteromers of Orai1 and Orai3 as the authors state. One cannot have it both ways – to conclude that there are heteromers, but concede that the evidence does not prove this.</p><p>Comments on the revised manuscript:</p><p>1. A major conclusion of the paper is that Orai3 and Orai1 are &quot;essential&quot; or &quot;crucial&quot; components of native CRAC channels in B cells. This is based on findings that deletion of either protein alone partially reduces SOCE, while the double KO almost completely eliminates it. The authors argue at several points in the paper that the CRAC channel may be a heteromultimer of Orai1 and Orai3, but the data fall short of demonstrating the molecular composition of CRAC channels. In regard to Figure 5 (and Figure S2), &quot;The slower rate of SOCE inhibition by 2-APB in wildtype B cells compared to Orai1 knockout B cells suggests that the native CRAC channel in B cells is a heteromer of Orai1 and Orai3.&quot; I disagree – the data could just as well be explained by separate populations of channels containing Orai1 or Orai3. In that case, 2-APB would inhibit Orai1 but enhance Ca influx through Orai3 (Yamashita et al., JBC 2011); thus, knocking out Orai3 would be expected to increase the inhibitory effect of 2-APB, as seen in Figure 5B. Likewise, the fact that double KO is required to inhibit oscillations could be explained simply by oscillations not being sensitive to a partial loss of SOCE, and only cease when SOCE is largely eliminated. The subunit composition of the channel could be complex, with multiple populations of homomers and heteromers, and unfortunately, these experiments do not answer this question.</p><p>2. The patch-clamp recordings of whole-cell CRAC current are not convincing. The I/V plots are not inwardly rectifying as would be expected from normal CRAC currents, and there is no mention of correction for leak current. This throws into question the conclusion that Orai3 is &quot;a moderate negative regulator of CRAC channel activity,&quot; especially as the KO had no effect on SOCE of naïve cells, and actually decreased SOCE in pre-activated cells or A20 B cells. A careful analysis of current characteristics in the various wild-type and knockout B cells might provide evidence for heteromultimers, but these data do not.</p><p>3. The data from the Orai1 KO cells do not support the conclusion that NFAT activation depends specifically on native Orai1. Figure S3A shows that in the Orai1 KO cells, IgM and TG still dephosphorylate NFAT, just not as much as in control – this is to be expected, as SOCE is partially reduced by O1 KO. If Orai1 were the only isoform that supports NFAT activation, IgM or TG would not dephosphorylate NFAT in the KO cells.</p><p>4. The authors state that Orai1 and Orai3 are critical for primary B cell proliferation and survival (Figure 8). This conclusion needs to be toned down, as KO of either protein alone had little or no effect, and even the double KO had only a partial effect on proliferation. At any rate, the relevance of measuring viability effects after 72 hrs in vitro seems questionable, given that these conditions differ significantly from the environment of the cells in vivo (where there are no discernable functional effects of the DKO).</p><p>5. It is surprising (and disappointing!) that the deletion of Orai1 and Orai3 in B cells did not affect humoral immunity to influenza A infection in mice. In my view, this result seriously undermines the significance of the paper. If Orai channels are not required for B cell development or function in vivo, it is not clear how the in vitro results of the many different assays in this paper relate to the humoral immune response.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84708.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Verify the true extent of cell surface Orai1 expression in Orai1 KO B cells: The data in Figure 3A, B clearly show that expression in the MB1-Cre cells is ~75% of the wildtype controls implying that most Orai1 protein is in fact still retained at the cell surface. This makes it very difficult to draw any realistic conclusions about the role of Orai1, and by extension, Orai3 using the Orai1/Orai3 DKOs. The Orai1 antibody should be validated, and if it is not specific, a better one should be used with appropriate validation.</p></disp-quote><p>We sincerely apologize for mistakenly including the data in Figure 3A, B, which resulted in an unfortunate misunderstanding. Data in Figure 3A, B were preliminary and based on earlier experiments conducted without Fc block, resulting in non-specific binding of the anti-Orai1 antibody (via its Fc region) to B cells (via Fc receptors expressed on B cells). In this revision, we now show data from experiments that were performed with an Fc block. These data show that the surface expression of Orai1 in B cells from Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice is reduced by ~ 70%, as determined by flow cytometry with an updated intracellular staining protocol. The vast majority of the residual signal of ~ 30% above FMO (fluorescence minus one, i.e. the anti-Orai1 antibody signal) is likely due to non-specific binding of the Orai1 antibody by its variable region (not its Fc part) to other Orai homologues (Orai2, Orai3), which partially share the peptide epitope recognized by the anti-Orai1 antibody. We also would like to kindly point out other lines of evidence indicating that Orai1 is indeed deleted in B cells of Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice: (a) Our qPCR data show almost complete absence of Orai1 mRNA in their B cells. (b) Our SOCE data show strongly reduced SOCE in their B cells. (c) Cre-mediated deletion of Orai1<sup>fl/fl</sup> alleles was shown to be very efficient in other cell types including T cells (Kaufmann/Feske 2016, PMID 26673135) and neuronal progenitor cells (Somasundaram/Prakriya, PMID 24990931).</p><disp-quote content-type="editor-comment"><p>2) Related to the above point, the strong residual NFAT activation in Orai1 KO cells (surprising!), and lack of effect on B cell proliferation (which contradicts Gwack et al., 2008) seems consistent with the persistence of functional Orai1 protein at the cell surface.</p></disp-quote><p>The original study by Gwack et al. first reported on global Orai1<sup>-/-</sup> mice generated through targeted Orai1 gene deletion. B cells isolated from these Orai1<sup>-/-</sup> mice showed a robust (~70-75%) decrease in SOCE (see Figure 2C and Figure 4A) that agrees with data reported in our manuscript with B cells from Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice. Taking this and our response to the above comment into consideration, we conclude that while Orai1 expression in our B cells is not zero as is the case for data by Gwack et al., it is dramatically reduced in B cells from Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice. Although the NFAT activation is only partially inhibited in naive Orai1 KO B cells (Figure 7D, E), it correlates well the incomplete suppression of SOCE. Further, when one considers activated B cells (Figure 7F, G), NFAT dephosphorylation is dramatically inhibited. Gwack et al. showed a partial inhibition of proliferation in B cells from Orai1<sup>-/-</sup> mice. While we see a small inhibition of proliferation in Orai1 KO B cells, we see more reduction in viability of these cells. Based on our Orai1 antibody staining, SOCE measurements and qPCR data (the latter showing ~97% decrease of <italic>Orai1</italic> mRNA in B cells from Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice), we can only speculate that in the B cells from Orai1<sup>-/-</sup> mice in Gwack et al., Orai1 is knocked out from early B cell development in mice that are on mixed ICR background (otherwise mice would die) whereas in our Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice, Orai1 is deleted later in B cell development in mice that are on a pure C57Bl/6 background. Another potential explanation could be the complete deletion of Orai1 gene in the studies of Gwack et al. vs the 97% reduction in mRNA expression we observe in our B cells from Orai1<sup>fl/fl</sup> Mb1<sup>cre/+</sup> mice. Nevertheless, our results on B cell proliferation and NFAT dephosphorylation fully agree with B cell proliferation data from B cell specific STIM1/2 double KO mice (Matsumoto et al. 2011: PMID: 21530328 and Berry et al. 2020, PMID: 32563861).</p><disp-quote content-type="editor-comment"><p>3) The paper seems to imply that CRAC channels in B cells are heteromultimers of Orai1/Orai3 proteins. Without electrophysiological analysis, this claim realistically cannot be made and the study needs to demonstrate this point more definitively than simply looking at increases or decreases in cellular calcium concentrations.</p></disp-quote><p>We apologize if we seemed to imply that CRAC channels in B cells are heteromultimers of Orai1/Orai3. This was not our intention. Our statements were intentionally vague regarding his issue, something that reviewers noticed. As suggested, we have now included whole cell patch clamp measurements from primary B cells acutely isolated from mice (Figure 6) showing that Orai1 KO and Orai3 KO have additive effects on CRAC currents with Orai3 KO causing a small but significant enhancement of CRAC currents. While these data (along with the faster rate of SOCE inhibition by 2-APB in Orai3 KO B cells; Figure 5B, D) provide some evidence that Orai1 and Orai3 potentially heteromultimerize, they do not rule out the presence of homohexamers of Orai1 and Orai3. We have tempered our conclusions to reflect these possibilities.</p><disp-quote content-type="editor-comment"><p>4) The difference in phenotypes between Orai1 and Orai1/3 DKO B cells needs to be presented side by side to allow direct comparison. This should be done for Ca oscillations, NFAT activation and kinetics, proliferation, OCR, and respiration. See reviewer 2's comments on this matter. Experiments pertaining to Orai1 KO B cells in Figures 3 and 4 should also include those from Orai1/3 DKO B cells.</p></disp-quote><p>We appreciate the convenience of showing data from Orai1 and Orai1/3 DKO B cells side by side to allow comparison. We have opted to present side by side data only when experiments were performed side by side. We have the Orai1 and Orai1/3 DKO B cell data side by side for SOCE, NFAT activation, proliferation, OCR, respiration, and whole cell patch clamp (Figures5-9 and Figure 5—figure supplement 1; Figure 7—figure supplement 1). The only time where only Orai1 data (ca<sup>2+</sup> oscillations and B cell development) is shown is in Figures3-4 as pointed out by the reviewer. These experiments were performed much earlier when we were still breeding mice to generate double Orai1/3 B cell knockout. Unfortunately, we do not have the means to evaluate B cell development in Orai1/3 DKO B cells, as we no longer have the double Orai1/3 KO mice due to our recent move to the University of Pittsburgh. However, please see our response to comment 6 below.</p><disp-quote content-type="editor-comment"><p>5) The functional significance of the study in its current form is very limited. Additional functional analysis to include cytokine production or antibody production is needed to increase the significance of the study.</p></disp-quote><p>We are grateful for this suggestion. In this revision, we now provide a heat map of the B cell cytokine and cytokine receptor profile (after IgM stimulation) from the RNA-seq results (Figure 11—figure supplement1). Furthermore, we have performed additional experiments to address this important issue using an in vivo mouse infection model. We reasoned that considering the contribution of Orai1 and Orai3 to B cell NFAT activation and metabolism, we hypothesized that deletion of <italic>Orai1</italic> and <italic>Orai3</italic> would compromise immune responses, including antibody production in response to influenza A virus (IAV) infection. These data, which are now reported in Figure 11 show that B cell-specific deletion of <italic>Orai1</italic> and <italic>Orai3</italic> does not significantly impair immune responses to influenza virus infection. We have discussed the implication of these findings in the manuscript.</p><disp-quote content-type="editor-comment"><p>6) B cell development. Check whether B cell development is affected in Orai1/3 Mb1cre KO mice. As noted by reviewer 2, Orai3 KO alone is unlikely to affect B cell development, however, does co-deletion of Orai1 and Orai3 affect B cell development or mature B cell populations in the spleen and peritoneum (Figure 4)?</p></disp-quote><p>Unfortunately, we cannot perform these experiments as we no longer have the double Orai1/3 KO mice due to our recent move to the University of Pittsburgh. However, we would like to respectfully argue that based on our data with Influenza virus infection (Figure 11) and on data from mice with double STIM1/2 KO mice (Matsumoto et al. 2011: PMID: 21530328 and Berry et al. 2020, PMID: 32563861), it is highly unlikely that B cell development would be affected in Orai1/3 KO mice.</p><disp-quote content-type="editor-comment"><p>7) What is the reason for reduced respiration in the Orai1/3 KO B cells which seems more than that observed in Orai1 KO cells? Use RNA-seq to examine this question.</p></disp-quote><p>This is an important observation. We have included GSEA analysis on previously performed RNA-seq comparing control B cells to Orai1 KO B cells and control B cells to Orai1/3 KO B cells. As suggested, we now include these data in the manuscript (Figure 9—figure supplement 1) that show that only Orai1/3 KO (and not Orai1 KO) B cells have defects in OXPHOS genes and MYC targets genes. These data indicate that Orai3 function complements that of Orai1 and could be explained by the patch clamp data where deletions of Orai1 and Orai3 have additive effects on CRAC currents. Alternatively, it is also possible that Orai3 might regulate ca<sup>2+</sup>-independent gene programs supporting OXPHOS. Future studies are needed to shed light on this issue.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>In this study, Emrich and coworkers examine the consequences of ablating Orai3 and Orai1 on store-operated calcium entry and B cell functions. It is known that SOCE is important for T cell function including T cell activation, proliferation, and cytokine synthesis. But less is known about Orai channel contributions to B cell function. Using conditional deletion of Orai1 and Orai3 in B cells, the authors examine several functional endpoints including B cell proliferation, development, and metabolism. These endpoints are diminished by Orai1 deletion. Deletion of Orai3 evokes no phenotype for most endpoints. The results indicating a lack of developmental effects on B cells with Orai1 deletion are not surprising and replicate previous work on these topics both in B cells and in T cells (relevant papers from Feske lab). Orai1 deletion also prevents NFAT activation, a well-known consequence of Orai1 inhibition in many cells. However, in several cases, the double Orai1/Orai3 knockout shows phenotypes that are slightly larger than those seen in Orai1-alone deficient B cells, suggesting that Orai3 plays a modest role in residual calcium entry and cellular functions.</p><p>While the experiments are carefully conducted, I think the paper exaggerates the role of Orai3 in B cell function. Many statements such as &quot;Orai3 and Orai1 coordinate for efficient B cell proliferation&quot; are not meaningful and vague and overstate the role of Orai3. In fact, Orai1 or Orai3 deletion has no effect on B cell proliferation. The lack of effect of Orai1 deletion is somewhat surprising and contradicts earlier findings (Gwack et al., 2008) indicating that Orai1 is critical for B cell proliferation and this contradiction is not explained. The double Orai3/Orai1 KO evokes a modest reduction of B cell proliferation but it is unclear whether this is a specific effect or downstream of more general suppression of metabolism since it is well known that rapidly proliferating cells require a high level of metabolism and glycolysis which is suppressed in the double KO. Perhaps the most interesting part of the paper is that the double KO shows a greater suppression of oxygen consumption and maximal respiration than Orai1 KO cells alone. But no effect is seen with Orai3 KO ablation and none on basal respiration even though deletion of Orai1 alone evokes the strongest effects. Thus, statements indicating that Orai1/Orai3 channels are crucial for metabolic reprogramming do not easily follow from the data shown, which seem to indicate very minor contributions of Orai3 for these endpoints.</p></disp-quote><p>We thank reviewer 1 for their critical reading of our manuscript. In this revision, we have added several new experiments, including RNA-seq data showing the OXPHOS genes are only altered in Orai1/3 KO B cells, and not in Orai1 KO B cells. We have also altered our interpretations of the data to reflect the evidence presented, by removing vague or exaggerated statements. We have also discussed our results on B cell proliferation considering the findings by Gwack et al. 2008 (please see response to essential comment # 2 above).</p><disp-quote content-type="editor-comment"><p>Overall, the role of Orai3 is greatly over-emphasized and is not supported by the results. One could easily conclude based on the results that Orai3 is largely dispensable/redundant for the B cell responses that were studied here. But it is also worth noting that only a small subset of physiologically relevant B cell responses was assessed and notably cytokine and antibody production were not studied at all. These issues reduce the significance of the study.</p></disp-quote><p>We agree with the reviewer that for the parameters analyzed herein, Orai3 is largely dispensable. Orai3 contribution, to OXPHOS in particular, becomes apparent only within the context of double Orai1/Orai3 knockout. We now show in vivo data with B cell Orai1/3 double KO mice in a model of Influenza infection.</p><disp-quote content-type="editor-comment"><p>Additional comments:</p><p>1) What is the effect of deleting Orai3 on NFAT1 activation? A lack of effect on cell proliferation in vitro is not surprising and is reminiscent of the lack of effects on proliferation in T cells with non-function Orai1 channels (McCarl, Feske et al., JI 2010).</p></disp-quote><p>Data in Figure 7—figure supplement 1 shows that deletion of Orai3 alone has no effect on NFAT1 dephosphorylation, which is expected.</p><disp-quote content-type="editor-comment"><p>2) Are Orai channels in a complex with Orai1 and Orai3 subunits in the same channel or are they expressed separately to form distinct channels in B cells? 2-APB appears to inhibit the residual SOCE in Orai3 deficient cells but not in Orai1 deficient cells. What are the implications of this result? The 2-APB experiment is uninterpreted in terms of the molecular composition of the SOCE channels.</p></disp-quote><p>We thank the reviewer for this comment. This is a very important question that is hard to answer within the context of native channel expression. Unlike the case where a molecular complex ceases to function when one of its subunits are absent, each Orai isoform is capable of mediating CRAC currents either in a heterocomplex or on its own. The 2-APB data showing faster rate of SOCE inhibition by 2-APB in Orai3 KO B cells compared to wildtype B cells (Figure 5B, D) suggest that Orai3 and Orai1 form a heterocomplex. We now present whole cell recordings of CRAC currents (Figure 6), which also suggest Orai1/3 heteromultimerization. However, these data do not exclude that at least a portion of Orai1 and Orai3 proteins are functional as homohexamers. We have discussed these possibilities in the text.</p><disp-quote content-type="editor-comment"><p>3) In order to really assess the contributions of Orai3 to B cell physiological responses, it is important to directly compare the outcomes side-by-side for the different endpoints. Thus, the metrics for NFAT activation, proliferation, OCR, respiration, etc. should be directly compared as in Figure 2.</p></disp-quote><p>Please see our response to essential comments #4 above.</p><disp-quote content-type="editor-comment"><p>4) Figure 6: the fact that Orai1 deletion in primary B cells causes a substantial decrease in NFAT1 activation but has no effects on Ca oscillations (Figure 2/3) implies that the Ca oscillations have no direct relevance for NFAT activation in B cells. This result seems to contradict previous literature on this issue and should be discussed. Is NFAT1 activation more dependent on the plateau Ca responses instead of oscillations?</p></disp-quote><p>Thank you for raising this important point. We have recently shown using combinations of Orai and STIM CRISPR KO in HEK293 cells that regardless of the nature of the ca<sup>2+</sup> signal (plateau vs Oscillatory) NFAT activation depends on the ca<sup>2+</sup> signal generated by native Orai1 (Yoast et al. 2020; PMID: 32415068). Specifically, ca<sup>2+</sup> oscillations were intact in Orai1 KO cells (oscillations in Orai1 KO cells were mediated by Orai2/3) but NFAT nuclear translocation was abrogated. We now discuss this issue in the manuscript.</p><disp-quote content-type="editor-comment"><p>5) There is a large discrepancy between mRNA and protein levels in Figure 3. What is the true efficiency of deletion?</p></disp-quote><p>Please see new data in Figure 3 and please refer to our response to essential comment #1.</p><disp-quote content-type="editor-comment"><p>6) Two key functions of B cells are antibody production and secretion of cytokines that fosters T cell activation. It is hard to assess the importance of Orai channels for B cell physiology without at least some measurement of these functions. As such, the narrow focus on the study on B cell proliferation and metabolism falls short of truly understanding the role of SOCE in B cell physiology.</p></disp-quote><p>To address this comment, we now include in vivo data in Figure 11 and we provide a discussion of the meaning of these in vivo results considering the defects in B cell NFAT activation and metabolism in Orai1/3 KO B cells.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This manuscript examines the roles of Orai channels, the predominant ca<sup>2+</sup> channels in T cells, in the development and activation of B cells. This manuscript evaluates the detailed role of the members of the Orai family, Orai1, Orai2, and Orai3 channels, in ca<sup>2+</sup> signaling, proliferation, and metabolism in B cells. The authors find a positive contribution of Orai1 and Orai3 in B cell activation and metabolic functions using knockout mouse studies. This study has significant novelty and impact.</p></disp-quote><p>We thank reviewer 2 for their positive comments on our manuscript.</p><disp-quote content-type="editor-comment"><p>Overall, the manuscript has novelty in terms of examining the role of the Orai channels in B lymphocytes, which is currently understudied. While the role of Orai1 in B cell activation and proliferation has been described before, that of Orai3 is not studied. The major weakness of the current work is that the authors need to emphasize experiments showing comparative studies between Orai1 KO, Orai3 KO, and Orai1/3 DKO B cells. Ideally, these results must be compared to Orai1/2 DKO B cells. To strengthen their conclusions, I have the following recommendations:</p></disp-quote><p>We thank reviewer 2 for their critical reading of our manuscript. While we agree with reviewer 2 assessment, it would take months or years for us to generate Orai1/2 DKO B cells, or ideally the Orai1/2/3 B cell triple KO mice. We hope the reviewer agrees that this should be considered under a separate study.</p><disp-quote content-type="editor-comment"><p>1. To emphasize the role of Orai3 in B cells, the authors should check whether B cell development is affected in Orai1/3 Mb1cre KO mice. Orai3 KO alone is unlikely to affect B cell development, however, does co-deletion of Orai1 and Orai3 affect B cell development or mature B cell populations in the spleen and peritoneum (Figure 4)?</p></disp-quote><p>Please see our response to essential comment #6.</p><disp-quote content-type="editor-comment"><p>2. The difference in phenotypes between Orai1 and Orai1/3 DKO B cells (which is the novelty of this paper) needs to be presented side by side. Experiments pertaining to Orai1 KO B cells in Figures 3 and 4 should also include those from Orai1/3 DKO B cells. For example, does the loss of both Orai1 and Orai3 affect ca<sup>2+</sup> oscillations in DKO primary B cells (Figure 4), similar to their observation with cell line in Figure 3? The NFAT immunoblots from Figure 6 supplement should move to the main Figure 6. And it will be useful to compare NFAT translocation kinetics shown in Figure 6A among Orai1 KO and Orai1/3 DKO B cells.</p></disp-quote><p>Please see our response to essential comment #4. We have side by side comparisons each time this was possible. Sadly, we are unable to perform two experiments with Orai1/3 double KO B cells requested by the reviewer, (i) B cell development and (ii) ca<sup>2+</sup> oscillations, due to the current unavailability of live Orai1/3 KO mice (it would take us months to bring up those colonies). We show that NFAT nuclear translocation in Orai1/3 DKO B cells is equivalent to that in Orai1 KO B cells based on Westerns of NFAT dephosphorylation (Figure S3). Although we cannot test the NFAT translocation kinetics in Orai1/3 DKO B cells by ImageStream for the same reason listed above, we do not expect this to differ from that in Orai1 KO B cells.</p><disp-quote content-type="editor-comment"><p>3. What is the physiological output of reduced proliferation in Orai1/3 DKO B cells seen in Figure 7? As shown in the STIM1/2 DKO B cell paper, the authors can check IL-10 production by all 4 genotypes by ELISA to get a quantitative comparison between Orai1 and Orai1/3 DKO cells. The authors should also show a heat map of the B cell cytokine profile (after IgM stimulation) from the RNA-seq results (Figure 7D and E).</p></disp-quote><p>We thank the reviewer for this suggestion. We know include the data of the B cell cytokine profile after anti-IgM stimulation (Figure 11—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>4. In Figure 8, are the mitochondria numbers affected in Orai1/3 DKO (Figure 8D)? What is the cause of reduced respiration (more reduction than that observed in Orai1 KO cells) in the Orai1/3 KO B cells? Using RNA-seq data can the authors uncover the mechanisms linking loss of mitochondrial metabolism to reduced SOCE via Orai1/3?</p></disp-quote><p>Due to limitations in obtaining large numbers of Orai1/3 KO mice during breeding, we have analyzed mitochondrial mass in one preliminary experiment that showed no obvious defect in mitochondria number of Orai1/3 DKO B cells. Hence, we did not pursue this avenue further. Per reviewer request, we now present RNA-seq data showing unique defects in OXPHOS genes in B cells from Orai1/3 DKO mice.</p><disp-quote content-type="editor-comment"><p>5. Ideally, the metabolomic analysis in Figure 9 should be compared between Orai1 KO and Orai1/3 DKO B cells.</p></disp-quote><p>We sincerely apologize for not including these data, while we performed RNA-seq from B cells of both Orai1 KO and Orai1/3 DKO mice, metabolomic analysis was performed only in B cells from Orai1/3 DKO mice.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Orai channels mediate calcium influx which is essential for immune cell activation. While the role of Orai1 and Orai2 are well established in T lymphocytes, the particular Orai isoforms that function in B cells are not well established. This study uses CRISPR-mediated gene deletion in the A20 B-cell line and primary B cells in mice to examine the functional roles of Orai1, 2, and 3. The authors show evidence that Orai1 and Orai3 are critical components of store-operated Ca channels in B cells and help drive downstream events in B cell activation. New findings include:</p><p>Orai1 and Orai3 are upregulated and Orai2 is downregulated during B cell activation by different stimuli in vitro, including anti-IgM, anti-IgM + anti-CD40, and LPS. The significance of this result is undetermined, as the impact of Orai regulation on B cell responses and Ca signal generation was not studied.</p><p>Based on the effects of CRISPR-mediated deletion, Orai1 and Orai3 both contribute to the magnitude of store-operated Ca entry evoked by full ER Ca depletion in A20 B cells and primary B cells. The combination of Orai1 and Orai3 was critical for the generation of sustained Ca oscillations after BCR stimulation, while deletion of one or the other channel had little effect. However, surface staining of the Orai1 knockout B cells with polyclonal anti-Orai1 antibodies indicated that despite complete suppression of mRNA, surface protein levels were ~75% of wild-type cells. The persistence of Orai1 protein weakens many of the conclusions about the functions of Orai1 based on the knockout cells, e.g. that Orai1 is dispensable for B cell differentiation in vivo, proliferation, and survival after stimulation in vitro, and has only a modest effect on NFAT activation in vitro.</p><p>The double knockout of Orai1 and Orai3 has greater effects on proliferation and survival than Orai1 knockout alone, and greatly inhibits metabolic reprogramming of B cells after in vitro stimulation. However, due to the persistence of Orai1 protein the magnitude of these effects may underestimate the true contribution of Orai1.</p></disp-quote><p>We thank the reviewer for the accurate representation of our findings. Please see our response to essential comment 1. Regarding two specific critiques of Reviewer 3, we would like to respectfully point out that “<italic>CRISPR-mediated deletion of Orai1 in mouse B cells”</italic> is not correct, but that Orai1 was deleted by conditional gene targeting. The papers by (Kaufmann/Feske 2016, PMID 26673135) and (Somasundaram/Prakriya, PMID 24990931) have shown deletion of Orai1 in T cells and neuronal progenitor cells in these mice. Regarding the comment “<italic>The characteristics of this antibody are not described, and there are questions about its specificity”,</italic> we have specified in the Methods (under flow cytometry section) the origin of the anti-Orai1 antibody (Gwack 2008, PMID 18591248 and McCarl 2009, PMID 20004786).</p><disp-quote content-type="editor-comment"><p>1. Orai1 and Orai3 are shown to be upregulated, while Orai2 is downregulated after stimulation of B cells in vitro (Figure 1), and the effects are dependent on the type of stimulating agent. These same stimulation conditions are used later in experiments on NFAT activation, proliferation and survival, and metabolic reprogramming. However, an essential link between upregulation and functional effects is how are the Ca signals affected? SOCE (with TG) and oscillations (with anti-IgG) should be measured.</p></disp-quote><p>We thank the reviewer for this suggestion. We have explored the link between Orai1 and Orai3 transcript upregulation and SOCE, but only in the condition of 48hr stimulation with anti-IgM+anti-CD40. Please compare Figure 5B, C to Figure 5—figure supplement 1. We do not see any apparent increase in SOCE in activated B cells. However, since activated B cells become lymphoblasts with a bigger volume, we propose that the upregulation of Orais is likely meant to maintain SOCE, commensurate with the enhanced volume of activated B cells.</p><disp-quote content-type="editor-comment"><p>2. A serious problem that affects many of the conclusions of the paper is that CRISPR-mediated deletion of Orai1 in mouse B cells causes only a ~25% decrease in Orai1 protein as detected by the polyclonal antibody. The characteristics of this antibody are not described, and there are questions about its specificity. Has it been validated against cells known to lack Orai1? Was it directly labeled or was a secondary Ab used for FACS? Surface labeling should also be assessed in the A20 Orai1 KO lines.</p><p>Assuming the antibody is specific, the persistence of 75% of the surface Orai1 undermines or changes the interpretations of many of the experiments in the paper:</p><p>a) Cannot say that Orai1 is dispensable for ca<sup>2+</sup> oscillations (line 206-7), B cell development (Figure 4), B cell proliferation and survival (Figure 7), or increased mitochondrial mass in activated B cells (Figure 8).</p><p>b) The enhancement of SOCE in Orai2 KO cells does not actually indicate that residual SOCE in Orai1/Orai3 DKO is due to Orai2 (Figure 5; lines 251-2). An alternative explanation is that the residual SOCE is due to Orai1, and the very low SOCE seen is from Orai2 suppressing the already reduced function of Orai1.</p><p>c) Cannot conclude that Orai3 is an &quot;essential&quot; component of the native SOCE pathway in B cells if Orai1 was not totally eliminated in the Orai1 KO (and therefore had a minimal effect) (line 413).</p><p>It is also worth noting that because Orai1 is the only isoform that supports NFAT activation, the persistence of NFAT translocation in the Orai1 KO cells is another sign that Orai1 protein is still present and functional at significant levels (Figure 6). Moreover, the persistence of residual Orai1 may explain why the phenotype of the Orai1/Orai3 DKO is not as severe as the STIM1/STIM2 DKO studied by other groups (line 446-8).</p></disp-quote><p>Please see our response to essential comment 1.</p><disp-quote content-type="editor-comment"><p>3. At several points in the paper, the authors imply that the CRAC channel in B cells is a heteromultimer of Orai1 and Orai3 (e.g., lines 259-60). Orai3 contributes to SOCE, but no arguments are made to rule out the alternative that Orai1 and Orai3 make separate channels. Pharmacology, kinetic profiling (CDI), or permeation properties of CRAC currents in whole-cell recordings may be an approach to distinguish between these possibilities. Otherwise, it remains an open question.</p></disp-quote><p>We agree with the reviewer that the oligomeric state of native CRAC channels in B cells (or any other cell type for that matter) remains an open question, and we have clearly stated this in the manuscript. While our attempts to study CDI have been unsuccessful due the small nature of these native currents, we provide whole-cell CRAC measurements in primary B cells from different Orai KO mice as requested by the reviewer. Based on the increased CRAC current size in B cells from Orai3 KO mice, we propose that Orai1 and Orai3 likely heteromultimerize. However, we concede that this does not rule out the existence of homohexameric channels and that these recordings do not represent in themselves proof of heteromultimerization. More studies beyond the scope of this manuscript are needed to resolve the CRAC channel composition in native cells.</p><p>[Editors’ note: what follows is the authors’ response to the second round of review.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining key issues that need to be addressed in the reviewers' comments. The essential points are:</p><p>1) The patch-clamp data are not credible and the currents do not show the classic inward rectification that is the hallmark of CRAC. Given that no other features are shown, these data should be removed as they are not critical for the study.</p></disp-quote><p>Thank you! We agree. These data have been removed.</p><disp-quote content-type="editor-comment"><p>2) There continue to be claims indicating that Orai3 and Orai1 form heteromeric channels. There is no evidence in the study to support this conclusion and the results can be fully explained considering that Orai1 and Orai3 form functional but separate channels. Since the conclusions don't depend on this finding, these claims should be removed.</p></disp-quote><p>Thank you! We have revised the manuscript so there are no claims in the conclusions as to the composition of CRAC channels in B cells. We apologize, our statements were not meant as conclusions but as speculation on the different possibilities. This is obviously a complex question that is not easy to address. The native CRAC channel in a single B cell is likely dynamic and complex with both homomers and different heteromeric assemblies.</p><disp-quote content-type="editor-comment"><p>3) Reviewers had a problem with language that make claims about Orai3 being essential (or &quot;critical&quot;) for CRAC channel function, or other things such as proliferation (in the Title, Abstract, Discussion, and Results headers). These appear to be left over from the previous version and were not revised. Since the SOCE measurements clearly show that Orai3 is not critical or essential for CRAC channel activity nor &quot;essential&quot; for function including proliferation the language should be changed to &quot;involved&quot; in or something analogous.</p></disp-quote><p>The manuscript has been revised accordingly. We changed the title, abstract and text to reflect this. In the Abstract we specified that Orai3 alone is not essential: “The combined loss of Orai1 and Orai3, but not Orai3 alone, impairs SOCE, proliferation and survival….” In the results subheadings and throughout the text, we emphasize that only the combined deletion of Orai1 and Orai3 has an effect on different cellular parameters. Statements such as “Orai3 is essential for SOCE” were replaced by “Orai3 is involved in SOCE” or “Orai3 and Orai1 mediate SOCE”</p><disp-quote content-type="editor-comment"><p>4) Discuss why the Orai3 cKO cells have a respiration defect as SOCE measurements do not show any change in SOCE (Figure 5).</p></disp-quote><p>We now discuss this issue in the manuscript’s discussion. Please note that although Orai3 KO alone has no measurable effect on SOCE in naïve B cells, the data with activated B cells show a partial contribution of Orai3 to B cell SOCE (Figure. 5—figure supplement 1). These data are consistent with the bioenergetics data, which are from B cells activated for 24hrs with anti-IgM (naïve B cell are metabolically quiescent).</p><disp-quote content-type="editor-comment"><p>5) Kudos to the authors for evaluating several in vivo metrics of B cells lacking both Orai1 and Orai3 for B cell cytokine production, IgG antibodies, receptors, and overall immunity for infection (Figure 11). The lack of any effects is extremely surprising. This raises a key concern regarding the in vivo significance of Orai1 and Orai3 for B cell function. In particular, what do all the in vitro data mean if knocking out Orai1 and Orai3 has no effect on B cell development or function? This should be tackled in the Discussion.</p></disp-quote><p>We agree that the lack of any effects of B cell double knockout of Orai1 and Orai3 on humoral immunity to Influenza A infection is extremely surprising. However, these are the results we obtained and no matter how disappointing, they reflect reality. We believe that scientific reality should never be referred to as concerning or disappointing. Otherwise, we set our trainees on the path of “magical realism”, where “exciting” results “must be obtained” if they wish their papers accepted for publication. At the very least, our results offer a contrast with the function of SOCE in T cells, offer further evidence that the immune defects of CRAC channelopathies in humans are mostly T cell driven and emphasize the evolutionary hierarchy of SOCE between lymphocyte subsets, which is important to know from an academic standpoint and might be useful for future targeting of CRAC in a T cell-driven vs a B cell driven disease. We now provide in the discussion some ideas on why the results in vivo do not reflect the in vitro requirement of SOCE for NFAT induction, and metabolic reprogramming (please see end of the discussion).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>This revised manuscript by Emrich et al. has addressed most of the concerns brought up in the previous round of reviews. The authors have done a nice job and appropriately revised the text and discussion, but a couple of key points remain. Please see the detailed comments below.</p><p>– The new patch-clamp data in Figure 6 are confusing; the currents do not show the classic inward rectification of CRAC currents, and the ramps shown in A-C in fact seem to have the wrong curvature. Since these data do not support the idea of heteromeric Orai1/Orai3 channels and are of unclear origin, I suggest removing these data as they are not needed to support the main conclusions.</p></disp-quote><p>Thank you! Yes, it has not escaped our attention that the I/V relationships of these currents are indeed not typical. Therefore, we did not include these recordings in the first version (R0) of the manuscript. Although we think these recordings contain a contribution from CRAC currents, the currents are very small and most likely contaminated. In any case, we agree that these recordings should be removed from the manuscript as they do not offer more clarity or insight.</p><disp-quote content-type="editor-comment"><p>– Supplementary Figure 10: An interesting result here is that upregulation of most polar metabolites co-stimulated with anti-IgM + anti-CD40 is similar to that of control cells stimulated with IgM alone and much larger than the levels seen in WT cells exposed to the GSK compound. This difference means that the effects of the GSK compound are not equivalent to that of the compound. This should be discussed in light of the fact that the DKO eliminates SOCE almost entirely.</p></disp-quote><p>Thank you for this observation. We have added an explanation to the discussion. We recently characterized GSK-7975A for its equal inhibitory effect on CRAC currents mediated by each Orai isoform (Orai isoforms were individually co-expressed with STIM1 in Orai1/2/3 triple KO HEK cells), compared to differential effects on Orai isoforms with other common SOCE inhibitors like Synta66 (PMID: 32896813). While the more pronounced inhibition of the upregulation of metabolites by GSK-7975A in B cells compared to the inhibition observed in Orai1/Orai3 double KO B cells could be an off-target effect of the drug, a more likely explanation is that Orai2 contributes to this difference by mediating the residual ca<sup>2+</sup> influx in Orai1/Orai3 double KO B cells.</p><disp-quote content-type="editor-comment"><p>– On page 6, the heading &quot;Both Orai3 and Orai1 are essential components of SOCE in B cells&quot;. The word essential here is incorrect as the data shows that removing Orai3 has no effects on SOCE (Figure 5B, C, and Figure 6E). Please remove the word &quot;essential&quot; in this heading.</p></disp-quote><p>Thank you! The word “essential” was removed here, from the title, the abstract and throughout the text.</p><disp-quote content-type="editor-comment"><p>Similarly, in the abstract, the sentence &quot;We show that Orai3 and Orai1 are essential components of native CRAC channels in B cells …&quot; should be modified to remove the word essential for the reason above.</p></disp-quote><p>Done. Please see response to essential comments 2 and 3.</p><disp-quote content-type="editor-comment"><p>– Finally, the title remains unchanged from the previous version. The title should be amended since the data clearly shows that Orai3 is not essential for CRAC channel function. Please revise.</p></disp-quote><p>Done. Please see response to essential comments 2 and 3.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Comments on authors' rebuttal:</p><p>1. The effects of Orai protein up- or down-regulation in response to stimulation in vitro need to be related to their effects on NFAT activation, proliferation and survival, and metabolic reprogramming. The authors compare SOCE in naïve vs. stimulated cells after full store depletion (TG), but a comparison of Ca oscillations evoked by IgM stimulation is the relevant one and should be done since these are presumably the kind of Ca signals that are involved in regulating downstream behavior under more physiological conditions.</p></disp-quote><p>We respectfully disagree with reviewer 3 assessment. Our view on oscillations has evolved based on models where each STIM and Orai isoforms were deleted individually and in combination. The real correlation is between the magnitude of SOCE and NFAT nuclear translocation and not between ca<sup>2+</sup> oscillations and NFAT translocation (please see our response to the second comment 3 below). We found this to be the case for HEK 293 cells (PMID: 32415068 and PMID: 33657364), B cells (the current study) and T cells (work currently in progress).</p><disp-quote content-type="editor-comment"><p>2. The updated data on Orai1 expression in the Orai1fl/fl Mb1cre/+ cells makes more sense than the original dataset. It is still not totally clear why there is only a 70% reduction in Orai1 staining. The argument that the antibody for Orai1 crossreacts with Orai2 and Orai3 is not documented here, but the fact that qPCR data show an almost complete absence of Orai1 mRNA is sufficient here to conclude that Orai1 protein is effectively suppressed.</p></disp-quote><p>Thank you!</p><disp-quote content-type="editor-comment"><p>3. The new patch clamp data are problematic (see comment #2 below) and cannot be used to support the idea that CRAC channels are heteromers of Orai1 and Orai3 as the authors state. One cannot have it both ways – to conclude that there are heteromers, but concede that the evidence does not prove this.</p></disp-quote><p>Please see our response to essential comments #1 and 2 (also, please see below)</p><disp-quote content-type="editor-comment"><p>Comments on the revised manuscript:</p><p>1. A major conclusion of the paper is that Orai3 and Orai1 are &quot;essential&quot; or &quot;crucial&quot; components of native CRAC channels in B cells. This is based on findings that deletion of either protein alone partially reduces SOCE, while the double KO almost completely eliminates it. The authors argue at several points in the paper that the CRAC channel may be a heteromultimer of Orai1 and Orai3, but the data fall short of demonstrating the molecular composition of CRAC channels. In regard to Figure 5 (and Figure S2), &quot;The slower rate of SOCE inhibition by 2-APB in wildtype B cells compared to Orai1 knockout B cells suggests that the native CRAC channel in B cells is a heteromer of Orai1 and Orai3.&quot; I disagree – the data could just as well be explained by separate populations of channels containing Orai1 or Orai3. In that case, 2-APB would inhibit Orai1 but enhance Ca influx through Orai3 (Yamashita et al., JBC 2011); thus, knocking out Orai3 would be expected to increase the inhibitory effect of 2-APB, as seen in Figure 5B. Likewise, the fact that double KO is required to inhibit oscillations could be explained simply by oscillations not being sensitive to a partial loss of SOCE, and only cease when SOCE is largely eliminated. The subunit composition of the channel could be complex, with multiple populations of homomers and heteromers, and unfortunately, these experiments do not answer this question.</p></disp-quote><p>Please see our response to essential comments #1, 2 and 3. We cleansed the paper from the words “essential” and “crucial” and from any reference to the oligomeric state. The patch clamp data was removed from the manuscript as requested. In the first round of review (R0), we were asked to interpret the 2-APB data, which we did in the R1 version. Yes, we agree that based on the known potentiation of overexpressed Orai3 by 2-APB, the data are compatible with both homomeric and heteromeric scenarios. We would kindly caution the reviewer against extrapolating the 2-APB potentiation of overexpressed Orai3 to physiological settings. Although we do not understand it yet, we have extensive experience in many primary cell types lacking combinations of Orai isoforms (through CRISPR/Cas9 KO) where potentiation by 2-APB is not always apparent with native levels of Orai3 expression, the case of B cells herein included. In our defense, our interpretation of the 2-APB data seemed reasonable since the remaining ca<sup>2+</sup> signal in Orai1 KO cells is not potentiated by 2-APB. Regardless, we deleted those statements because we don’t think the 2-APB data, or the patch clamp data, even testing 2-APB on currents (we tried) can offer definitive answers to this complex question. We agree it is better to remove any reference to the oligomeric state of these channels, which we did.</p><disp-quote content-type="editor-comment"><p>2. The patch-clamp recordings of whole-cell CRAC current are not convincing. The I/V plots are not inwardly rectifying as would be expected from normal CRAC currents, and there is no mention of correction for leak current. This throws into question the conclusion that Orai3 is &quot;a moderate negative regulator of CRAC channel activity,&quot; especially as the KO had no effect on SOCE of naïve cells, and actually decreased SOCE in pre-activated cells or A20 B cells. A careful analysis of current characteristics in the various wild-type and knockout B cells might provide evidence for heteromultimers, but these data do not.</p></disp-quote><p>Please see our response to essential comments #1 and 2. All these statements were deleted. While we agree with the reviewer statement that “A careful analysis of current characteristics in the various wild-type and knockout B cells might provide evidence for heteromultimers”, reliable CRAC current recordings from primary B cells (as opposed to T cells) is not an easy task to achieve at least in our hands, as documented by our own shortcomings with those recordings.</p><disp-quote content-type="editor-comment"><p>3. The data from the Orai1 KO cells do not support the conclusion that NFAT activation depends specifically on native Orai1. Figure S3A shows that in the Orai1 KO cells, IgM and TG still dephosphorylate NFAT, just not as much as in control – this is to be expected, as SOCE is partially reduced by O1 KO. If Orai1 were the only isoform that supports NFAT activation, IgM or TG would not dephosphorylate NFAT in the KO cells.</p></disp-quote><p>We apologize. We should have been more careful in wording these statements. A look at our study in HEK293 cells (PMID<bold>:</bold> 32415068) shows that while Orai1 is the major contributor to NFAT nuclear translocation, Orai1 KO, Orai1/2 double KO and Orai1/3 double KO cells show some level of NFAT induction when compared to lack of NFAT nuclear translocation in Orai1/2/3 triple KO cells, suggesting that Orai2 and Orai3 can alone or together support moderate levels of NFAT induction. What is striking though is that the oscillations in Orai1 KO cells are indistinguishable from those of wildtype cells while NFAT induction and SOCE (in response to thapsigargin) are significantly inhibited in HEK293 (above reference) and in B cells (Figure 6 and Figure 6—Supplement 1 of the current study). In the current study, and as pointed out by reviewer 3, NFAT dephosphorylation is partially inhibited in naïve Orai1 KO B cells (more so in activated B cells), suggesting that Orai3 and/or Orai2 can mediate the remaining NFAT dephosphorylation. We have changed the statements in the manuscript to reflect this.</p><disp-quote content-type="editor-comment"><p>4. The authors state that Orai1 and Orai3 are critical for primary B cell proliferation and survival (Figure 8). This conclusion needs to be toned down, as KO of either protein alone had little or no effect, and even the double KO had only a partial effect on proliferation. At any rate, the relevance of measuring viability effects after 72 hrs in vitro seems questionable, given that these conditions differ significantly from the environment of the cells in vivo (where there are no discernable functional effects of the DKO).</p></disp-quote><p>We have toned down these statements and specifically stated that the effect on proliferation is observed only with the combined deletion of Orai1 and Orai3 and can be partially rescued with ani-CD40 co-stimulation.</p><disp-quote content-type="editor-comment"><p>5. It is surprising (and disappointing!) that the deletion of Orai1 and Orai3 in B cells did not affect humoral immunity to influenza A infection in mice. In my view, this result seriously undermines the significance of the paper. If Orai channels are not required for B cell development or function in vivo, it is not clear how the in vitro results of the many different assays in this paper relate to the humoral immune response.</p></disp-quote><p>Indeed, this result is surprising, but we prefer a disappointing truth over an exciting artifact or falsehood as we much prefer, at the behest of reviewers, to admit our ignorance than publish our fantasies. Perhaps our manuscript deserves to be rejected because we did not obtain an “exciting” result, perhaps not. Perhaps the in vivo function of SOCE in B cells could be revealed with another in vivo model such as an autoimmunity model, perhaps not. We are truly at loss as to why we do not see any effects in the double Orai1/Orai3 knockout. In this revision, we offer a discussion of the discrepancy between the results in vivo and those in vitro and some ideas on what might explain this discrepancy.</p></body></sub-article></article>